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Abstract 
Senescence was first described by the pioneering work of Hayflick whereby human 
diploid fibroblasts underwent repeated population doublings, and the cells 
demonstrated a finite replicative limit in culture. It is now recognised that most 
replicative cells have the capability to undergo senescence. More recently 
senescence-like properties have been described in terminally differentiated cells, 
including skeletal muscle, although the nature of this senescence remains unclear. 
There is limited data examining the role of senescence in the determination of 
terminally differentiated tissues such as skeletal muscle.  
The overall hypothesis of this thesis was that senescent cells accumulate in old mice, 
either locally to skeletal muscle or distally, and that they produce an inflammatory 
Senescence Associated Secretory Phenotype (SASP) which may contribute at least in 
part to the chronic NF-κB activation and the loss of muscle mass and function seen in 
the muscles of old compared with adult wild type (WT) mice. This programme of work 
tested this hypothesis by utilising different models of senescence in vitro and in vivo 
and using a senolytic and transgenic intervention. 
Initial studies examined the potential for mouse skeletal muscle myoblasts (C2C12 
myoblasts) to undergo senescence when treated with the DNA damaging agent, 
etoposide. Treatment of cells with etoposide resulted in cell cycle arrest, increased 
levels of p21, increased SA-β-Gal activity, and altered morphology, providing proof-
of-principle that mononuclear myoblasts can become senescent. Further, the 
senescent myoblasts produced a proinflammatory SASP detectable in the cell media 
that was able to increase NF-κB transcription factor activity in mature C2C21 
myotubes. Interpretation and comparison of data from senescent cells and control 
cells proved a challenge since under normal conditions, control myoblasts continue 
to divide until reaching confluence and contact inhibition occurs. At this point muscle 
cells initiate differentiation, with expression of some indices common to senescence. 
Examination of muscles of old WT mice showed no evidence of the presence of 
classical senescent cells in muscles of old mice although old mice showed evidence 
of increased levels of cytokines and chemokines in the plasma. Data suggest that 
muscle may partially contribute to the increase in some of these plasma 
cytokines/chemokines by a non-senescent mechanism. In support of this conclusion, 
studies using either a transgenic or a pharmacological approach to remove whole 
body senescent cells in old mice had some minor effects on plasma 
cytokine/chemokine levels but provided no protection against the age-related loss of 
muscle mass and function.  
Evidence for the presence of senescence cells in old mice remains unclear but some 
studies have suggested that removal of senescent cells provides protection against 
age-related muscle loss. One potential reason for the difference with the current 
study is the age of the mice used whereby studies that have demonstrated 
senescence within skeletal muscle have commonly made use of geriatric (32-months-
old) mice suggesting that senescence is only involved in the very late stages of 
sarcopenia.   
Page 3 of 300 
Acknowledgments 
I would like to thank my supervisors, Professor Anne McArdle, Dr Aphrodite Vasilaki, 
and Dr Caroline Staunton, for their help and support and all the opportunities they 
gave me throughout my PhD. I would also like to thank the rest of the research group, 
especially Professor Jackson, for their guidance and support.  
I would like to thank Sue Brooks, Jennifer Judge, Steven Guzman, and the research 
group at the University of Michigan for their help, support, and data. Thank you for 
making my first visit to Michigan a wonderful experience. 
Thank you to my fellow cohort PhD students, especially Euan Owen for the cytokine 
data from adult and old mice. 
I would also like to thank the Biomedical Service Unit (BSU), especially for their 
ceaseless support and patience with our experiments. 
Finally, I would like to thank my funders – the British Society for Research in Ageing 
(BSRA), and the Rosetrees Trust, without whom I would not have had this 
opportunity.  
  
Page 4 of 300 
Dedications 


















Page 5 of 300 
Table of Contents 
 
Investigating the role of cellular senescence in skeletal muscle and sarcopenia ....... 1 
Abstract ........................................................................................................................ 2 
Acknowledgments ........................................................................................................ 3 
Dedications ................................................................................................................... 4 
Table of Contents ......................................................................................................... 5 
Figures ........................................................................................................................ 18 
Tables ......................................................................................................................... 22 
Abbreviations ............................................................................................................. 23 
1. Chapter 1: General Introduction ........................................................................ 26 
1.1 Cellular senescence ..................................................................................... 27 
1.1.1 Hallmarks of Senescence ..................................................................... 28 
1.1.2 Molecular markers of senescence ....................................................... 30 
1.1.2.1 P53 ................................................................................................ 30 
1.1.2.2 P21 ................................................................................................ 31 
1.1.2.3 P16 ................................................................................................ 31 
1.1.2.4 Senescence Associated Heterochromatin Formations (SAHF) ..... 32 
1.1.2.5 Senescence-associated β-galactosidase activity .......................... 33 
1.1.3 Mechanisms of induction of senescence ............................................. 33 
1.1.3.1 The Cell Cycle ................................................................................ 33 
1.1.3.2 Chemical Inducers of cellular senescence .................................... 35 
1.1.3.3 The DNA-Damage Response (DDR) and senescence .................... 36 
Page 6 of 300 
1.1.4 NF-κB signalling in cellular senescence ................................................ 38 
1.1.4.1 Inflammaging and senescence...................................................... 41 
1.1.4.2 The role of NF-κB signalling and production of inflammatory 
cytokines by senescent cells ........................................................................... 41 
1.1.5 Role of Senescence in vivo ................................................................... 42 
1.1.6 A comparison of senescence across tissues ........................................ 44 
1.1.7 Animal models of senescence .............................................................. 46 
1.1.7.1 Senescence Accelerated Mouse-Prone (SAMP) mice ................... 46 
1.1.7.2 INK-ATTAC mice ............................................................................ 47 
1.1.7.3 P16-3MR ....................................................................................... 50 
1.1.8 Senolytics ............................................................................................. 51 
1.1.8.1 Polyphenols in vivo ....................................................................... 53 
1.1.8.2 Other Senolytics ............................................................................ 54 
1.1.8.3 mTOR signalling ............................................................................ 56 
1.1.9 A comparison of senescence in mouse and human cells .................... 58 
1.1.10 Summary .............................................................................................. 60 
1.2 Introduction to skeletal muscle ................................................................... 60 
1.2.1 Skeletal muscle structure and function ............................................... 61 
1.2.2 Sliding filament theory of muscle contraction ..................................... 63 
1.2.3 Skeletal muscle fibre types .................................................................. 65 
1.2.4 Sarcopenia – loss of muscle mass and function with ageing ............... 66 
1.2.4.1 Mechanisms responsible for the development of sarcopenia ..... 68 
1.2.4.2 Satellite cells and sarcopenia ........................................................ 69 
1.2.4.3 Protein turnover and sarcopenia .................................................. 71 
1.2.4.4 Fat, fibrosis, and sarcopenia ......................................................... 73 
Page 7 of 300 
1.2.4.5 ROS, mitochondria, and sarcopenia ............................................. 73 
1.2.4.6 Inflammation and sarcopenia ....................................................... 74 
1.3 Evidence of senescence in skeletal muscles in ageing ................................ 76 
1.3.1 Exercise and cellular senescence ......................................................... 78 
1.4 Hypothesis and Aims ................................................................................... 80 
2 Chapter 2: Methods ........................................................................................... 82 
2.1 Animals ........................................................................................................ 83 
2.1.1 Animal husbandry & Home Office licence permissions ....................... 83 
2.1.2 P16-3MR mice ...................................................................................... 83 
2.1.3 Senolytic dietary intervention study .................................................... 83 
2.1.4 Determination of muscle force generation ......................................... 84 
2.2 Cell Culture of C2C12 myoblasts and myotubes ......................................... 85 
2.2.1 Induction of cellular senescence in C2C12 Myoblasts ......................... 87 
2.2.2 Differentiating myoblasts into myotubes ............................................ 88 
2.2.3 Treatment C2C12 myotubes with conditioned media from senescent 
myoblasts ........................................................................................................... 89 
2.2.4 Measurement of myotube diameter ................................................... 90 
2.2.5 Determination of cell number ............................................................. 92 
2.3 Measurement of senescent markers .......................................................... 93 
2.3.1 Cell Viability Assay of C2C12 myoblasts ............................................... 93 
2.3.2 Senescence Associated β-Galactosidase Staining ................................ 94 
Page 8 of 300 
2.3.3 Immunohistochemical analysis of senescence markers in etoposide 
treated C2C12 myoblasts ................................................................................... 95 
2.3.4 Cryosectioning of frozen mouse tissue ................................................ 97 
2.3.5 Sudan Black B staining or autofluorescence measurement of muscle 
tissue sections for evidence of lipofuscin .......................................................... 98 
2.3.6 Immunohistochemical analysis of muscle sections for senescence 
markers  .............................................................................................................. 99 
2.4 Protein Quantification ............................................................................... 101 
2.4.1 Generation of tissue homogenates.................................................... 101 
2.4.2 Bicinchoninic acid assay of tissue or cell homogenates .................... 101 
2.4.3 Bradford Assay of tissue or cell homogenates ................................... 103 
2.5 Western blotting of tissue homogenates for detection of senescence 
markers ................................................................................................................ 104 
2.5.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS 
PAGE)  ............................................................................................................ 105 
2.5.2 Western Blotting ................................................................................ 107 
2.5.3 Analysis of membranes for specific proteins ..................................... 109 
2.5.4 Western blotting analysis ................................................................... 110 
2.5.5 List of Primary antibodies .................................................................. 110 
2.5.5.1 H2AX ........................................................................................... 110 
2.5.5.2 IKBα ............................................................................................. 111 
2.5.5.3 p65 .............................................................................................. 111 
Page 9 of 300 
2.5.5.4 Phosphorylated p65 .................................................................... 111 
2.5.5.5 p21CIP1 ......................................................................................... 111 
2.5.5.6 p53 .............................................................................................. 111 
2.6 Quantitative PCR for senescence markers ................................................ 112 
2.6.1 RNA Extraction ................................................................................... 112 
2.6.2 cDNA Synthesis................................................................................... 113 
2.6.3 Quantitative PCR ................................................................................ 114 
2.7 Multiplex Cytokine Analysis ...................................................................... 115 
2.8 Electromobility Shift Assay (EMSA) for NF-κB transcription factor activity .... 
  ................................................................................................................... 119 
2.8.1 Competition and Supershift experiments .......................................... 123 
2.9 Gene Ontology Term Analysis ................................................................... 125 
2.10 Statistics ................................................................................................. 125 
3 Chapter 3: An In vitro Model of Cellular Senescence in C2C12 Muscle Myoblasts 
  .......................................................................................................................... 126 
3.1 Introduction ............................................................................................... 127 
3.1.1 Cellular Senescence ............................................................................ 127 
3.1.2 Etoposide and the DNA Damage Response ....................................... 127 
3.1.3 The Role of Cell dependant Kinase Inhibitors in Cell Cycle Arrest ..... 128 
3.1.4 Markers of cellular senescence .......................................................... 129 
3.1.5 The Senescence Associated Secretory Phenotype (SASP) produced by 
senescent cells in vivo: role in the development of sarcopenia ...................... 130 
Page 10 of 300 
3.1.6 The role of NF-κB in the Senescence Associated Secretory Phenotype of 
senescent cells ................................................................................................. 130 
3.1.7 Hypothesis .......................................................................................... 131 
3.2 Methods .................................................................................................... 132 
3.2.1 Inducing cellular senescence in C2C12 myoblasts ............................. 132 
3.2.2 Viability of etoposide treated C2C12 myoblasts ................................ 132 
3.2.3 Proliferation of etoposide treated C2C12 myoblasts ........................ 132 
3.2.4 Senescence Associated β-Galactosidase staining of cells .................. 133 
3.2.5 Western blotting for markers of senescence in C2C12 myoblasts .... 133 
3.2.6 Immunofluorescent analysis of senescence markers in etoposide 
treated C2C12 myoblasts ................................................................................. 134 
3.2.7 Multiplex cytokine analysis of the media from etoposide treated C2C12 
myoblasts ......................................................................................................... 135 
3.2.8 Analysis of myotubes treated with SASP from senescent myoblasts: 
effect on Electromobility Shift Assay (EMSA) for NF-κB transcription factor 
activity and myotube diameter ........................................................................ 135 
3.3 Results ....................................................................................................... 136 
3.3.1 Viability of etoposide treated C2C12 myoblasts ................................ 136 
3.3.2 Proliferation of etoposide- and DMSO-treated C2C12 myoblasts .... 138 
3.3.3 SA-β-gal activity of etoposide- and DMSO- treated C2C12 myoblasts .... 
  ............................................................................................................ 139 
Page 11 of 300 
3.3.4 Detection of senescence markers in etoposide treated C2C12 myoblasts
  ............................................................................................................ 141 
3.3.5 Analysis of the SASP from etoposide- and DMSO-treated C2C12 
myoblasts. ........................................................................................................ 144 
3.3.6 Effects of treating C2C12 myotubes with SASP enriched media from 
senescent C2C12 myoblasts on NF-κB DNA binding activity. .......................... 145 
3.4 Discussion .................................................................................................. 150 
3.4.1 Treatment C2C12 myoblasts with etoposide induced senescence ... 150 
3.4.2 C2C12 myoblasts demonstrated characteristic features of senescence . 
  ............................................................................................................ 151 
3.4.3 Characterising the SASP produced by senescence C2C12 cells ......... 154 
3.4.4 Treatment of C2C12 myotubes with media containing the SASP from 
senescent C2C12 myoblasts promoted inflammation. .................................... 154 
3.5 Conclusions ................................................................................................ 156 
4 Chapter 4: Characterising senescence in skeletal muscle of adult and old mice in 
vivo  .......................................................................................................................... 157 
4.1 Introduction ............................................................................................... 158 
4.1.1 The role of senescence in inflammation-mediated sarcopenia ........ 158 
4.1.2 Evidence of senescence in skeletal muscle fibres .............................. 159 
4.1.3 Hypothesis and aims .......................................................................... 162 
4.2 Methods .................................................................................................... 163 
Page 12 of 300 
4.2.1 Western blotting for senescence markers ......................................... 164 
4.2.2 Quantitative PCR for senescence markers ......................................... 165 
4.2.3 Senescence Associated β-Galactosidase staining of muscle sections 165 
4.2.4 Sudan Black B staining of muscle sections for lipofuscin ................... 166 
4.2.5 Immunohistochemistry for senescence markers in etoposide- and 
DMSO-treated C2C12 myoblasts ..................................................................... 166 
4.2.6 Multiplex Cytokine Analysis ............................................................... 166 
4.2.7 Gene Ontology Term Analysis ............................................................ 167 
4.3 Results ....................................................................................................... 168 
4.3.1 Molecular markers of senescence in muscle of adult and old mice. . 168 
4.3.2 Detection of senescence markers in histological sections of muscle from 
adult and old mice. ........................................................................................... 168 
4.3.3 Immunohistochemical staining for the senescence marker p21 ....... 174 
4.3.4 Multiplex cytokine analysis of plasma and muscle from adult and old 
mice  ............................................................................................................ 176 
4.4 Discussion .................................................................................................. 180 
4.4.1 Characterisation of senescence markers in the skeletal muscle of adult 
and old mice ..................................................................................................... 180 
4.4.1.1 Protein and mRNA levels of p16 and p21 in the muscles of adult 
and old mice. ................................................................................................. 180 
4.4.1.2 Immunohistochemistry for SA-β-Gal and Lipofuscin .................. 181 
Page 13 of 300 
4.4.2 Characterisation of the inflammatory cytokine profiles of adult and old 
mice  ............................................................................................................ 183 
4.4.2.1 Chemotaxis and the immune system ......................................... 184 
4.4.2.2 Skeletal muscles as a source of cytokines .................................. 184 
4.5 Conclusion ................................................................................................. 189 
5 Chapter 5: Removal of senescent cells in p16-3MR mice: effect on age-related 
loss of skeletal muscle .............................................................................................. 190 
5.1 Introduction ............................................................................................... 191 
5.1.1 The p16-3MR mouse model ............................................................... 191 
5.1.2 Hypothesis and aims .......................................................................... 194 
5.2 Methods .................................................................................................... 195 
5.2.1 GCV treatment of P16-3MR mice ...................................................... 196 
5.2.2 Measurements of force generation of muscles in situ and ex vivo ... 196 
5.2.3 qPCR of inflammatory markers .......................................................... 197 
5.2.4 EMSA for NF-κB transcription factor activity ..................................... 197 
5.2.5 Multiplex cytokine analysis ................................................................ 197 
5.3 Results ....................................................................................................... 198 
5.3.1 Effects of GCV treatment of p16-3MR mice on muscle mass and 
morphology. ..................................................................................................... 198 
5.3.2 Effects of GCV or PBS treatment of P16-3MR mice on muscle force 
generation. ....................................................................................................... 201 
Page 14 of 300 
5.3.3 Effects of GCV or PBS (control) treatment of P16-3MR mice on the 
inflammatory cytokine profile of plasma and muscle. .................................... 203 
5.4 Discussion .................................................................................................. 207 
5.4.1 Effects of elimination of p16 expressing cells from p16-3MR mice on 
skeletal muscle mass and function. ................................................................. 207 
5.4.2 Effects of elimination of p16 expressing cells from p16-3MR mice on 
plasma cytokine levels. .................................................................................... 208 
5.4.3 The effects of G-CSF on skeletal muscle ............................................ 212 
5.4.4 Comparison with the INK-ATTAC mouse model ................................ 213 
5.4.5 The use of P16-3MR mice in other studies ........................................ 215 
5.4.6 Limitations of this and other studies ................................................. 215 
5.5 Conclusion ................................................................................................. 217 
6 Chapter 6: The effects of intervention with the senolytic fisetin on muscle mass 
and function in old mice .......................................................................................... 219 
6.1 Introduction ............................................................................................... 220 
6.1.1 Senolytics ........................................................................................... 220 
6.1.2 Polyphenols as senolytics ................................................................... 221 
6.1.3 Fisetin as a senolytic .......................................................................... 222 
6.1.4 Fisetin treatment and cell signalling .................................................. 224 
6.1.5 Hypothesis .......................................................................................... 225 
6.2 Methods .................................................................................................... 226 
Page 15 of 300 
6.2.1 Senolytic intervention study .............................................................. 226 
6.2.2 Force measurements ......................................................................... 227 
6.2.3 EMSA for NF-κB activity in muscle ..................................................... 228 
6.2.4 Luminex analysis of plasma cytokine content ................................... 228 
6.3 Results ....................................................................................................... 229 
6.3.1 Effect of Fisetin treatment on the survival and body weight of old mice 
  ............................................................................................................ 229 
6.3.2 Effect of Fisetin treatment on the organ weights of old mice ........... 230 
6.3.3 Effect of fisetin treatment on the muscle mass of old mice .............. 231 
6.3.4 Effect of Fisetin treatment on force generation of the EDL muscles of 
old mice ............................................................................................................ 231 
6.3.5 Multiple cytokine analysis of the plasma from fisetin treated and 
control mice ..................................................................................................... 231 
6.3.6 NF-κB activity in skeletal muscle of fisetin treated and control mice 235 
6.4 Discussion .................................................................................................. 236 
6.4.1 The effect of fisetin treatment on body weight of old mice ............. 237 
6.4.2 Fisetin treatment, survival, and potential toxicity ............................. 237 
6.4.3 Fisetin treatment and organ weights ................................................. 238 
6.4.4 Fisetin treatment of old mice: effect on muscle mass and force 
generation of the EDL muscle .......................................................................... 239 
6.4.5 Comparison of the current study with published studies. ................ 242 
Page 16 of 300 
6.5 Conclusion ................................................................................................. 242 
7 Chapter 7: General Discussion and Future Directions ..................................... 244 
7.1 Hypothesis. ................................................................................................ 245 
7.2 Aims of the thesis ...................................................................................... 245 
7.3 Summary of the findings of the thesis ...................................................... 246 
7.4 General discussion ..................................................................................... 248 
7.4.1 Senescence in a cell culture model. ................................................... 248 
7.4.2 Senescence in skeletal muscle tissue ................................................. 249 
7.4.3 Senescence may only be evident in very old (geriatric) mice. ........... 251 
7.4.4 Use of transgenic mouse models to eliminate senescent cells ......... 252 
7.5 Limitations of the current studies ............................................................. 253 
7.6 Future directions. ...................................................................................... 256 
7.6.1 Identification of the source of increased plasma cytokines in old mice 
and humans. ..................................................................................................... 256 
7.6.2 Examination of the local effects of muscle – derived cytokines on other 
cells and tissues. ............................................................................................... 256 
7.6.3 Lack of clear markers of senescence, particularly in terminally 
differentiated muscle cells. .............................................................................. 257 
8 References ........................................................................................................ 258 
9 Appendix .......................................................................................................... 290 
Page 17 of 300 
9.1 Abstracts .................................................................................................... 290 
9.1.1 BSRA - 2017 ........................................................................................ 290 
9.1.2 Rosetrees Trust Symposium – 2017 ................................................... 291 
9.1.3 Institute of Ageing and Chronic Disease Science Day - 2018 ............. 292 
9.1.4 Experimental Biology – 2018 ............................................................. 293 
9.1.5 Experimental Biology – 2018 ............................................................. 294 
9.1.6 BSRA - 2018 ........................................................................................ 295 
9.2 Posters ....................................................................................................... 296 
9.2.1 BSRA – 2017 ....................................................................................... 296 
9.2.2 Institute of Ageing and Chronic Disease Science Day - 2018 ............. 297 
9.2.3 Experimental Biology – 2018 ............................................................. 298 
9.2.4 Experimental Biology – 2018 ............................................................. 299 
9.2.5 BSRA – 2018 ....................................................................................... 300 
 
  
Page 18 of 300 
Figures 
Figure 1.1 Senescence Signalling Pathway. ................................................................ 37 
Figure 1.2. NF-κB signalling pathway. ........................................................................ 39 
Figure 1.3 Schematic of INK-ATTAC mice transgene ................................................. 48 
Figure 1.4 Schematic of the p16-3MR transgene. ..................................................... 50 
Figure 1.5 The MAPK/ERK and mTOR signalling pathways ........................................ 56 
Figure 1.6 Structure of skeletal muscle ...................................................................... 61 
Figure 1.7 Skeletal muscle contraction. ..................................................................... 63 
Figure 2.1 Coomassie Brilliant Blue G-250 reaction................................................. 103 
Figure 2.2 Schematic of western blot semi dry transfer assembly. ......................... 108 
Figure 2.3 Overview of Luminex Assay. ................................................................... 116 
Figure 2.4 Overview of the gel shift assay method. ................................................. 124 
Figure 3.1 LIVE/DEAD viability assay of etoposide treated myoblasts. ................... 137 
Figure 3.2 Cell number of C2C12 myoblasts treated with etoposide. ..................... 138 
Figure 3.3 SA-β-Gal staining of etoposide treated myoblasts. ................................ 140 
Figure 3.4 .................................................................................................................. 142 
Figure 3.5 .................................................................................................................. 143 
Figure 3.6 Cytokine analysis of the total SASP from senescent compared with 
proliferating C2C12 myoblasts. ................................................................................ 146 
Page 19 of 300 
Figure 3.7 Cytokine analysis of the acute SASP from senescent compared with 
proliferating C2C12 myoblasts. ................................................................................ 147 
Figure 3.8 .................................................................................................................. 148 
Figure 3.9 EMSA for NF-κB/p65 transcription factor DNA binding activity in C2C12 
myotubes cultured in SASP enriched media. ........................................................... 149 
Figure 4.1 A brief overview of the methodology used for this chapter. ................. 163 
Figure 4.2 .................................................................................................................. 170 
Figure 4.3 .................................................................................................................. 171 
Figure 4.4 Sudan Black B staining of gastrocnemius muscle from adult and old mice.
 .................................................................................................................................. 172 
Figure 4.5 Detection and quantification of lipofuscin particles by autofluorescence 
within the gastrocnemius muscle from adult and old mice. ................................... 173 
Figure 4.6 .................................................................................................................. 174 
Figure 4.7 .................................................................................................................. 175 
Figure 4.8 .................................................................................................................. 177 
Figure 4.9 .................................................................................................................. 178 
Figure 4.10 ................................................................................................................ 179 
Figure 5.1 Schematic of the p16-3MR transgene. ................................................... 191 
Figure 5.2 Overview of methodology used for Chapter 5 ....................................... 195 
Figure 5.3 Experimental design for treatment of P16-3MR mice with GCV. ........... 196 
Figure 5.4 Hind limb muscle mass of GCV or PBS treated p16-3MR mice............... 199 
Page 20 of 300 
Figure 5.5 Fibre size and type analysis of PBS treated (control) or GCV treated p16-
3MR mice. ................................................................................................................ 200 
Figure 5.6 Specific force generation by hind limb muscles of GCV and PBS treated P16-
3MR mice. ................................................................................................................ 202 
Figure 5.7 Absolute tetanic force generation by hind limb muscles of GCV and PBS 
treated P16-3MR mice. ............................................................................................ 202 
Figure 5.8 NFκB/p65 activity in muscles of GCV treated p16-3MR mice. ............... 204 
Figure 5.9 Cytokine mRNA levels in muscle of PBS or GCV treated p16-3MR mice.204 
Figure 5.10 Multiplex cytokine analysis of plasma from GCV and PBS treated p16-3MR 
mice. ......................................................................................................................... 205 
Figure 5.11 Heatmap and Dendritic Clustering of cytokines from the plasma of GCV 
and PBS treated p16-3MR mice. .............................................................................. 206 
Figure 5.12 Total body luminescence of p16 expressing cells of p16-3MR mice with 
increasing age........................................................................................................... 208 
Figure 6.1 A brief overview of the methodology used for this chapter .................. 226 
Figure 6.2 Effects of fisetin treatment on body weight and survival of mice .......... 229 
Figure 6.3 Organ weights following fisetin treatment ............................................. 230 
Figure 6.4 Hind limb muscle weights of fisetin treated mice after 4 months of senolytic 
treatment compared with mice fed the control diet. ............................................. 232 
Figure 6.5 Force generation by EDL muscles of fisetin treated and control mice. .. 233 
Page 21 of 300 
Figure 6.6 Multiple cytokine analysis of plasma from mice after 4 months of 
treatment with fisetin compared with control mice. .............................................. 234 
Figure 6.7 NF-κB activity in muscles of fisetin treated and control mice. ............... 235 
 
  
Page 22 of 300 
Tables 
Table 2.1 Workflow for co-culture experiment. ........................................................ 91 
Table 2.2 Senescence β-Galactosidase Cell Staining Solution. .................................. 95 
Table 2.3 Preparation of Diluted Albumin (BSA) Standards .................................... 102 
Table 2.4 SDS PAGE formula .................................................................................... 106 
Table 2.5 cDNA synthesis reaction ........................................................................... 113 
Table 2.6 cDNA thermal cycler settings ................................................................... 114 
Table 2.7 Preparing a fourfold dilution series for the Luminex ............................... 119 
Table 2.8 EMSA binding reaction ............................................................................. 122 
Table 3.1 Antibody dilutions for western blotting of senescence markers in C2C12 
cells ........................................................................................................................... 134 
Table 4.1 Antibody dilutions for western blotting of senescence markers in skeletal 
muscles of adult and old mice ................................................................................. 164 
Table 4.2 Primer sequences for senescence markers .............................................. 165 
Table 4.3 Immunohistochemistry antibody dilutions of senescence markers ........ 166 
Table 4.4 ................................................................................................................... 185 
Table 5.1 ................................................................................................................... 211 
Table 6.1 Body weight of C57BL/6 mice on a standard diet over time ................... 236 
Table 6.2 ................................................................................................................... 241 
Table 7.1 ................................................................................................................... 255 
Page 23 of 300 
Abbreviations 
 ADP    Adenosine Diphosphate 
 APS    Ammonium Persulphate 
 ATM     Ataxia Telangiectasia-Mutated  
 ATP    Adenosine Triphosphate 
 ATR     ATM-and-Rad3-related  
 BCA    Bicinchoninic acid 
 CDK     cyclin-dependent kinase 
 CDKI    cyclin-dependent kinase inhibitor 
 CuZnSOD/SOD1   Copper Zinc Superoxide Dismutase 
 DAPI     4′,6-diamidino-2-phenylindole 
 DDR    DNA-damage response 
 DMEM    Dulbecco’s modified Eagle’s medium 
 DNA    Deoxyribonucleic acid 
 DSB    Double strand breaks 
 EMSA    Electrophoretic Mobility Shift Assay 
 g     Grammes 
 H20    Water 
 H2AX    H2A histone family member X 
 HBSS    Hepes buffered PBS solution 
 IFN-γ    Interferon gamma 
 IGF-1    Insulin growth factor 1 
 IGF1    Insulin-like growth factor 1 
Page 24 of 300 
 IκB     Inhibitor of nuclear factor kappa B 
 IL     Interleukin 
 IP10    Interferon Gamma Induced Protein 10 
 Kg     Kilogrammes 
 KO     Knock-out 
 MAPK    Mitogen-activated protein kinase 
 MCP1    Monocyte Chemoattractant Protein 1 
 M-CSF    Macrophage Colony-Stimulating Factor 
 mg     Milligrammes 
 MHC     myosin heavy chain 
 Mip1α    Macrophage inflammatory protein 1-alpha 
 Mip3α    Macrophage inflammatory protein 3-alpha 
 MnSOD/SOD2   Manganese Superoxide Dismutase 
 mRNA    Messenger RNA 
 mtDNA    Mitochondrial Deoxyribonucleic Acid 
 mTOR    Mechanistic Target of Rapamycin 
 nm     Nano Metre 
 NF-κB    Nuclear Factor Kappa-Light-Chain-Enhancer of 
Activated B cells 
 OIS     Oncogene-induced senescence 
 PBS    Phosphate buffered PBS 
 PCR    Polymerase Chain Reaction 
 PI3K     phosphatidyilinositol-3-OH-kinases 
Page 25 of 300 
 qPCR    Quantitative Polymerase Chain Reaction 
 RNA    ribonucleic acid 
 RS     Replicative Senescence 
 SAHF    Senescence Associated Heterochromatin Foci 
 SASP     senescent associated secretory phenotype 
 SA-β-Gal    senescence-associated β-galactosidase 
 SDS PAGE    Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis 
 SEM    Standard Error of the Mean 
 SIPS     stress-induced premature senescence 
 TBE    Tris/Borate/EDTA 
 TBS    Tris-buffered PBS 
 TBST    Tris-buffered PBS, 0.1% Tween 20 
 TEMED    Tetramethylethylenediamine 
 TNF-α    Tumour Necrosis Factor Alpha 
 UV     Ultraviolet 
 μM     Micrometre 
  









1. Chapter 1: General Introduction 
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1.1 Cellular senescence 
The word “senescence” is derived from Latin senex, meaning "old" and generally 
refers to the ageing process. The first introduction to, and demonstration of cellular 
senescence was led by the pioneering study from Hayflick and Moorhead (1961). 
Human diploid fibroblasts underwent repeated population doublings, and the cells 
demonstrated a finite replicative limit in culture. Hayflick and Moorhead named this 
event senescence, to describe the phenomenon of permanent growth arrest after 
extensive serial passaging in culture.  
This phenomenon is now known as "replicative senescence" (von Zglinicki, 2002). The 
replicative senescence (RS) described by Hayflick and Moorhead, was attributed to 
telomere attrition, a process that leads to chromosomal instability and promotes 
tumorigenesis (Bodnar et al., 1998). A telomere is a region of repeated nucleotide 
sequences at each end of a chromosome, which protects the end of the chromosome 
from deterioration, or from fusion with other neighbouring chromosomes (Jiang et 
al., 2018). The attrition of telomeres ultimately activates the DNA-damage response 
(DDR), resulting in senescence (von Zglinicki, 2002).  
There are other forms of senescence that are not linked to proliferation-dependent 
telomere attrition, and are similar but not identical to replicative senescence (Section 
1.1.1). Many proliferative cell types can undergo stress-induced premature 
senescence (SIPS) upon exposure to damaging but non-lethal stresses (UV light, 
ionizing radiation, H2O2, hyperoxia, etc.) (Toussaint et al., 2002, Toussaint et al., 
2000a, Toussaint et al., 2000b).  
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First described by Serrano et al. (1997), oncogene-induced senescence (OIS) is a 
senescent phenotype that depends on the activation and/or overexpression of 
oncogenes. An oncogene is a gene that has the potential to cause cancer. Serrano et 
al. (1997) identified that the activation of an oncogenic mutant rat sarcoma viral 
oncogene homolog (RAS) in cultured cells resulted in senescence. Ultimately, all of 
these forms of senescence may present some of the hallmarks of senescence 
(Hernandez-Segura et al., 2017) (Section 1.1.1).  
Senescence is an example of antagonistic pleiotropy (Kirkwood and Austad, 2000). 
Historically, most organisms evolved in environments rich in hazards, which often 
eliminated older individuals from populations due to selective pressure. 
Unfortunately, there are not many selective pressures for cellular senescence, 
allowing senescent cells to accumulate in old age. 
1.1.1 Hallmarks of Senescence 
There are a number of hallmarks and molecular markers of senescence, some of 
which are described below senescent cells are diverse and their profiles are 
dependent on the cell type of origin and methods used to induce the senescence 
(Wiley et al., 2017). However, the consensus is that senescent cells demonstrate 
classic morphological changes and express several common markers (Avelar et al., 
2020). These include but are not limited to:  
 Changes in morphology  
Senescent cells undergo important morphological changes, such as becoming flat and 
enlarged, due to CDK5-dependent activation and increased expression of the 
cytoskeleton proteins (Yang and Hinds, 2003). 
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 Cell cycle arrest/absence of proliferative markers 
Several molecules play an important role in establishing and maintaining the cell cycle 
arrest of senescent cells. Of these, p53, p21 and p16 are often used to characterise 
senescence 
 Senescence-associated β-galactosidase (SA-β-GAL) activity 
In senescent cells, a lysosomal beta-galactosidase accumulates and can be exploited 
in a cytochemical assay that leaves a blue precipitate at pH 6.0 (Dimri et al., 1995).  
 Chromatin structure (Senescence Associated Heterochromatin Foci [SAHF]) 
Narita et al. (2003) initially demonstrated that Retinoblastoma (Rb) and other 
heterochromatin-associated proteins can accumulate on the E2F-responsive 
promoters in senescent but not quiescent cells. E2F are a group of genes that are 
involved in the cell cycle regulation (Serrano et al., 1997). These results are associated 
with more stable repression of E2F responsive genes, permanent cell cycle arrest, and 
altered heterochromatin formation. 
 Senescence associated secretory phenotype (SASP). 
A senescent cell is a persisting, metabolically active cell that has undergone 
widespread changes in protein expression and secretion, ultimately developing the 
senescence-associated secretory phenotype (SASP) (Evan and d'Adda di Fagagna, 
2009, Coppe et al., 2010a, Campisi, 2013). The SASP has also been referred to as the 
senescence messaging secretome (SMS) or secretome (Kuilman and Peeper, 2009). 
Coppe et al. (2010a) highlight some of the factors found in the SASP of senescent 
cells, including cytokines, chemokines, growth factors and regulators, and proteases. 
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Thus, the SASP is a complex cocktail of compounds capable of influencing the 
surrounding microenvironment of the senescent cells. 
Identification of senescence has been an issue for the field since its inception. None 
of the markers available are able to detect senescence exclusively (Wiley et al., 2017). 
Thus, rather than single markers, senescent cells are normally identified by whether 
they test positive for a range of markers. For example, maturing tissue macrophages 
(Bursuker et al., 1982) can give false positive results for SA-β-gal activity, and so other 
indices are required. Furthermore, p53 activation is not required for the SASP (Coppe 
et al., 2008).  
1.1.2 Molecular markers of senescence 
1.1.2.1 P53 
Tumour protein p53 (tp53), also known as p53, is a crucial protein that plays large 
role in a number of pathways including: apoptosis, cell cycle arrest, and DNA damage 
repair (DDR) (Serrano et al., 1997, Ou and Schumacher, 2018). At DNA damage 
checkpoint, for example when a cell moves from G1 to S phase, the kinases ATM and 
ATR become activated, stabilising p53 and preventing its proteasomal degradation 
(Matsuoka et al., 2000, Ou and Schumacher, 2018). Furthermore, the transcriptional 
activity of p53 is enhanced, allowing for the transcription cell dependant kinase 
inhibitors to arrest the cell cycle (Dumaz and Meek, 1999, Ou and Schumacher, 2018). 
The importance of p53 is highlighted in transgenic mouse models. Over-expression 
of p53 has been shown to protect against the development cancer and tumours, at 
the expense of accelerated ageing phenotypes (Tyner et al., 2002, Maier et al., 2004) 
(Dumble et al., 2007). Indeed, “super-p53” mice which contained 3 copies of the p53 
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alleles had normal lifespan, and extended lifespan with the addition of an additional 
copy of the ARF tumour suppressor (Garcia-Cao et al., 2002, Matheu et al., 2007). 
Transgenic mice with reduced expression of MDM2 and concomitant increased 
activation of p53 showed increased resistance to cancer and a normal lifespan 
(Mendrysa et al., 2006). On the other hand, murine models with reduced functional 
p53 often result in increased incidences of cancer and poor survival (as reviewed by 
Lozano (2010)). 
1.1.2.2 P21 
Cyclin-dependent kinase inhibitor 1, also known as p21Cip1 or p21Waf1, functions to 
inhibit cell cycle progression (Xiong et al., 1993) by binding to a range of targets 
(Gartel and Radhakrishnan, 2005). What distinguishes p21 from other CDKI molecules 
is that it is a downstream target of p53. The accumulation of p21, a cyclin-dependent 
kinase inhibitor, suppresses Cyclin E/Cdk2 kinase activity thereby resulting in G1 
arrest (Bartek and Lukas, 2001). Transgenic, p21 knockout mice have been shown to 
be susceptible to osteoarthritis, due in part to increased levels of circulating 
inflammatory cytokines (Kihara et al., 2018).  
1.1.2.3 P16 
Phosphorylation of p53 results in increased transcription of p16INK4A (Serrano et al., 
1997). First described by (Serrano et al., 1993), cyclin-dependent kinase inhibitor 2A, 
also known as p16INK4, is a tumour suppressor protein under expression of the 
CDKN2A gene (Nobori et al., 1994). As a cyclin-dependant kinase (CDK) inhibitor, p16 
functions to inhibit cell cycle progression (Hara et al., 1996) from G1 to S phase by 
binding to CDK 4/6. By doing so, it can no longer bind cyclin D and phosphorylate the 
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Retinoblastoma protein (pRb). The phosphorylation frees up E2F1 from pRb, allowing 
E2F1 to enter the nucleus and act a transcription factor for genes related to cell cycle 
progression.  
1.1.2.4 Senescence Associated Heterochromatin Formations (SAHF) 
Senescence Associated Heterochromatin Formations (SAHFs) were first described by 
Narita et al. (2003), who observed that the nuclei of senescent cells contained bright, 
punctate DNA-stained dense foci which is readily distinguishable from chromatin in 
normal cells. SAHFs are not associated with cells undergoing quiescence, indicating 
that SAHF formation is not associated with a reversible exit from the cell cycle (Narita 
et al., 2003). 
SAHF also play a role in the epigenetic regulation of proliferation promoting genes 
(Narita et al., 2003). An example of which is E2F target genes such as cyclin A (Zhang 
et al., 2007), which are required for the progression through S-phase of the cell cycle 
(Pagano et al., 1992). This epigenetic regulation extends further as the SAHF contain 
no active transcription sites, contributing to the permanent cell cycle arrest we see 
in senescence. SAHFs can be seen in several models of senescence: Oncogene induces 
senescence (OIS) (Martin et al., 2010, Michaloglou et al., 2005), and stress induced 
premature senescence (SIPS) (Narita et al., 2003, Kosar et al., 2011). SAHFs are not to 
be confused with DNA-SCARS (DNA segments with chromatin alterations reinforcing 
senescence) (Rodier and Campisi, 2011). SAHF formation and senescence are not 
always coupled. Several studies have demonstrated this, for instance, activation of 
AKT and knockdown of PTEN do not cause SAHF formation (Kennedy et al., 2011, Tu 
et al., 2011). Furthermore, SAHF formation is cell-line dependent (Kosar et al., 2011). 
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Extensive passaging induced senescence (replicative senescence) of IMR90 and WI38 
cells is associated with SAHF, whereas in BJ cells (primary human foreskin fibroblasts) 
it is not (Narita et al., 2003). This difference in SAHF formation between cell lines is 
correlated to the p16/pRb pathway and its activation (Kosar et al., 2011).  
1.1.2.5 Senescence-associated β-galactosidase activity 
The most widely used assay for evidence of senescence is the histochemical detection 
of β-galactosidase activity at pH 6.0, which is known as senescence-associated β-
galactosidase (SA-β-GAL) (Dimri et al., 1995). In senescent cells, a lysosomal beta-
galactosidase accumulates and can be exploited in a cytochemical assay that leaves 
a blue precipitate at pH 6.0 (Lee et al., 2006). SA-β-gal is often used alongside other 
markers, such as p16 (Hall et al., 2016). Example senescence-associated β-
galactosidase in C2C12 cells (Jadhav et al., 2013) 
1.1.3 Mechanisms of induction of senescence 
1.1.3.1 The Cell Cycle 
Understanding the cell cycle is necessary to determine the potential mechanisms of 
induction of senescence. There exist checkpoints in the cell cycle that regulate the 
progression of the cell, preventing damaged DNA from progressing through to 
daughter cells during mitosis. In 2001, Hartwell, Hunt, and Nurse were awarded the 
Nobel Prize in Physiology and Medicine for the discovery of the two key classes of 
molecules used in these checkpoints: cyclins and cyclin-dependant kinases (CDKs) 
(2001). First identified in yeast, cyclins work by forming heterodimers with CDKs, 
activating the ability of CDKs to phosphorylate key molecules in signalling pathways 
involved in cell cycle progression (Spellman et al., 1998).  
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There are four distinct phases of the cell cycle of dividing cells: 
G0 – Also known as the resting phase where cells have left the cell cycle and stopped 
dividing. This phase encompasses post-mitotic cells, such as muscle or nerves, as well 
as quiescent and senescent cells. For some cell types, such as terminally 
differentiated or senescent cells, this arrest is permanent. Whereas for some 
quiescent cells, like stem cells, they enter and exit the cells cycle when stimulated. 
G1 – The first stage on interphase, the growth phase, where the cells gather 
resources, grow, and synthesise new proteins and organelles. During G1 phase, the 
cell may leave the cell cycle for G0, or move on to S phase and begin DNA replication. 
Passage from this phase is controlled by cyclins. 
S – S phase, or synthesis phase, is where DNA synthesis occurs. Here, the 
chromosomes are replicated to provide equal genetic material to each daughter cell 
in mitosis.  
G2 – This is the second growth phase, where the cells undergo rapid protein synthesis 
and growth to prepare for mitosis. To pass through to M phase, the cells must pass 
another checkpoint to identify and DNA damage that may have occurred in S phase. 
The G2 checkpoint is regulated by p53, which can either repaired the DNA or cause 
the cell to undergo apoptosis if the damage is irreparable.  
M phase – this phase is the physical division of the nucleus (karyokinesis) in to two 
halves for each of the daughter cells. The M phase is further broken down into more 
steps: prophase, prometaphase, metaphase, anaphase, and telophase.  
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Two families of genes that act as inhibitors for cell cycle progression, the cip/kip (CDK 
interacting protein/Kinase inhibitory protein) gene family and the INK4a/ARF 
(Inhibitor of Kinase 4/Alternative Reading Frame) gene family. The cip family includes 
p21, a downstream molecule activated by p53. The INK4a family includes p16, which 
binds to CDK4 and causes arrest in the G1 phase (Section 1.1.2). 
1.1.3.2 Chemical Inducers of cellular senescence 
The number of stimuli that have been identified to induce senescence is continually 
increasing and the mechanisms involved have been extensively reviewed: (Campisi 
and d'Adda di Fagagna, 2007, Collado et al., 2007, Collado and Serrano, 2010, 
Gorgoulis and Halazonetis, 2010, Kuilman et al., 2010, van Deursen, 2014, Salama et 
al., 2014). A publication by Petrova et al. (2016) has listed and reviewed a number of 
low molecular weight compounds that can induce senescence (e.g. doxorubicin, 
H2O2), and an example of which is etoposide.  
Etoposide, is a chemotherapeutic agent used to treat a wide variety of cancers 
(Pommier et al., 2010, Montecucco et al., 2015). Etoposide is derived from 
podophyllotoxin, a toxin found in Podophyllum peltatum (AKA American Mayapple). 
Etoposide was first produced in 1966, and then approved for cancer therapy in 1983 
by the U.S. Food and Drug Administration (FDA) (Hande, 1998, Montecucco et al., 
2015). Etoposide functions by forming complexes with DNA and the topoisomerase 
II enzyme, which is used to unwind DNA during mitosis. Complexes of 
etoposide/topoisomerase II prevents DNA unwinding and the subsequent re-ligation 
of the DNA strands; and by doing so causes DNA double strand breaks (Pommier et 
al., 2010, Montecucco et al., 2015). Inhibiting DNA replication drives apoptosis and 
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has been exploited to eliminate rapidly dividing, cancerous cells (Hande, 1998, 
Montecucco et al., 2015). 
Etoposide has been used in a number of studies to induce senescence to investigate 
tumour progression in several different cell lines (te Poele et al., 2002), apoptosis in 
WI38 fibroblasts (Probin et al., 2006), and vimentin cytoskeletal alterations in A549 
cells (Litwiniec et al., 2013). 
1.1.3.3 The DNA-Damage Response (DDR) and senescence 
Damage to nuclear DNA is triggers a rapid response (von Zglinicki, 2002). In cases 
where the damage is too extensive and not repairable, the cell may undergo 
apoptosis to prevent propagation of corrupted genomic material (d'Adda di Fagagna, 
2008). Cells have several mechanisms termed the DNA-damage response (DDR) to 
detect DNA damage, signal its presence, and promote DNA damage repair (Jackson 
and Bartek, 2009).  
Two key molecules in DDR signalling are the protein kinases: 1) Ataxia Teleangectasia-
Mutated (ATM), and 2) and ATM-and-Rad3-related (ATR), both of which initiate DNA 
repair or induce cell cycle arrest (Zou, 2007). Two downstream targets of ATM/ATR 
are the protein kinases CHK1 and CHK2, which work in tandem with ATM/ATR to 
modulate cyclin-dependent kinase (CDK) activity by activation of the p53 
transcription factor.  
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In healthy cells, p53 levels are low due to p53 binding with MDM2, which targets p53 
for nuclear export and then for proteasome-mediated degradation in the cytoplasm 
(Alarcon-Vargas and Ronai, 2002). Following DNA damage, ATM activates 
downstream kinase CHK2, which in turn phosphorylates of p53 at S20 (Serine 20) 
(Matsuoka et al., 2000). Phosphorylation of S20 of p53 blocks the p53/MDM2 
interaction, resulting in p53 accumulation in the nucleus. ATM also exerts a second 
control measure on p53 stability by directly phosphorylating MDM2 on S395 (Maya 
et al., 2001). This phosphorylation of MDM2 allows the MDM2/p53 interaction but 
prevents p53 nuclear export to the cytoplasm where degradation would normally 
occur. ATR also phosphorylates and stabilises p53 at S20 via the ATR-dependent 
kinase CHK1 (Shieh et al., 2000). 
Figure 1.1 Senescence Signalling Pathway.  
A simplified description of the cell signalling pathways implicated in establishing 
and maintaining senescence. 
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Indeed, p53 can also be phosphorylated at S15 directly by ATM and/or ATR in 
response to DNA damage, enhancing p53 transcriptional activity (Dumaz and Meek, 
1999). Activated p53 then up-regulates transcription of several target genes, many of 
which are also involved in the DNA damage response (MDM2, GADD45a, and p21/Cip 
(CDK-interacting protein)). The accumulation of p21, a cyclin-dependent kinase 
inhibitor, results in the suppression of Cyclin E/Cdk2 kinase activity thereby resulting 
in G1 arrest (Bartek and Lukas, 2001). 
Phosphorylation of p53 also results in increased transcription of p16INK4A (Serrano et 
al., 1997). Upregulation of p16INK4A leads to the prevention of Retinoblastoma (Rb) 
phosphorylation. Normally, CDKs phosphorylate Rb to its hyper-phosphorylated 
form, releasing E2F transcription factors. E2Fs are a group of genes that encode a 
family of transcription factors in mammalian cells, all of which are involved in 
regulation of the cell cycle (Serrano et al., 1997). During p16INK4A upregulation, Rb 
hypo-phosphorylation is inhibitory, resulting in inhibition of E2F-dependent 
transcription. The cell does not progress from G1 phase into S phase, resulting in cell 
cycle arrest. Furthermore, to ensure the stable repression of E2F-target genes and 
permanent cell cycle arrest, Rb promotes heterochromatin formation at E2F-
regulated gene promoters. The E2F gene promoters are epigenetically silenced, in a 
process called Senescence-Associated Heterochromatin Foci (SAHF) formation 
(Narita et al., 2003). 
1.1.4 NF-κB signalling in cellular senescence 
Activation of NF-κB occurs in senescent cells and is key to establishing the SASP (Chien 
et al., 2011). NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
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are a family of transcription factors, which regulates a large array of genes involved 
in different processes of the immune and inflammatory responses (Oeckinghaus and 
Ghosh, 2009). The NF-κB family is composed of five structurally related monomer 
proteins: NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB, and c-Rel. By binding as 
various hetero- or homo-dimers, NF-κB mediates transcription of many target genes 
(Sun et al., 2013). NF-κB family proteins are usually sequestered to the cytoplasm by 
another family of inhibitory proteins, including the IκB family and related proteins, 
characterised by the presence of ankyrin repeats (Sun, 2011). Ankyrins are another 
family of proteins that mediate the attachment of membrane proteins to the 
membrane cytoskeleton (Bennett and Baines, 2001). The inhibitor of nuclear factor 
kappa B (IκB) family members of note are: IκBα (inhibitor of κBα), p105, and p100. 
Figure 1.2. NF-κB signalling pathway. 
A simplified signalling pathway for canonical NF-κB signalling, in the context of 
cellular senescence.  
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Both p105 and p100 are precursor proteins of NF-κB1 and NF-κB2 respectively 
(Beinke and Ley, 2004). NF-κB activation involves two major signalling pathways, the 
canonical pathway and the non-canonical (or alternative) pathway. Both pathways 
are important for regulating immune and inflammatory responses despite their 
differences in signalling mechanism (Sun, 2011). The focus of this thesis is the 
canonical pathway. 
The primary mechanism for canonical NF-κB activation is the inducible degradation 
of IκBα, which is triggered through by site-specific phosphorylation by the IκB kinase 
(IKK) complex (Oeckinghaus and Ghosh, 2009). Upon activation, IKK phosphorylates 
IκBα at two N-terminal serines, whereby triggering ubiquitin-dependent IκBα 
degradation by the proteasome (Karin, 1999). Degradation of IκBα results in nuclear 
translocation of NF-κB members: p50/RelA and p50/c-Rel dimers (Beinke and Ley, 
2004).  
IKK is composed of two catalytic subunits, IKKα (IKK1) and IKKβ (IKK2), and the 
regulatory subunit, NF-κB essential modulator (NEMO or IKKγ) (Karin, 1999). NEMO 
acts as a scaffold for IKK subunits to multimerise, and for activation via trans‐auto-
phosphorylation, whilst also bringing them in proximity to upstream kinases (E.G. 
TAK1) (Iwai, 2012, Adhikari et al., 2007). IKK can be activated by different stimuli, 
including cytokines, growth factors, mitogens, microbial components, and stress 
agents (Mitchell et al., 2016).  
A well-recognized function of NF-κB is regulation of inflammatory responses. Not 
surprisingly, dysregulated NF-κB activation is a hallmark of chronic inflammatory 
diseases. Mice lacking NEMO or IKKβ die early during embryogenesis with liver 
Page 41 of 300 
degeneration, a phenotype like that of p65/RelA-deficient animals (Makris et al., 
2000, Pasparakis et al., 2006). Mice lacking IKKα die shortly after birth and show 
defective epidermal keratinocyte differentiation and skeletal abnormalities (Hu et al., 
1999, Pasparakis et al., 2006). 
1.1.4.1 Inflammaging and senescence 
Inflammaging is the term used to describe the chronic, low-grade systemic 
inflammation seen in ageing (Franceschi et al., 2000). The source of such 
inflammatory cytokines is unclear, but this inflammation occurs in the absence of 
infection and is primarily driven by endogenous signals. A major characteristic of 
inflammaging is the chronic activation of the innate immune system and 
macrophages (Franceschi et al., 2000). 
Data suggest that besides persistent infections; cell debris, misplaced self-molecules, 
and misfolded/oxidized proteins are major contributors to inflammaging (Franceschi 
and Campisi, 2014). One potential contributor to inflammaging are senescent cells 
and the accompanying senescence associated secretory phenotype (SASP).  
1.1.4.2 The role of NF-κB signalling and production of inflammatory cytokines by 
senescent cells 
Several studies have clearly demonstrated that NF-κB plays a significant role in the 
expression of most SASP factors (e.g. IL-6 and CXCL1) in several models of senescence 
(Reviewed by Malaquin et al. (2016)).  
The molecular mechanisms leading to NF-κB activation in the context of senescence 
remain poorly defined. However, genotoxic stress activates NF-κB through distinct 
sumoylation; sumoylation is a post-translational modification which involves addition 
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of SUMOs (small ubiquitin-like modifiers) (Mabb et al., 2006). In response to DNA 
damage NEMO is localized to the nucleus as a result of SUMO‐1 attachment to 
NEMO/IKKγ, assisting in the complex formation (Huang et al., 2003). The DDR can 
also activate NF-κB via ATM (Wu et al., 2006). ATM can interact with NEMO 
(Miyamoto, 2011), a regulator of the IKK complex. Activation of the DDR results in 
the export of an ATM/NEMO complex into the cytoplasm. NEMO then binds and 
activates IKKα/β, degrading IκB proteins. Degradation of IκB then results in the 
activation of NF-κB (Mitchell et al., 2016). 
Alternatively, the p38MAPK pathway may contribute to NF-κB activation. Increased 
p38MAPK signalling leads to the activation of the mitogen and stress activated 
protein kinase MSK1 (Kefaloyianni et al., 2006). MSK1 can phosphorylate the p65/NF-
κB subunit, resulting in activation (Vanden Berghe et al., 1998). Indeed, small 
molecule inhibitors of p38 MAP kinase can inhibit secretion of cytokines and the SASP 
in human fibroblasts (Alimbetov et al., 2016). 
1.1.5 Role of Senescence in vivo 
Senescence can have both positive and negative effects, depending on the context. 
Originally, senescence was thought of as a tumour suppression mechanism. Several 
studies to date have reinforced the importance of cellular senescence as a guard 
against cancer (Serrano et al., 1997, Braig et al., 2005, Collado and Serrano, 2010). 
This makes sense as the permanent cell cycle arrest described in senescence stands 
in perfect antithesis to the uncontrolled replication in cancer. Senescent cells can be 
observed in premalignant stages of tumours, although they disappear in the more 
malignant stages (Chen et al., 2005). Examples in which senescent cells have been 
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found include: prostatic intraepithelial neoplasia, lung adenomas, and melanocyte 
nevi (Michaloglou et al., 2005).  
However, other studies have shown that senescent cells develop altered secretory 
activities (SASP) that may induce changes in the tissue microenvironment, relaxing its 
control over cell behaviour and instead promoting tumorigenesis (Krtolica et al., 
2001).  
In liver fibrosis, senescent myofibroblasts accumulate in fibrotic scars following liver 
damage (Wiemann et al., 2002). These senescent cells attract immune cells, resulting 
in partial elimination of the fibrotic scars (Krizhanovsky et al., 2008).  
Another mechanism in which senescence has a positive role in is wound healing. Jun 
and Lau (2010) investigated the cell adhesive protein CCN1/CYR61, which is 
expressed at sites of wound repair (Chen and Lau, 2009). CCN1 was shown to induce 
senescence in fibroblasts via p53 activation. The resulting senescent fibroblasts have 
been shown to accumulate in granulation tissues of healing cutaneous wounds in 
mice and secrete an anti-fibrotic SASP, in wild type mice. Demaria et al. (2014) also 
investigated the role of senescent cells in wound healing. The P16-3MR animal model 
(described in Section 1.1.7) was used to demonstrate that senescent cells promote 
wound healing compared with wound healing in mice where the senescent cells were 
removed. This protection appears to be due to the senescent endothelial and 
mesenchymal cells expressing platelet derived growth factor-A (PDGF-A) as part of 
their SASP, inducing myofibroblast differentiation at the site of injury.  
Senescence and the SASP have a central role in tissue remodelling during 
embryogenesis of mammals, including humans (Munoz-Espin et al., 2013), chickens 
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(Storer et al., 2013), and quails (Nacher et al., 2006). These findings also suggest that 
this is a conserved feature of embryonic development across vertebrates. 
Senescent cells accumulate in the tissues of aged rodents (Krishnamurthy et al., 
2004), primates (Kreiling et al., 2011), and humans (Waaijer et al., 2012, Herbig and 
Sedivy, 2006). Work by Baker et al (Baker et al., 2016, Baker et al., 2004, Baker et al., 
2008, Baker et al., 2013, Baker et al., 2011) has shown a causal link between the 
accumulation of senescent cells and ageing; whereby elimination of senescent cells 
delays the onset of age related phenotypes (expanded upon in Section 1.1.7.2).  
Furthermore, studies show that senescent cells can induce senescence in 
neighbouring cells through paracrine mechanisms: (Acosta et al., 2013, Nelson et al., 
2012, Faggioli et al., 2012). Acosta et al. (2008) suggests that the SASP may act in an 
autocrine feedback loop to reinforce growth arrest. Senescent cells secrete IL-8, 
which binds to IL-8 receptor β, inducing senescence in a p53 dependant manner in 
other cells. This SASP mediated effect on other cells has been called the bystander 
effect (Nelson et al., 2012). 
1.1.6 A comparison of senescence across tissues 
A systematic review and meta-analysis of cellular senescence across different tissues 
with age was performed by Tuttle et al. (2020). The authors identified 38 articles, 
which together described 83 associations between senescence and chronological 
age, with pancreas, brain and lung showing the highest correlation.  Senescence in 
adipose, gut, prostate, and thymus tissues was not significantly correlated with age. 
Senescence associated DNA damage markers had the highest correlation with age, 
followed by cell cycle regulators, whilst proliferation markers had the lowest 
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correlation with age. Whilst there was a positive correlation between senescence in 
skin with age, there was significant heterogeneity within skin sections (dermis, 
epidermis, facial, and abdominal). This heterogeneity between sub-tissues was also 
seen in kidneys. The authors then go on to investigate the association of senescence 
with age where multiple senescent markers have been used in one tissue sample 
(Tuttle et al., 2020).  
The authors go on to investigate the association of senescence markers in multiple 
tissue sections within a specific tissue. Overall, a positive association between 
senescence and age was observed, irrespective of the marker used to determine 
senescence. However, significant heterogeneity was observed within each tissue 
type, as the expression of senescent markers varied between different subtypes 
(Tuttle et al., 2020).   
There are little data available on senescence within different organ systems from the 
same individual. Dock et al. (2017) investigated cellular senescence by comparing 
intra-individual differences in multiple parameters of human T cells in two distinct 
immune compartments, namely the peripheral blood and gut mucosa. To summarise, 
changes that occur in CD8+ T cells peripheral blood in ageing are not reflected in T 
cells from the gut mucosa. Studies that investigated the difference in senescence 
within tissues of the same organ showed that, despite higher senescence within these 
tissues, the degree of senescence varied based on the tissue/cell type investigated 
(Tuttle et al., 2020). Indeed, Chatsirisupachai and colleagues investigated the RNA‐
Seq‐based gene expression of noncancerous tissues from humans and reported 
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higher and yet varying expression of senescence‐associated genes in aged tissue 
samples (Chatsirisupachai et al., 2019).  
Some of these differences may be attributed to post-mitotic tissue within the 
samples investigated. There has been limited interest in senescence in post-mitotic 
tissue. However, von Zglinicki et al. (2020) investigated indices of senescence in 
several different post-mitotic tissues in geriatric mice and showed that post-mitotic 
tissue, including skeletal muscle fibres can display evidence of senescence. The 
heterogeneity may also be due to the senescence markers used. Many of the studies 
used only a single marker to validate cellular senescence, which can cause issues as 
DNA damage does not always equal cellular senescence (von Zglinicki, 2002), SA-β-
Gal is expressed by cells at confluence and quiescent cells, and by some differentiated 
cells, such as adult melanocytes (Dimri et al., 1995) and maturing tissue macrophages 
(Bursuker et al., 1982). 
1.1.7 Animal models of senescence  
1.1.7.1 Senescence Accelerated Mouse-Prone (SAMP) mice 
The earliest animal models designed to investigate cellular senescence are the 
Senescence Accelerated Mouse (SAM) model, described in detail by Takeda et al. 
(1991). In 1968, several pairs of the AKR/J strain of mice were donated by the Jackson 
Laboratory (Bar Harbor, USA) to the Department of Pathology, Chest Disease 
Research Institute, Kyoto University, Japan. Whilst maintaining the strain, 
researchers identified accelerated onset of age-related pathologies within the 
population. The strain was refined to produce the first Senescence Accelerated 
Mouse-Prone (SAMP) mice (Takeda et al., 1981). At present, there are 12 strains of 
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these mice, all originated from the original strain. SAMP strains include SAMP1-3, 6-
ll; and the senescence-resistant inbred strains (SAMR): SAMR1, SAMR4, and SAMR5. 
These mice showed accelerated onset of age-related pathologies such as loss of fur, 
coarse skin, lordokyphosis (a measure of sarcopenia), as well as shortened lifespans.  
1.1.7.2 INK-ATTAC mice 
Baker et al. (2011) designed a transgenic mouse model to examine the effect of the 
presence and clearance of senescent cells on tissue function. These transgenic mice 
were based on FAT-ATTAC (fat apoptosis through targeted activation of caspase) 
mice, a model where adipocytes were induced into apoptosis by administering a 
synthetic drug AP20187 (Pajvani et al., 2005). The drug induces dimerisation of 
membrane-bound myristoylated FK506-binding-protein–caspase 8 (FKBP–Casp8) 
fusion protein, expressed specifically in adipocytes via the Fabp4 promoter. 
Myristoylation is when a myristoyl group, derived from myristic acid, is covalently 
attached via an amide bond, to the alpha-amino group of an N-terminal glycine 
residue. 
The FAT-ATTAC model was adapted for the p16INK4A gene, a common marker of 
senescence where it has been shown to increase in senescent cells (Section 1.1.2). 
The Fabp4 promoter was replaced with a 2,617-bp fragment of the p16INK4A gene 
promoter. The mice were named INK-ATTAC, after the INK4A gene. 
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Baker et al. (2008) investigated the accumulated of senescent cells in ageing using 
BubR1H/H mice, a mitotic checkpoint protein, a mouse model that suffers from DNA 
damage due to premature separation of sister chromosomes and is a model of 
accelerated ageing. These mice have been characterised and display phenotypes such 
as a shortened lifespan, lordokyphosis (abnormally excessive curvature of the spine), 
and sarcopenia, amongst other pathologies (Baker et al., 2004). BubR1H/H were bred 
with p16 knockout mice (p16Ink4a−/−) to give BubR1H/H: p16Ink4a−/− mice. To determine 
whether BubR1 may have a role in normal skeletal muscle ageing, protein levels were 
measured, and transcripts were quantified in the gastrocnemius of 2- and 35-month-
old mice. There was an age-related decline in the expression of BubR1 in skeletal 
muscle, as well as an age-related increase in p16 expression. Gastrocnemius of 2- and 
5-month-old BubR1H/H mice also had high p16 expression. Furthermore, BubR1H/H 
mice showed an increase in SASP components IGFBP2, MMP13, and Pai1. Knocking 
out p16 in this animal model improved fibre size in gastrocnemius, reduced the 
instances of lordokyphosis, and reduced the expression of SASP.  
Figure 1.3 Schematic of INK-ATTAC mice transgene 
Myristolyated FKBP bound Cas8 dimerise at the cell membrane in the presence of 
AP20187, inducing apoptosis. Adapted from Baker et al. (2011).  
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The INK-ATTAC mice were first used by Baker et al. (2011). The authors had crossed 
the INK-ATTAC model with a BubR1H/H progeroid strain, to investigate the role of 
cellular senescence in the age-related disorders linked to BubR1H/H progeroid 
syndromes. Results showed that in the BubR1H/H progeroid mouse background, INK-
ATTAC removed p16Ink4a-positive senescent cells upon treatment with AP20187. 
This study demonstrated that lifelong elimination of p16 positive cells delayed the 
onset of age-related pathologies in adipose tissue, skeletal muscle, and eye; 
compared with the BubR1H/H mice alone.  
Much of this work was undertaken in mice of or 10 months of age. Baker et al. (2016) 
revisited the model, using older mice between 12 and 18 months old. Furthermore, 
two different cohorts of INC-ATTAC mice were established and analysed. The first 
cohort consisted of mice of a mixed 129Sv (40% ±5%) × C57BL/6J (35% ±5%) × FVB 
(20% ±5%) genetic background. These mice were treated with 0.2μg/g body weight 
of AP20817, between 12 and 18 months; and 2.0 μg/g body weight AP20187 thereon. 
The second cohort was established onto a pure C57BL/6J genetic background, which 
received 2.0 μg/g body weight AP20187 from 12 months of age until end of life. Both 
groups received the appropriate vehicle controls.  
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1.1.7.3 P16-3MR 
Another mouse model used to investigate cellular senescence is the p16-3MR model. 
This animal model was first presented by Demaria et al. (2014). To identify, isolate, 
and selectively kill senescent cells, the 3MR (trimodality reporter) fusion protein, 
which contains functional domains of a synthetic Renillaluciferase (LUC), monomeric 
red fluorescent protein (mRFP) and truncated herpes simplex virus 1 (HSV-1) 
thymidine kinase (HSV-TK) (Ray et al., 2004) were used. The LUC allows the detection 
of cells via luminescence. The mRFP further permits sorting of these positive cells 
from other tissues. Finally, HSV-TK allows selective elimination of p16 expressing cells 
by ganciclovir (GCV), a nucleoside analogue. GCV has a high affinity for HSV-TK but 
low affinity for the cellular thymidine kinase. HSV-TK converts GCV into a toxic DNA 
chain terminator; in non-dividing senescent cells, GCV causes fragmentation of 
mitochondrial DNA, with subsequent death by apoptosis (Laberge et al., 2013). 
Figure 1.4 Schematic of the p16-3MR transgene. 
P16 expressing cells express a fluorescent mRFP, as we all HSV-Tk which 
phosphorylates GCV to GCV-P inducing apoptosis. Adapted from Demaria et al. 
(2014). 
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Much of the work conducted using these mice focused on senescent fibroblasts and 
endothelial cells in response to cutaneous wounds. At the site of injury, senescent 
cells accelerate wound closure inducing myofibroblast differentiation through the 
secretion of platelet-derived growth factor AA (PDGF-AA). Elimination of senescent 
cells resulted in poor wound healing, compared with control mice. The work 
presented is novel as it is demonstrating a beneficial role of the SASP in tissue repair 
and adding an evolutionary context to the SASP. 
Whilst transgenic animal models provide a powerful tool to investigate the roles of 
cellular senescence, genetic modifications of humans would not be equally possible. 
Therefore, a more pharmacological approach would be more appropriate in the 
development of interventions to remove senescent cells. 
1.1.8 Senolytics 
Senolytics (from the words “senescence” and “lytic” – destroying) are small molecule 
compounds that selectively induce the death of, or clearance of senescent cells. The 
aim of senolytics are to reverse the negative phenotype caused by the presence of 
senescent cells. Senescent cells accumulate with ageing, and have been linked with 
the ability to compromise the structure and function of tissue and their 
microenvironments (Herbig et al., 2006, Krishnamurthy et al., 2004, van Deursen, 
2014, Waaijer et al., 2012). In part, this is due to the previously described senescent 
associated secretory phenotype (SASP), which includes cytokines, chemokines, and 
matrix remodelling proteins (Section 1.1.5). Several reviews have highlighted the 
potential role of senescent cells and the SASP in ageing-related conditions 
(LeBrasseur et al., 2015, Munoz-Espin and Serrano, 2014). Furthermore, studies that 
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have removed senescent cells via drug-inducible ‘suicide’ genes (i.e. INK-ATTAC 
(Section 1.1.7.2), P16-3MR (Section 2.1.2)) showed enhanced health span, and delays 
in the development in multiple age-related phenotypes in genetically modified 
progeroid mice (Baker et al., 2011).  
Thus, pharmacological interventions that target senescent cells and/or the SASP may 
potentially ameliorate age-related chronic diseases and disabilities, and even extend 
health span. Zhu et al. (2016) used a bioinformatics-based approach to identify 
potent senolytic agents that would induce apoptosis preferentially in senescent cells 
without damaging proliferating, quiescent, or differentiated cells throughout the 
body. From this approach, two compounds were selected as candidate senolytics, 
and were tested in vivo: Dasatinib and Quercetin.  
Dasatinib, also named Sprycel, is an oral chemotherapy medication used to treat 
chronic myelogenous leukaemia (CML), and acute lymphoblastic leukaemia (Talpaz 
et al., 2006). Dasatinib is an inhibitor of multiple tyrosine kinases and platelet-derived 
growth factor (PDGFR)-β. Dasatinib can have side effects, occasionally including 
pulmonary oedema, which can occur after months of daily administration (Montani 
et al., 2012). 
Quercetin, a plant flavonol from the flavonoid group of polyphenols can be found in 
appreciable amounts in organic produce such as fruits, vegetables, leaves, grains, red 
onions, and kale. Quercetin is used as an ingredient in dietary supplements, 
beverages, and foods. Quercetin has been reported to be an antioxidant (Williams et 
al., 2004, Russo et al., 2014). 
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1.1.8.1 Polyphenols in vivo  
Dasatinib and quercetin both have short elimination half-lives (Christopher et al., 
2008, Graefe et al., 2001), supporting the possibility that their beneficial effects on 
late-life function and survival are at least partially due to a mechanism that persists 
long after the drugs are no longer present, such as senescent cell elimination 
Xu et al. (2018) transplanted senescent cells into mice and demonstrated that the 
presence of small number of senescent cells were sufficient to cause persistent 
physical dysfunction and reduced survival. Furthermore, treatment of these mice and 
old mice (24- to 27-month-old) with dasatinib (5 mg/kg) and quercetin (50 mg/kg) via 
oral gavage alleviated physical dysfunction and increased survival in both models.  
Ogrodnik et al. (2017) investigated the use of dasatinib and quercetin in INK-ATTAC 
transgenic mice. AP20187 (10 mg/kg) was administered to 24-month-old mice by 
intraperitoneal injection every 3 days, for 3 months. For senolytic treatment, 
dasatinib (5 mg kg 1) and quercetin (10 mg/kg) in combination were administered by 
oral gavage once per month for 3 months. The elimination of senescent cells by 
suicide gene-meditated ablation of p16Ink4a-expressing senescent cells in INK-ATTAC 
mice or by treatment with a combination of the senolytic drugs dasatinib and 
quercetin reduced overall hepatic steatosis. 
Schafer et al. (2017) treated mice with dasatinib plus quercetin to prevent 
pulmonary disease by potentially clearing senescent cells. The secretome of 
senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib 
plus quercetin, is fibrogenic. Thus, these findings establish that fibrotic lung 
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disease is mediated, in part, by senescent cells, which can be targeted by senolytics 
to improve health and function. 
Roos et al. (2016) treated 24-month-old mice with dasatinib plus quercetin to 
reduce senescent cell burden and improve vascular function in old mice. C57BL/6J 
mice were treated with dasatinib and quercetin once per month from 24-27 months 
of age. This was the first study to demonstrate that chronic clearance of senescent 
cells improved established vascular phenotypes associated with ageing and chronic 
hypercholesterolemia and may be a viable therapeutic intervention to reduce 
morbidity and mortality from cardiovascular diseases related to ageing. 
1.1.8.2 Other Senolytics  
The earliest, commonly accepted definition of polyphenols, the White–Bate-Smith–
Swain–Haslam (WBSSH) definition (Haslam and Cai, 1994) describes polyphenols as 
water soluble compounds, molecular weight of 500–4000 Da with >12 phenolic 
hydroxyl groups, and 5–7 aromatic rings per 1000 Da. 
Several hundred different polyphenols are found in plant-based foods including 
vegetables (particularly, broccoli, onion and cabbage), fruits (grapes, pears, apples, 
cherries. and various berries contain up to 200–300 mg polyphenols per 100 g fresh 
weight), legumes (soybean), cereals, plant-derived beverages and chocolate 
(extensively reviewed by Tressera-Rimbau et al. (2017)). 
The majority of polyphenols are not absorbed in their native form, but are instead 
metabolised by intestinal enzymes and/or colonic microflora (Scalbert et al., 2002). 
These metabolites are further modified to allow entry into the blood and tissues. 
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Thus the state of the polyphenols that are present in food are often very different to 
the ones that reach the blood and tissues (Scalbert et al., 2002). 
Current research on polyphenols in health and disease has focused on their role as 
therapeutics, due to their antioxidant and anti-inflammatory properties (Hussain et 
al., 2016) and this has been extensively reviewed (Serino and Salazar, 2018). The 
consensus appears to be that improved cardiovascular disease (CVD) outcomes are 
seen in humans with increased dietary polyphenol consumption.  
Fisetin (7, 3′, 4′-flavon-3-ol) is a plant-based polyphenol from the flavonoid group. 
Fisetin can be found in a wide variety of plants, examples of which includes fruits and 
vegetables such as strawberries, apples, and grapes (Arai et al., 2000).  
The role of fisetin as a senolytic is unclear but a study by Yousefzadeh et al. (2018) 
used fisetin in mice as a senolytic. These authors reported an increase in lifespan, 
reduction of senescence cell markers as well as reduction of age-related pathologies. 
The effect appears to be derived from the ability of fisetin to block the 
PI3K/AKT/mTOR pathway (Syed et al., 2013) (See Section 1.1.8.3), as well as the 
ability to interfere with cell cycle progression (Gupta et al., 2014). In contrast, fisetin, 
as well as some other flavonoids, have been described as topoisomerase inhibitors, 
which may cause DNA damage and carcinogenic effects. Furthermore, whilst fisetin 
may be safe, metabolites generated from it may have harmful side effects and 
caution should therefore be used (Kroon et al., 2004). 
Fisetin is a sirtuin activating compound, like many other polyphenols. Sirtuins are a 
heavily conserved class of proteins with deacetylase activity. There are 7 sirtuins in 
mammals, in 4 different classes: SIRT1‐3 are in class I, SIRT4 in class II, SIRT5 in class 
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III, and SIRT6‐7 in class IV (O'Callaghan and Vassilopoulos, 2017). Sirtuins can also be 
categorized by which subcellular compartment they reside in, SIRT1, 6, and 7 in the 
nucleus, SIRT3, 4, and 5 in the mitochondria, and SIRT2 is predominately in the 
cytoplasm (O'Callaghan and Vassilopoulos, 2017). Sirtuins have been shown to 
extend the life span of simple organisms like yeast, worms and flies (Baur, 2010, 
O'Callaghan and Vassilopoulos, 2017). However, the efficacy of sirtuins are still being 
elucidated (Aunan et al., 2016).  
1.1.8.3 mTOR signalling 
The MAPK/ERK pathway (also 
known as the Ras-Raf-MEK-ERK 
pathway) communicates 
mitogen binding to receptors on 
the cell membrane. These 
signals are passed along a chain 
of proteins to elicit cellular 
effects.  
In brief, the binding of mitogen 
to receptors allows for the 
GTPase, Ras, to replace GDP 
with GTP; allowing Ras to 
activate Raf (MAP kinase kinase kinase, MAP3K, or MEKK). Raf in turn activates 
Mitogen-activated protein kinase kinase (MAP2K, MEK, MAPKK) which in turn 
activates mitogen-activated protein kinase (MAPK, MAP kinase). MAPK, originally 
Figure 1.5 The MAPK/ERK and mTOR signalling 
pathways 
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called ERK (extracellular regulated kinases), can activate transcription factors, 
compounding the signalling cascade.  
An interesting downstream target of the MAPK/ERK pathway is mTORC1. ERK1 and 
ERK2 phosphorylate TSC2, inhibiting the GTPase activating protein (GAP) activity of 
TSC1–TSC2 towards Ras homologue enriched in brain (Rheb) (Ma et al., 2005). Rheb-
GTP directly interacts with mTORC1 and strongly stimulates its kinase activity, 
whereas Rheb-GDP little activity (Long et al., 2005). 
The mTOR signalling pathway is a powerful target to modulate ageing and lifespan; 
as shown by studies in yeast (Kaeberlein et al., 2005), worms (Vellai et al., 2003), flies 
(Bjedov et al., 2010), and mice (Harrison et al., 2009). In skeletal muscle, mTOR 
signalling pathways play a key role in cellular growth (Deldicque et al., 2005). Chronic 
inflammation, as seen with inflammaging and sepsis, has been shown to decrease 
activation of the mTORC1 signalling pathway, resulting in reduced muscle mass (Frost 
and Lang, 2011). 
Castilho et al. (2009) demonstrated that chronic expression of Wnt1 protein in the 
epidermis of FVB/N mice results in chronic mTOR signalling and lead to excessive 
proliferation of epithelial stem cells. This hyper-proliferation led the stem cell to 
become senescent, expressing SA-β-Gal and p21, and further diminished the stem 
cell niche. This phenotype could be rescued via inhibition of mTOR signalling 
pathways.  
Chen et al. (2009) constitutively activating of mTORC1, in haematopoietic stem cells 
(HSC) of mice resulted in the HSCs becoming senescent, expressing p16 and p21. 
Furthermore, inhibition of mTOR with rapamycin also reversed the age-associated 
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loss of HSC function, enhancing the immune response of old mice and preserving the 
pool of HSCs to levels comparable of young mice.  
The mTOR signalling pathway promotes the pro-inflammatory phenotype of 
senescent cells. Laberge et al. (2015) demonstrated that administering rapamycin to 
senescent fibroblasts suppressed the secretion of inflammatory cytokines as part of 
the SASP. Rapamycin reduced the mRNA levels of IL-6 and other cytokines and 
suppressed translation of the membrane-bound cytokine IL-1a. Reduced IL-1a in turn 
diminished NF-κB transcriptional activity, which controls much of the SASP. 
1.1.9 A comparison of senescence in mouse and human cells 
Dimri et al. (1995) identified that human fibroblasts have a limited lifespan in culture, 
and enter terminal growth arrest after 50–80 population doublings. Soon after the 
limited lifespan of human cells was discovered, a similar phenomenon was described 
in mouse fibroblasts (Todaro and Green, 1963).  One difference between mouse and 
human cells is that human cells never spontaneously immortalise in culture, whereas 
murine cells do. Furthermore, the replicative lifespan of murine cells is much lower 
than that of humans. These differences may be attributed to telomeres (Gorbunova 
and Seluanov, 2010). A telomere is a region of repeated nucleotide sequences at each 
end of a chromosome, which protects the end of the chromosome from 
deterioration, or from fusion with other neighbouring chromosomes (Jiang et al., 
2018). Normal human somatic cells (except stem cells), have no detectable 
telomerase activity, and their telomeres shorten with every division (Harley et al., 
1990). In prolonged culture, the telomeres of human fibroblasts reach a critical length 
and lose protective protein structures. The attrition of telomeres ultimately activates 
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the DNA-damage response (DDR), resulting in senescence (von Zglinicki, 2002). 
Human telomeres are on average 8–15 kb long, whilst murine telomeres are much 
longer, although this varies significantly between rodent species. Indeed, common 
inbred mouse strains have telomeres of 150 kb, whilst wild mice have shorter 30 kb 
telomeres (Kipling and Cooke, 1990). Furthermore, telomerase is expressed in 
multiple tissues of adult mice, and in cultured mouse fibroblasts (Prowse and Greider, 
1995). These data suggest that the lower replicative lifespan of murine cells when 
compared with humans is independent of telomere length and telomerase activity 
(Gorbunova and Seluanov, 2010).  
The reason behind this difference was investigated by Judith Campisi, who 
demonstrated that mouse fibroblasts do not senesce when cultured in 3% oxygen 
(Parrinello et al., 2003). Under physiological oxygen concentration, mouse cells 
proliferate indefinitely, similar to immortalized human cells. Thus, senescence of 
mouse cells is caused by oxidative stress (Gorbunova and Seluanov, 2010). Indeed, 
replicative senescent murine fibroblasts under standard culture conditions (20% 
oxygen), do not express a human-like SASP, and differ from similarly cultured human 
cells in other respects. However, when cultured in physiological (3%) oxygen and 
induced to senesce by radiation, mouse cells more closely resemble human cells, 
including expression of a robust SASP (Coppe et al., 2010b). 
Cellular signalling may also be different between murine and human cells. As 
described in Section 1.1.3.3, senescence is typically activated in a p53 → p21 → pRb 
dependant manner (Gorbunova and Seluanov, 2010). The majority of mouse 
fibroblasts that spontaneously escape senescence carry a mutated p53, combined 
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with data from embryonic fibroblasts lacking p21 undergo senescence normally 
(Pantoja and Serrano, 1999) suggest that murine cells have different signalling 
pathways for cellular senescence than humans (Gorbunova and Seluanov, 2010).  
1.1.10 Summary 
In summary, senescence is proposed to play a major role in the development of age-
related pathologies and there is a potential for intervention in this process with 
senolytics. There is limited data examining the role of senescence in the 
determination of terminally differentiated tissues such as skeletal muscle.  
1.2 Introduction to skeletal muscle 
Skeletal muscle is one of three major muscle types within the human body, the others 
being cardiac muscle and smooth muscle. Skeletal muscle plays a significant role in 
maintaining posture, motility, and thermoregulation; and can act as a storage for 
amino acids and carbohydrates (Wolfe, 2006). Skeletal muscle accounts for 40% of 
total body weight, and 50-75% of total body protein (Frontera and Ochala, 2015).  
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1.2.1 Skeletal muscle structure and function 
The structural design of skeletal muscle is characterised by a logical, hierarchal 
arrangement of multinucleated, post-mitotic muscle fibres (also referred to as 
Figure 1.6 Structure of skeletal muscle 
The relationship of a whole muscle to a single muscle fibre (A-C). The features of 
a single myofibril (D). Cytoskeletal components of a myofibril (E). Adapted from 
(Frontera and Ochala 2015).  
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myofibres or muscle cells), connective tissue and other cell types (Frontera and 
Ochala, 2015) (Figure 1.6).  
Skeletal muscle is comprised of bundles of muscle fibres surrounded by connective 
tissue layers called fasciae. Fibres can encompass the entire length of the muscle and 
are approximately 10-100 µm in diameter. Muscle fibres are formed from the fusion 
of multiple myoblasts via myogenesis, resulting in a single post-mitotic, multinuclear 
muscle cell (Figure 1.6C). The force the whole muscle can generate is determined by 
number of parallel myofibres within these fascicles and the quality of the fascicles. 
The number of these myofibres in a muscle is determined at birth and little change 
occurs during life span (Alnaqeeb and Goldspink, 1987, Klein et al., 2003). However, 
the cross-sectional area of a muscle fibre is very plastic, capable of change 
throughout life in response to hypertrophy and atrophy (Maughan et al., 1984, Berg 
et al., 1991). Myofibres are comprised of numerous filaments called myofibrils.  
Skeletal muscle has a striated appearance created by overlapping region of thick 
myosin and thin actin filaments termed the sarcomere (Figure 1.6E). This filament 
patterning repeats the length of the muscle fibre. As illustrated, a single sarcomere is 
made up of dark A bands and light I bands. Thin filaments of actin make up the light 
I bands, whilst the H zones are comprised of myosin. The two sections cross in the A 
band to create a dark overlap. The A band is separated by a dark line known as the M 
line, and it is this distance between two Z discs that is known as a sarcomere (Figure 
1.6D). Other molecules that play a role in muscle architecture are titin and nebulin. 
Molecules of titin extend from the Z disc to the M line and act as springs to keep 
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myosin filaments centred in the sarcomere. Molecules of nebulin extend from the Z 
disc and are thought to determine the length of associated actin filaments. 
1.2.2 Sliding filament theory of muscle contraction 
First proposed by Huxley in 1954 (Huxley and Hanson, 1954) and verified in 1957 
(Huxley, 1957), the basic mechanism of skeletal muscle contraction is known as the 
“sliding filament hypothesis” (Figure 1.7) and has been adapted several times.  
Skeletal muscle contraction is reliant on nervous input, whereby an action potential 
arrives at the neuromuscular junction, releasing the neurotransmitter acetylcholine 
(Ach). Ach causes the depolarisation of the motor end plate, which travels throughout 
the muscle by the transverse tubules (T-tubules), resulting in the release of calcium 
(Ca2+) from the sarcoplasmic reticulum (Ashley and Ridgway, 1968). At rest, actin and 
Figure 1.7 Skeletal muscle contraction. 
Simplified diagram of the ATP fuelled power stroke of the myosin-actin cross 
bridge. Ca2+ binds to troponin, exposing the acting active site (1). Myosin binds to 
actin, forming a cross bridge (2). ADP and Pi are released as part of the power 
stroke (3). ATP binds myosin, uncoupling the cross bridge (4). Adapted from 
(Frontera and Ochala 2015). 
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myosin are not cross-linked due to the presence of the troponin-tropomyosin 
complex. Tropomyosin occupies the niche in the actin filament which contains the 
myosin binding region (Parry and Squire, 1973). At high concentrations, Ca2+ binds to 
troponin, changing conformational shape; moving tropomyosin from the binding site 
of actin (Lehman et al., 1994). Myosin filaments can now attach to the actin, forming 
a cross-bridge. The detailed structure of the myosin head was only described for the 
first time in 1993 (Rayment et al., 1993) and has further contributed to our 
understanding of this process (Frontera and Ochala, 2015).  
The hydrolysis of ATP into ADP and inorganic phosphate (Pi) releases energy, which 
enables the myosin to pull the actin filaments inwards and so shortening the muscle. 
Hydrolysis of ATP strengthens the cross-link between actin and myosin, and this 
ATPase activity of myosin dictates the speed of the power stroke (Barany, 1967). This 
occurs along the entire length of every myofibril in the muscle cell. When an ATP 
molecule binds to the myosin head, the myosin detaches from the actin and the 
cross-bridge is broken. When the ATP is then hydrolysed, the myosin head can again 
bind further along the actin filament and repeat the power stroke. This repeated 
pulling of the actin over the myosin is often known as the ratchet mechanism. 
Muscular contraction can last for as long as there is ATP and free Ca2+. Once the 
impulse stops, the Ca2+ is pumped back to the sarcoplasmic reticulum and the actin 
returns to its resting position causing the muscle to relax. A single power stroke 
results in only a shortening of approximately 10nm (Spudich, 2001).  
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1.2.3 Skeletal muscle fibre types 
Skeletal muscle can be divided into two types: type I and type II. Fibre types are 
identified by different isoforms of myosin heavy chain (MHC). MHCs are generally 
classified into groups: MHC I, MHC IIa, and MHC IIx; due to different isoforms of 
myosin ATPases: I, IIa and IIx (Brooke and Kaiser, 1970). 
Type I fibres are also known as slow twitch fibres. Type I fibres have a red colouring 
due to large volumes of intracellular myoglobin (Jansson and Sylven, 1983), high 
density capillary networks (Duey et al., 1997), and high numbers of mitochondria 
(Ingjer, 1979), compared with type IIB fibres. The energy type I fibres use primarily 
comes from the oxidative phosphorylation of triglycerides. The amount of ATP these 
fibres produce give them a high resistance to fatigue, thus making them capable of 
producing contractions for a long period under aerobic conditions. Type I fibres are 
typically weaker, producing less force than type 2 fibres (Bottinelli et al., 1996). 
Type IIA fibres, also known as fast-twitch oxidative fibres, are usually classified as 
intermediate fibres. These fibres contain moderate levels of mitochondria, 
capillaries, and myoglobin when compared with type I and type IIB fibres (Ingjer, 
1979, Jansson and Sylven, 1983). Type IIA fibres also make use of glycolysis, oxidative 
phosphorylation of glycogen, and creatine phosphate as sources of energy. These 
fibres are used during long-term, anaerobic exercise, and are moderately resistant to 
fatigue.  
Type IIB fibres are known as fast-twitch, glycolytic fibres. Type IIB fibres are generally 
whiter in colour as they have lower levels of mitochondria, myoglobin, and a less 
dense capillary network than type I fibres (Ingjer, 1979). Type IIB utilise the glycolysis 
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of ATP and creatine phosphate for energy. Type IIB fibres are used for short anaerobic 
exercises that require rapid high forces, and quickly become fatigued; an example of 
which would be a short distance sprint.  
A third type of fast-twitch fibre has also been identified, type IIX. Type IIX fibres have 
a phenotype and display physical properties in between that of types IIA and B 
(Schiaffino and Reggiani, 2011).  
In humans, the majority of muscles contain type I and type IIA/B/X fibres (Edgerton 
et al., 1975). These fibre types exist in a spectrum, from purely of one type to a hybrid 
composition, according to the scheme: I ↔ I/IIA ↔ IIA ↔ IIA/IIX ↔ IIX ↔ IIX/IIB 
↔ IIB (Schiaffino and Reggiani, 2011). The proportion of each fibre type can change 
following exercise (Simoneau et al., 1985). Human single fibres and single myosin 
molecules force generation have been measured in vitro and these studies show that 
type I myosin (slow) produce less force than type II myosin (fast) (Frontera et al., 
2000, Li and Larsson, 2010). However, no differences among sub-types of fast myosin 
(IIA, IIB, or IIX) were reported (Frontera et al., 2000, Li and Larsson, 2010). 
1.2.4 Sarcopenia – loss of muscle mass and function with ageing 
The term ‘sarcopenia’ is derived from the Greek phrase “poverty of flesh” and was 
first used over 25 years ago (Evans and Campbell, 1993) and has been shown to occur 
in human (Sousa-Victor et al., 2014) and animal models (Lushaj et al., 2008).  
The definition of sarcopenia has since been revised repeatedly. The European 
Working Group on Sarcopenia in Older People (EWGSOP) (Cruz-Jentoft et al., 2010), 
the European Society for Clinical Nutrition and Metabolism Special Interest Groups 
(ESPEN-SIG) (Muscaritoli et al., 2010), the International Working Group on Sarcopenia 
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(IWGS) (Fielding et al., 2011), the Asian Working Group for Sarcopenia (AWGS) (Chen 
et al., 2014), and the Foundation for the National Institutes of Health (FNIH) 
Sarcopenia Project (Studenski et al., 2014) have all published evolving definitions of 
sarcopenia, based on robust studies in humans. It was only recently that sarcopenia 
received a clinical definition, consensus diagnostic criteria, International 
Classification of Diseases 10th Revision (ICD-10) codes or treatment guidelines 
(Falcon and Harris-Love, 2017). Sarcopenia can be described as an age-related loss of 
skeletal muscle that may result in diminished muscle strength and functional 
performance (Falcon and Harris-Love, 2017). 
Sarcopenia affects humans from approximately the 4th decade of life (Lexell et al., 
1988), with a decrease of 30-50% in skeletal muscle mass and function by 
approximately 80 years of age (Akima et al., 2001). More recent studies have shown 
that after the age of 30, about 0.5–1% of skeletal muscle mass is lost per year, with 
the rate of loss accelerating after the age of 65 (Kyle et al., 2001, Melton et al., 2006). 
On average, 5–13% of individuals aged over 60 have low skeletal muscle mass, with 
the prevalence increasing to as high as 50% in those over of 80 (Morley et al., 2014). 
Rodents are commonly used as models of human muscle ageing and C57Bl6 mice are 
the most widely used strain as models of human ageing. The core changes that 
regulate muscle ageing in humans have been observed in rodents, indicating that 
mice and rats are model organisms to study human sarcopenia (Demontis et al., 
2013). Advantages of using rodent models for investigation of human ageing 
includes: a mammalian system with a relatively short life span, large cohorts of 
offspring, and ability for genetic manipulation.  
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Ageing humans show loss of muscle fibres and rats and mice also show reduced 
muscle fibres with ageing, particularly in the hind limb muscles (McArdle et al., 2004, 
Brooks and Faulkner, 1991, Brooks and Faulkner, 1988). The maximum isometric 
force decreases more than muscle mass during ageing in mice in a similar manner to 
humans, even when expressed relative to the cross-sectional area of the muscle 
(Faulkner et al., 1995, Gonzalez and Delbono, 2001). Thus, the age-related loss of 
muscle strength cannot be solely explained by the loss of muscle mass: both muscle 
‘quantity’ and ‘quality’ decline in aged animals (Demontis et al., 2013). Studies from 
our group, colleagues, and the community have shown that the time course and 
characteristics of contraction-induced muscle injury and recovery are similar for mice 
(Faulkner et al., 1989, Faulkner et al., 1995), rats (Macpherson et al., 1997, Van Der 
Meulen et al., 1997), and humans (Faulkner et al., 1993).  
1.2.4.1 Mechanisms responsible for the development of sarcopenia 
Sarcopenia presents as a reduced muscle mass and function. This may be attributed 
in part to a decrease in fibre number, with a decreased muscle cross-sectional area, 
atrophy of the remaining fibres, and poor regeneration following damage (Lexell et 
al., 1988, Brooks and Faulkner, 1990). There is also evidence for a change in the ratio 
of type II (fast) fibres to type I (slow) fibres since type II fibres have been shown to be 
more susceptible than type I fibres to sarcopenia, resulting in a further reduction in 
maximal force (Larsson et al., 1978, Lexell et al., 1988). However, there are some 
conflicting studies that provide evidence of no difference in the percentage of type I 
and type II fibres with age (Lexell et al., 1988). The functional capacity (i.e. strength 
and power) of skeletal muscle decreases with increasing age to a greater degree than 
muscle mass itself (Newman et al., 2003).  
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By the age of 70, the muscle fibre cross-sectional area (CSA) of skeletal muscle is 
reduced by approximately 30% (Porter et al., 1995). This loss of CSA is accompanied 
by loss in absolute force generation (Grimby and Saltin, 1983) as well as a decrease 
in specific force (normalized by CSA) of the remaining muscle (Morse et al., 2005).  
One mechanism which may contribute to the development of sarcopenia is the loss 
of motor units which innervate the muscle (Jackson, 2020). Motor units suffer 
damage and are subject to turnover, whereby new motor units and terminal axons 
sprout and regrow to re-innervate the muscle (Delbono, 2003). However, the re-
innervation of neuromuscular junctions does not occur as effectively in ageing, 
resulting in a loss of NMJs in old humans and mice (Larsson and Ansved, 1995). 
Indeed, A 25–50% reduction in the number of motor neurons occurs in both humans 
(Tomlinson and Irving, 1977) and mice (Rowan et al., 2012) with ageing. Our group 
has sought to elucidate the role of denervation in ageing in the development of 
sarcopenia and frailty (Jackson, 2020).  
The mechanisms underlying the development of sarcopenia are not completely 
understood. It is likely that sarcopenia is a multi-factorial disease with a network of 
interacting, dysfunctional systems. However, there are several proposed processes: 
1.2.4.2 Satellite cells and sarcopenia 
Satellite cells are stem cells present in muscle, found between the cell membrane and 
basal lamina, and are necessary for skeletal muscles to regenerate, especially 
following injury (Shafiq and Gorycki, 1965). Satellite cells are usually in a quiescent 
state and are activated during myogenesis and muscle regeneration. The activated 
satellite cells can then proliferate and either: differentiate to repair damage or self-
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renew to maintain the pool of satellite cells. The number of satellite cells has been 
shown to decline with increasing age (Day et al., 2010). The loss of satellite cells with 
age may occur in a fibre type specific manner. Verdijk et al. (2014) showed that in 
humans, type II muscle fibre size was substantially smaller with increasing age in 
adults and this was accompanied by an age-related reduction in type II muscle fibre 
satellite cell content. The decrease in number of satellite cells is a potential 
contributor to the detrimental phenotype of ageing muscle. McKay et al. (2013) 
showed that satellite cell activation in response to muscle damage was blunted in 
older adult men and that this was mediated by interleukin-6 (IL-6). Indeed, increased 
inflammation is chronically evident in the muscles of aged individuals (Vasilaki et al., 
2006, Vasilaki et al., 2003).  
The decline of the ability of satellite cells to divide following damage may play a role 
in sarcopenia. However, research by Carlson and Faulkner (1989) showed that the 
environment of the muscle during regeneration is crucial to successful regeneration. 
Thus, muscle from a two year old rat was repaired faster and better when grafted 
into two to three month old rats (Carlson and Faulkner, 1989).  
The decline in satellite cell function and so regeneration in an “old” environment may 
be due to inflammaging and the presence of SASP (Franceschi and Campisi, 2014). 
Increased TGF-β levels in old individuals have been suggested to have a negative 
impact on satellite cell function via Wnt signalling pathways, promoting a pro-fibrotic 
phenotype of satellite cells (Brack et al., 2007). Studies have shown that elevated 
levels of inflammatory cytokines regulate satellite cell function via the JAK/STAT3 
pathway, and inhibition of the JAK/STAT3 pathway improved satellite cell function 
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(Price et al., 2014, Tierney et al., 2014). The JAK/STAT pathway is also involved in 
cytokine production, whereby JAK inhibitors decreased cytokine production in 
senescent preadipocytes (Xu et al., 2015b). Increased p38α/βMAPK signalling has 
also been shown to be involved in the age-related decline in satellite cell function and 
proliferative capacity, and the inhibition of the p38α/βMAPK pathway rescued the 
self-renewal capacity of satellite cells in old age (Bernet et al., 2014, Cosgrove et al., 
2014).  
A landmark study using the transgenic AMPKγ3 KO mouse model with inducible 
depletion of satellite cells showed no effect on muscle fibre size, number, specific 
force, or myonuclear number between control old mice and old mice with genetically 
induced satellite cell depletion (Canto et al., 2010). On the other hand, the skeletal 
muscles of mice depleted of satellite cells showed significantly increased 
accumulation of collagen and fibrosis associated with ageing, suggesting that the 
ageing-associated loss of satellite cells contributes to muscle fibrosis in ageing but 
not to sarcopenia (Section 1.2.4.4) (Canto et al., 2010). 
1.2.4.3 Protein turnover and sarcopenia 
Protein degradation and synthesis, and the balance between the two play a key role 
in the homeostasis of skeletal muscle. Studies have investigated protein synthesis 
and degradation rates in muscles in ageing. Some studies have showed an overall 
decreased rate of protein synthesis in the muscles of old humans compared with 
adults (Hasten et al., 2000); with decreased rates of synthesis of individual muscle 
proteins such as myosin heavy chain proteins (Balagopal et al., 1997). However, 
studies have shown some conflicting results. Some studies have shown no difference 
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in protein synthesis rates in muscles of old humans compared with adults (Volpi et 
al., 2001, Wall et al., 2015).  
The ubiquitin-proteasome system (UPS) is a crucial protein degradation system in 
eukaryotes (Bilodeau et al., 2016). Ubiquitination is a post-translational modification 
to protein that targets them for proteasomes, which are protein complexes that 
degrade unneeded or damaged proteins by proteolysis via proteases (Bilodeau et al., 
2016). Conflicting evidence exists on the UPS in skeletal muscle, whereby proteasome 
activity was found decreased (Baehr et al., 2016), unchanged (Bossola et al., 2008), 
or increased (Altun et al., 2010) in aged rats. 
A key enzyme in the UPS system is E3 (ubiquitin ligase), which adds activated 
ubiquitin to lysine residues on the protein substrate, targeting the proteome for the 
UPS system. Two inducible E3 ubiquitin ligases have been identified, atrogin-1 (also 
known as MAFbx), and muscle RING finger protein 1 (MuRF1), both of which have 
been shown to be responsible for the degradation of the bulk of skeletal muscle 
protein in various conditions (Gomes et al., 2001, Bodine et al., 2001).  
There are increased levels of circulating inflammatory cytokines in old mice, which 
may stem from the SASP (Campisi and d'Adda di Fagagna, 2007). The SASP induces 
an unfolded protein response (UPR) in the endoplasmic reticulum in senescent 
fibroblasts, due to an accumulation of unfolded or damaged proteins (Soto-Gamez et 
al., 2019). This results in impairment of cell function and autophagy, or the potential 
to induce senescence within the other stressed cell (Soto-Gamez et al., 2019) and is 
potential contributor to the loss of protein in ageing (Altun et al., 2010). 
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1.2.4.4 Fat, fibrosis, and sarcopenia 
Fibrosis is the term for the accumulation of extracellular matrix (ECM) (Alnaqeeb et 
al., 1984, Goldspink et al., 1994). It has been well established that during ageing, 
fibrosis and infiltration of adipose tissue occurs in skeletal muscle. This decrease in 
the quality of skeletal muscle is thought to contribute to the age-related impairment 
in force generation (Faulkner et al., 2011). Satellite cells from old mice have been 
shown to become fibrogenic, due to canonical Wnt signalling pathway activation; 
contributing to tissue fibrosis with age (Brack et al., 2007). Collagen, a major 
component of the ECM, has been shown to accumulate within muscle following 
incomplete repair post-damage (Serrano and Munoz-Canoves, 2010).  
1.2.4.5 ROS, mitochondria, and sarcopenia 
Accumulation of mutations in mitochondria and mitochondrial DNA (mtDNA) during 
ageing have been well characterised (Miquel et al., 1980). ROS derived from the 
electron transport chain (ETC) are the suspected source of this damage. 
Mitochondrial DNA is particularly susceptible to damage, especially from ROS, due to 
fewer repair mechanisms (Clayton et al., 1974).  
There is significant evidence to indicate that there are fundamental changes in redox 
signalling and homeostasis, which occur during ageing (Jackson and McArdle, 2011). 
Skeletal muscles of old mice demonstrate significant oxidative damage to DNA, lipids, 
and proteins (Vasilaki et al., 2006). The imbalance in ROS homeostasis may ultimately 
initiate the upregulation of proinflammatory signals, resulting in chronic 
inflammation (Meng and Yu, 2010). Oxidative stress, such as muscle derived ROS, is 
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proposed to activate NF-κB and up-regulate the inflammatory response (Meng and 
Yu, 2010). 
1.2.4.6 Inflammation and sarcopenia  
An elevated level of low-grade, chronic systemic inflammation is seen in ageing 
mammals, called inflammaging (Franceschi and Campisi, 2014). This is characterised 
by increased serum proinflammatory cytokines such as interleukin-6 (IL-6); and a 
decrease in anti-inflammatory cytokines like interleukin-10 (IL-10) and interleukin-1 
receptor alpha (IL-1ra) (Lio et al., 2002). We have previously demonstration a chronic 
increase in NF-κB activation in muscles of old compared with adult mice (Vasilaki et 
al., 2006). Skeletal muscle is a source of cytokines, called myokines (Nielsen and 
Pedersen, 2008) and such chronic activation of NF-κB in muscles of old mice suggests 
that the production of cytokines by the muscles may also be increased. Examples of 
myokines include IL-6, IL-8, and IL-15, which have also been reported to be secreted 
as part of the senescence associated secretory phenotype (SASP). Such inflammation 
is proposed to be involved in the development of sarcopenic muscle. Muscle strength 
(Visser et al., 2002), muscle mass (Schaap et al., 2006), muscle protein synthesis and 
catabolism (Jo et al., 2012) have all been demonstrated to be affected by 
inflammatory cytokines.  
A positive association between chronically increased serum levels of 
proinflammatory cytokines such as IL-6 and TNFα and frailty measures such as grip 
strength have been demonstrated in several epidemiological studies (Leng et al., 
2004, Payette et al., 2003, Schaap et al., 2006). Indeed, centenarians have lower 
levels of IL-6 (Franceschi and Bonafe, 2003). McKay et al. (2013) showed that satellite 
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cell activation in response to muscle damage was blunted in older adult men and this 
was mediated by IL-6. IL-6 stimulates the ubiquitin proteasome muscle degradation 
pathway. Increased concentrations of IL-6 in plasma is associated with increased 
ubiquitin protein and mRNA expression (DeJong et al., 2005). Furthermore, chronic 
IL-6 signalling has also been shown to promote insulin resistance in liver, adipose, 
and skeletal muscle (Kim et al., 2009). Insulin resistance has been shown to supress 
important pathways involved in muscle synthesis, mainly the Akt-mTOR pathway 
(Franckhauser et al., 2008). 
Jurk et al. (2014) used a NF-κB1-/- mouse model to investigate the effects of chronic 
inflammation on telomere dysfunction; by increasing ROS-mediated DNA damage 
and thus accelerated accumulation of senescent cells. 44 weeks old NF-κB1-/- mice 
showed premature greying and fur loss, as well as kyphosis (loss of muscle mass). 
Mouse adult (ear) fibroblasts (MAFs) from NF-κB1-/- mice showed increased incidence 
of senescence, with increased senescence-associated β-galactosidase (SA-β-gal) 
activity.  
In order to examine the influence of systemic circulatory factors on progenitor cells 
from old mice, Conboy et al. (2005) performed a heterochronic parabiotic pairing 
between young and old mice. Parabiosis is the sharing of circulatory systems, 
exposing old mice to factors present in young serum. Parabiosis restored the 
activation of Notch signalling as well as the proliferation and regenerative capacity of 
aged satellite cells in a similar manner to the positive effect of the cross-age muscle 
transplant studies in Carlson and Faulkner (1989).  
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Immune cells such as neutrophils migrate in response to chemo-attractants, from the 
blood to a site of infection or tissue damage. Neutrophils release proteases, such as 
neutrophil elastase, at their leading edge and damaging healthy tissue in the process, 
resulting in inflammation (Wilson et al., 2017). Furthermore, the efficiency of 
chemotaxis decreases in ageing, leading to greater tissue damage and secondary 
systemic inflammation (Wilson et al., 2017). 
Cai et al. (2004) has shown that the constitutively active expression of IKKβ causes a 
significant increase in the expression of the MuRF1 gene in transgenic mice. The IKKβ-
expressing mice displayed muscle wasting, which was significantly reduced by 
crossing them with MuRF1-knockout mice. In contrast, Mourkioti et al. (2006) 
created a skeletal muscle-specific deletion of IKKβ in transgenic mice, which 
prevented the expression of MuRF1 gene and atrophy in the skeletal muscles in 
response to nerve injury. Thus, activation of NF-κB contributed to muscle loss, 
through the increased expression of MuRF1 E3 ubiquitin ligase in skeletal muscle.  
1.3 Evidence of senescence in skeletal muscles in ageing 
As skeletal muscle is mainly terminally differentiated, post mitotic tissue, there was 
initially limited interest in investigating cellular senescence in this tissue. However, 
there is a body of literature highlighting the presence and influence of senescent cells 
within skeletal muscle.  
Increased expression of senescence markers such as p53 and p21 has been detected 
in the muscles of mice (Edwards et al., 2007), monkeys (Kayo et al., 2001), and 
humans (Welle et al., 2004), although the source of these markers is unclear.  
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Sousa-Victor et al. (2014) demonstrated that satellite cells from geriatric mice (32+ 
months of old) were unable to maintain their quiescent state, and switch to an 
irreversible pre-senescence state, caused by de-repression of p16INK4a. 
Furthermore, satellite cells showed an age-dependent increase in DDR marker γ-
H2AX in mice. These cells in turn failed to activate and expand in response to injury, 
instead converting to a fully senescent state; in a process called ‘geroconversion’. 
Silencing of the p16 gene, CDKN2A, restored the quiescence and regenerative 
capacity of satellite cells from these geriatric mice.  
As discussed in Section 1.1.7.2, Baker et al. (2008) investigated ageing using BubR1 
(BubR1 hypomorphic or BubR1H/H) progeroid mice, a model of accelerated ageing. 
These mice have been characterised and display phenotypes such as a shortened 
lifespan, lordokyphosis, and sarcopenia, amongst others (Baker et al., 2004). These 
BubR1H/H were crossed with p16 knockout mice (p16Ink4a−/−) to give BubR1H/H: 
p16Ink4a−/− mice. To determine the role of BubR1 in normal skeletal muscle ageing, 
senescence markers in the gastrocnemius of 2- and 35-month-old mice were 
measured. There was an age-related decline in the expression of BubR1 in skeletal 
muscle, as well as an age-related increase in p16 expression. Gastrocnemius of 2- and 
5-month-old BubR1H/H mice also showed high p16 expression. Furthermore, BubR1H/H 
mice showed an increase in SASP components IGFBP2, MMP13, and Pai1. Knocking 
out p16 in this animal model improved fibre size in gastrocnemius, reduced instances 
of lordokyphosis, and reduced the expression of SASP.  
Zhu et al. (2019) have also shown that peri-muscular adipose tissue (PMAT), an 
ectopic fat deposit surrounding muscle, may drive muscle wasting. Transplanting 
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PMAT from obese mice into non-obese mice resulted in increased nuclear 
translocation of FoxO transcription factors. This resulted in the upregulated 
expression FoxO targets associated with proteolysis (Atrogin1 and MuRF1), and 
cellular senescence (p19 and p21) in whole muscle lysates. Furthermore, PMAT 
removal in obese mice attenuated denervation-induced muscle atrophy; suppressing 
upregulation of genes related to proteolysis and cellular senescence in muscle.  
1.3.1 Exercise and cellular senescence 
Cellular senescence has been shown to play a role in ageing and inflammation 
(Hernandez-Segura et al., 2018), however the role of exercise on cellular senescence 
is an ongoing investigation. Exercise and diet have been shown to be determinant of 
healthy ageing and sarcopenia (Jackson, 2020). Exercise has been associated with an 
upregulation of proteins such as telomeric repeat-binding factor 2 (TRF2), telomerase 
activity and DNA repair pathway Ku proteins which protect DNA, and downregulation 
of proteins of such as chk2, p16, and p53 in middle-aged athletes (Werner et al., 2009, 
Rebelo-Marques et al., 2018). Furthermore, although exercise acutely increases 
oxidative stress, chronic training is associated with antioxidant activity and inferior 
levels of ROS, favouring the REDOX balance, protecting from DNA damage and 
subsequently shorter telomere attrition (Gomes et al., 2012, Rebelo-Marques et al., 
2018). 
Schafer et al. (2016) investigated the effect of “fast-food diet” and exercise on the 
onset and progression of cellular senescence and the SASP, using adult transgenic 
p16-EGFP mice. Male mice (8 months old) were fed either a normal diet (ND), “fast-
food” diet (FFD), ND + exercise, or FFD + exercise for 16 weeks. The FFD group had 
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increased body weight, fat mass, circulating insulin levels and β-cell mass compared 
with the ND control group after treatment. These changes were partially prevented 
in the FFD + exercise group. The mRNA expression of p16, p21, p53, and SASP 
cytokines were significantly increased in several tissues (muscle was not measured), 
SA-β-Gal activity in visceral adipocytes in the FFD group compared with the ND group. 
Exercise, in both the FFD and the ND group, reduced several indices of senescence 
and SASP. These findings showed the harmful consequences of excessive nutrient 
intake and the remarkably protective influence of exercise on this biological process 
and, in turn, measures of physical, cardiovascular, and metabolic function.  
In contrast, Saito et al. (2020) investigated the role of muscle resident senescent 
fibro-adipogenic progenitor (FAP) cells in the context of muscle regeneration and 
inflammation. Damage to skeletal muscle/exercise triggers a transient FAP 
proliferation and protein expression that promotes muscle stem cell differentiation, 
followed by a return to baseline with apoptosis and subsequent phagocytic clearance 
of these cells. However, in chronic inflammation, FAP proliferation and protein 
expression are more robust due to the accumulation of apoptosis-resistant FAPs.  The 
authors investigated the role of FAPs in chronically inflamed environments and 
hypothesised that the effects of exercise on muscle regeneration or fibrosis depend 
on the FAP phenotype. The authors showed that FAPs increased after injury in 
regenerating muscle (barium chloride induced acute muscle injury) (AMI-FAP) and 
subsequently declined to pre-damage levels. However FAPs continued to accumulate 
for 14 days after injury by acquiring cell death resistance in degenerating muscle 
(chronic inflammatory myopathy) (CIM-FAP). In addition, AMI-FAPs acquired 
increased expression of Cdkn2a, Trp53, p21, and p19Arf, whereas CIM-FAPs showed 
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decreased expression of senescent factors. Exercise promoted FAP senescence in 
normal mice, but exercise in CIM mice decreased the expression of senescent factors 
to levels seen in sedentary CIM mice. AICAR, a cell-permeable APMK activator, was 
used to induce senescence in FAPs. CIM mice treated with combined exercise and 
AICAR treatment showed increased stamina, grip strength, and myofibre CSA. In the 
AMI model, exercise with AICAR treatment resulted in a pro-inflammatory cytokine 
expression and pro-apoptotic FAP phenotype that promoted muscle regeneration. 
Taken together, the authors have shown that FAP senescence promotes muscle 
regeneration by inducing SASP expression and apoptosis, creating a state of 
regenerative inflammation. FAPs that fail to senescence following AMI or exercise 
accumulate with an anti-apoptotic and pro-fibrotic phenotype. These findings show 
that positive role of senescence in tissue repair, similar to that of Demaria et al. 
(2014). This further highlights the multifaceted nature of senescent cells in vivo and 
that total ablation of senescent cells from an organism may have complex 
ramifications.  
These studies demonstrate that senescent cells may play a role in the age related loss 
of muscle mass and function with age, and that skeletal muscle may play a role in 
this, although the nature of the senescence phenotype of skeletal muscle remains 
unclear.  
1.4 Hypothesis and Aims 
The overall hypothesis of this thesis was that senescent cells accumulate in old mice, 
either locally to skeletal muscle or distally and that they produce an inflammatory 
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SASP that may contribute, at least in part, to the chronic NF-κB signalling and the loss 
of muscle mass and function seen in the muscles of old compared with adult mice.  
This programme of work tested this hypothesis by utilising different models of 






























2 Chapter 2: Methods 
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All reagents were purchased from Sigma Aldrich (Poole, U.K) unless stated otherwise. 
Cell culture supplies were purchased from GibcoBRL (Paisley, U.K). 
2.1 Animals 
2.1.1 Animal husbandry & Home Office licence permissions 
All experiments complied with UK Home Office Animal Licensing Laws for the care 
and use of laboratory animals. All animals were housed in the specific pathogen free 
Biomedical Services Unit at the University of Liverpool where they were monitored 
daily. The animals had standardised lighting system (12-hour light cycles), controlled 
temperatures (22±2°C) and access to food and water ad libitum. 
2.1.2 P16-3MR mice 
Twenty-one 20-months-old P16-3MR mice of both genders were given 25mg/kg 
Ganciclovir by intraperitoneal (I.P) injection in PBS, over 10 days using a regime of 5 
days of injections with 2 days of rest. Following I.P injection, mice were treated every 
4 weeks with a 5-day course of GCV, until 26 months old where the mice were 
sacrificed for tissue harvest and force measurement.  
2.1.3 Senolytic dietary intervention study 
Eighteen 20-months old C57BL/6 male mice were divided into two groups, one of 
which was fed 500 ppm (500 mg/kg) of fisetin as part of their chow (CRM(P), Special 
Diet Services, 801722) ad libitum (approximately 2.5 mg/day/mouse or 8.7 
µM/day/mouse). The second group were fed CRM(P) chow without fisetin. Mice were 
maintained on the diet for 16 weeks, when force generation of EDL muscle was 
determined and mice were sacrificed for tissue collection.  
Page 84 of 300 
2.1.4 Determination of muscle force generation 
Muscle force measurements of P16-3MR mice were performed in situ at the 
University of Michigan. Gastrocnemius stimulation, both nerve and by direct muscle 
activation, were performed in vivo. Muscle force measurements of the extensor 
digitorum longus (EDL) and soleus were also performed ex vivo.  
The protocol was adapted from McArdle et al. (2004). Mice were anaesthetised with 
isoflurane and maintained under anaesthesia throughout the procedure. The knee of 
the right hind limb was fixed. The distal tendon of the extensor digitorum longus (EDL) 
muscle was exposed and attached to the lever arm of a servomotor (Cambridge 
Technology). The lever served as a force transducer. The peroneal nerve was 
exposed, and electrodes were placed across the nerve. The EDL muscle of the 
contralateral limb served as a non-exercised control. 
Stimulation voltage and muscle length were each adjusted to produce maximum 
twitch force. The optimal length for maximum twitch force is also the optimal length 
(L0) for the development of maximum tetanic force (P0; (Brooks and Faulkner, 1988)). 
With the muscle at L0, the P0 was determined during 300msec of voltage stimulation 
(10V). The P0 was identified by increasing the frequency of stimulation at 2-min 
intervals until the maximum force plateaued. Muscle fibre length (Lf) and cross-
sectional area were calculated (Brooks and Faulkner, 1988). For the mice used for the 
senolytic intervention study, electrodes were also placed directly across the EDL 
muscle and the procedure above was repeated. This was to determine any deficits 
due to poor neuronal function.  
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Following the final measurement, the mouse was removed from the platform. Mice 
were sacrificed by cervical dislocation and blood was collected from the descending 
aorta. The mouse was weighed, and the EDL muscles were removed immediately. 
The muscle length was measured, and mass weighed.  
The hind limb muscles and internal organs were weighed and snap frozen in liquid 
nitrogen. Half of the anterior tibialis (AT) muscle was mounted on to a cork disk, 
surrounded with mounting medium (O.C.T., Merck, UK), frozen rapidly in liquid 
nitrogen cooled iso-pentane and sectioned for histological analysis. EDL muscles 
were pinned and fixed using neutral buffered formalin (NBF), and later stored at 4°C 
in PBS + 0.1% sodium azide. The specific P0 was calculated as the absolute P0/ muscle 
cross-sectional area (Brooks and Faulkner, 2001). 
2.2  Cell Culture of C2C12 myoblasts and myotubes 
C2C12 cells are an immortalized mouse myoblast cell line. The cell line was initially 
obtained by Yaffe and Saxel (Yaffe and Saxel, 1977). C2C12 cells are mononuclear 
myoblasts, capable of rapid proliferation under high serum conditions. C2C12 
myoblasts can fuse to form multinucleated myotubes under conditions of low or no 
serum. This serum deprivation results in functional skeletal muscle cells (McMahon 
et al., 1994). All media were stored at 4°C and warmed in a heated water bath to 37°C 
before use. C2C12 Myoblasts were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% heat inactivated foetal bovine serum 
(FBS), 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were grown at 37°C in a 
humidified 5% CO2/95% air incubator.  
Reagents: 
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 Dulbecco’s Phosphate Buffered PBS (DPBS) (Sigma Aldrich, Dorset, UK) 
 0.25% Trypsin (Sigma Aldrich, Dorset, UK) 
 C2C12 growth media 
o Dulbecco’s Modified Eagle’s Medium 
o 10% (v/v) foetal bovine serum, heat inactivated 
o 100 μmol/ml penicillin, and 0.1 mg/ml streptomycin 
o 4 mM L-glutamine 
 C2C12 differentiation media 
o Dulbecco’s Modified Eagle’s Medium 
o 2% (v/v) horse serum, heat inactivated 
o 100 μmol/ml penicillin, and 0.1 mg/ml streptomycin 
o 4 mM L-glutamine 
Method: 
Myoblasts were passaged at 65-75% confluence. Cell culture medium was removed 
and discarded. The cell layer was briefly rinsed with PBS to remove of serum. An 
appropriate volume of 0.25% (w/v) Trypsin-0.53 mM EDTA/PBS solution was added 
to the flask and placed into a 37°C in a humidified 5% CO2/95% air incubator. 
Myoblasts were observed under an inverted light microscope (Nikon Diaphot, Tokyo, 
Japan) until the cell layer was non-adherent. 
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Seven millilitres of growth media was added to neutralise the Trypsin-EDTA solution 
and the cell suspension was collected before centrifuging the solution at 500g for 5 
minutes. The supernatant was discarded, and the cell pellet was aspirated with 10 
mL growth media. A 15µL aliquot of resuspended myoblasts were removed at this 
point for determination of cell number, as described in Section 2.2.5. 
A T-75 flask was inoculated with myoblasts at a concentration of between 1.5x105 
and 1.0x106 cells/75 cm2 to maintain a population of cells. Myoblasts were incubated 
at 37°C in a humidified 5% CO2/95% air incubator. Alternatively, for experiments such 
as inducing cellular senescence, myoblasts were seeded into 6 or 12 well plates at 
1x104 or 5x103 cells per well respectively and incubated at 37°C in a humidified 5% 
CO2/95% air incubator overnight to adhere.  
2.2.1  Induction of cellular senescence in C2C12 Myoblasts 
Reagents: 
 C2C12 growth media 
o Dulbecco’s Modified Eagle’s Medium 
o 10% (v/v) foetal bovine serum, heat inactivated 
o 100 μmol/ml penicillin, and 0.1 mg/ml streptomycin 
o 4 mM L-glutamine 
 etoposide (Sigma, Dorset, UK, E1383) 
 Dimethyl Sulfoxide (DMSO) (Sigma Aldrich, Dorset, UK) 
Method: 
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Myoblasts were seeded into 6 or 12 well plates at 1x104 or 5x103 cells per well 
respectively and incubated at 37°C in a humidified 5% CO2/95% air incubator 
overnight to adhere.  
Etoposide powder (Sigma, E1383) was reconstituted in Dimethyl Sulfoxide (DMSO) to 
a concentration of 100 mM, and this was diluted 1 in 10 to a stock concentration of 
10mM in growth media. Myoblasts were then treated with different concentrations 
(30-3.75µM) of etoposide or DMSO carrier control in growth media for 24 hours and 
incubated appropriately. Etoposide and DMSO containing media was then removed 
and replaced with standard growth media and further incubated for up to 5 days. 
Cells were monitored daily to check for progression of senescent morphology, using 
a light (Nikon Diaphot, Tokyo, Japan) microscope. 
2.2.2  Differentiating myoblasts into myotubes 
Reagents: 
 C2C12 differentiation media 
o Dulbecco’s modified eagle’s medium 
o 2% (v/v) horse serum, heat inactivated 
o 100 μmol/ml penicillin, and 0.1 mg/ml streptomycin 
o 4 mM L-glutamine 
Method: 
C2C12 myoblasts were passaged and plated as previously described in Section 2.2and 
allowed to reach >85% confluence within the well or flask, to promote fusion. Growth 
media was replaced with differentiation media. Myotubes were differentiated for 
between 7-10 days, with media changes every 3 days.  
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2.2.3 Treatment C2C12 myotubes with conditioned media from senescent 
myoblasts 
Reagents: 
 Dulbecco’s Phosphate Buffered PBS (DPBS) (Sigma Aldrich, Dorset, UK) 
 C2C12 growth media 
o Dulbecco’s Modified Eagle’s Medium 
o 10% (v/v) foetal bovine serum, heat inactivated 
o 100 μmol/ml penicillin, and 0.1 mg/ml streptomycin 
o 4 mM L-glutamine 
 C2C12 differentiation media 
o Dulbecco’s Modified Eagle’s Medium 
o 2% (v/v) horse serum, heat inactivated 
o 100 μmol/ml penicillin, and 0.1 mg/ml streptomycin 
o 4 mM L-glutamine 
Method: 
Senescent C2C12 myoblasts were prepared as described in Section 2.2.1. DMSO 
treated cells were used as a vehicle control. Media from these myoblasts was 
collected at 3, 5, and 7 days post-treatment. C2C12 myotubes were incubated with 
the media collected from senescent C2C12 myoblasts, for 24 hours in 37°C in a 
humidified 5% CO2/95% air incubator. Light microscopic images were recorded 
before the addition of the media from senescent and controls myoblasts, and 24 
hours after treatment. The myotubes were harvested for analysis. Table 2.1 
illustrates the workflow in detail.  
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2.2.4 Measurement of myotube diameter 
Four images of C2C12 myotubes were taken at 10x magnification using a light 
microscope (Nikon Diaphot, Tokyo, Japan). Myotubes in the field of view were 
analysed using Image J (US National Institutes of Health, Maryland, USA). For each 
image, myotubes were traced and the minimum Ferets diameter was measured. 
Measurements for approximately 20 single myotubes from 6 wells were pooled to 
give an average value per condition.
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  Table 2.1 Workflow for co-culture experiment. 
At day 1, C2C12 myotubes were seeded and differentiated to form myotubes, reaching maturity at day 12. On days 3, 5, and 7, myoblasts 
were treated with etoposide to generate senescent myoblasts, or the DMSO vehicle controls. On day 12, the conditioned media from the 
senescent myoblasts were used to treat the mature myotubes, for 24 hours. On day 13, the media was removed and the myotubes harvested. 
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2.2.5 Determination of cell number 
Trypan Blue is commonly used in microscopy for cell counting (Strober, 2015). Trypan 
blue is an impermeable dye and cannot penetrate the intact cell membranes of live 
cells, therefore will only stain non-viable cells blue, allowing dead and live cells to be 
distinguished. 
Reagents: 
 Dulbecco’s Phosphate Buffered PBS (DPBS) (Sigma Aldrich, Dorset, UK) 
 0.025% Trypsin containing EDTA (Sigma Aldrich, Dorset, UK) in DPBS 
 C2C12 growth media 
o Dulbecco’s Modified Eagle’s Medium 
o 10% (v/v) foetal bovine serum, heat inactivated 
o 100 μmol/ml penicillin, and 0.1 mg/ml streptomycin 
o 4 mM L-glutamine 
 0.4% Trypan Blue (Invitrogen, Paisley, UK) in DPBS 
Method: 
Cells were detached from the surface they were adhered to using trypsin as 
previously described in Section 2.2, and resuspended in 10 mL fresh growth media. 
The cell suspension was gently, but thoroughly mixed. Fifteen microliters of cell 
suspension was mixed 1:1 with trypan blue solution. Ten microliters of the cell 
suspension was loaded onto a haemocytometer. The numbers of viable cells was 
determined in triplicate using a light microscope (Nikon Diaphot, Tokyo, Japan) at 10x 
magnification and an average cell number was calculated.  
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2.3 Measurement of senescent markers 
2.3.1 Cell Viability Assay of C2C12 myoblasts 
Cell viability was determined using a LIVE/DEAD© reduced Biohazard 
Viability/Cytotoxicity Kit (Molecular Probes, UK). The assay determines the viability 
of samples by exploiting the permeability of the cell to the kit’s dyes. SYTO 10 is a cell 
permeable, fluorescent dye that will stain the entire cell green, including the nucleus. 
The red fluorescent protein only penetrates the membranes of compromised cells 
and incorporates into the nucleus; whereby only staining the nuclei of dead cells red. 
Thus, viable cells are stained green and the nuclei of dead cells are stained red. 
Reagents: 
 LIVE/DEAD® Viability/Cytotoxicity Kit containing: 
o Component A – SYTO 10 green-fluorescent nucleic acid stain in DMSO 
o Component B – DEAD Red (Ethidium homodimer-1) nucleic acid stain in 
DMSO/H2O 1:4 (v/v) 
 Hepes Buffer PBS Solution (HBSS) (Sigma Aldrich, Dorset, UK) 
 4% glutaraldehyde (Sigma Aldrich, Dorset, UK) in DPBS 
 Sterile H20 
Method: 
Briefly, myoblasts were aspirated and washed in HBSS. The myoblasts were then 
treated with SYTO 10 and DEAD Red diluted 1 in 500 in HBSS; and incubated at room 
temperature for 15 minutes in the dark. Following this, the staining solution was 
removed, myoblasts were washed with HBSS and then fixed with 4% glutaraldehyde. 
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Cells were visualised using a florescent microscope (Nikon Eclipse TE2000, Tokyo, 
Japan) at 560–520 nm and 700–635 nm wavelengths for the green and red 
fluorophores, respectively.  
2.3.2 Senescence Associated β-Galactosidase Staining  
SA-β-gal detection was performed using the Senescence β-Galactosidase Staining Kit 
(Cell Signalling Technologies, #9860). A lysosomal beta-galactosidase accumulates in 
senescent cells and can be exploited in a cytochemical assay that produces a blue 
precipitate at pH 6.0 (Dimri et al., 1995).  
Reagents: 
 Senescence Associated β-Galactosidase Staining Kit (Cell Signalling Technology, 
London, UK) containing: 
o 10x Fixative Solution 
o 10x Staining Solution 
o 100x Solution A 
o 100x Solution B 
o X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) 
  N,N-Dimethylmethanamide (DMF), 99% (Sigma Aldrich, Dorset, UK) 
 Dulbecco’s Phosphate Buffered PBS (DPBS) (Sigma Aldrich, Dorset, UK) 
Method: 
Twenty milligrams of X-gal were dissolved in 1 ml DMF to prepare a 20 mg/ml stock 
solution. The solution can be stored at -20°C in foil for up to one month. Myoblasts 
and tissue sections were prepared as described in Sections 2.2.1 and 2.3.3 
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respectively. Samples were washed with PBS, and then placed in the Fixative Solution 
(diluted 1 in 10 in H20) for 10 minutes at room temperature. Samples were then 
washed twice with PBS, followed by the addition of the Staining Solution (pH 6.0) 
(Table 2.2). Samples were then incubated at 37°C overnight, in a low CO2 
environment. The Staining Solution was then removed and replaced with DPBS for 
imaging under a light microscope (Nikon Diaphot).  
 Volume (µL) 
1X Staining Solution 930 
100X Solution A 10 
Solution B 10 
20mg/ml X-gal stock solution 50 
Table 2.2 Senescence β-Galactosidase Cell Staining Solution. 
 
2.3.3 Immunohistochemical analysis of senescence markers in etoposide treated 
C2C12 myoblasts 
Reagents: 
 Dulbecco’s Phosphate Buffered PBS (DPBS) (Sigma Aldrich, Dorset, UK) 
 Triton X-100 (Sigma Aldrich, Dorset, UK) 
 Polyoxyethylene-sorbitan monolaurate (Tween-20) (Sigma Aldrich, Dorset, UK)  
 4% Paraformaldehyde (PFA) in DPBS 
 Blocking solution 
o 10% donkey serum (Sigma Aldrich, Dorset, UK) in DPBS 
Page 96 of 300 
 
 Diluting solution 
o 0.25% sodium azide (Sigma Aldrich, Dorset, UK), 0.25% of donkey serum, 
and 0.2% Triton in DPBS 
 Primary antibody 
o anti-p21 antibody [EPR3993] (ab109199) 
 Secondary antibody 
o Goat anti-rabbit 488 
 DAPI (4′,6-diamidino-2-phenylindole) ) (Sigma Aldrich, Dorset, UK) 
 Vector Shield aqueous mounting solution 
Method: 
C2C12 myoblasts were seeded on to coverslips in a 6 well plate and treated with 
etoposide to induced senescence as described in Section 2.2.1. The cells were then 
washed with PBS, and ice-cold 4% PFA was added to each sample for 5 minutes at 
room temperature. Cells were then aspirated to remove the PFA, followed by three 
washes with PBS. Myoblasts were then incubated for 1 hour at room temperature in 
blocking solution. 
Primary antibody, anti-p21 antibody [EPR3993] (ab109199) (1 in 400), was diluted in 
the diluting solution. Blocking solution was removed and the myoblasts were 
incubated in primary antibody overnight at 4°C. 
Myoblasts were then washed three times with DPBS before the secondary antibody 
was added. Anti-rabbit 488 secondary antibody was used, diluted 1 in 1000 in diluting 
solution. Cells were incubated for 1 hour at room temperature in the dark. Myoblasts 
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were then washed twice time with DPBS and then DAPI (1 in 10,000 in dH20) was 
added and cells were incubated for a further 10 minutes at room temperature in the 
dark. Myoblasts were washed three times with PBS to remove any excess antibody 
and DAPI. Cells were then sealed under a cover slip using Vector Shield aqueous 
mounting solution. Finally, the cells were washed with distilled water. 
Cells were then imaged using a fluorescent microscope (Nikon Eclipse TE2000) using 
IP Lab 3.0 Software.  
2.3.4 Cryosectioning of frozen mouse tissue 
Reagents: 
 Optimal Cutting Temperature (OCT) compound (Sigma Aldrich, Dorset, UK) 
 Isopentane (Sigma Aldrich, Dorset, UK) 
 Histological cork (Sigma Aldrich, Dorset, UK) 
 SuperFrost Plus™ Adhesion Microscopy slides (Sigma Aldrich, Dorset, UK) 
Methods: 
Muscle harvested from sacrificed mice were mounted transversely on to a 
histological cork. The cork and tissue were covered in OCT resin and snap frozen in 
liquid nitrogen cooled iso-pentane. Frozen muscle blocks were stored at -80°C long 
term. Frozen muscle sections were acclimatised to -24°C before sectioned at 12µM 
thickness using a cryostat (Leica CM1800, Wetzlar, Germany) set to -24°C. Sectioned 
tissues were then adhered to microscopy slides and stored at -20°C.  
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2.3.5 Sudan Black B staining or autofluorescence measurement of muscle tissue 
sections for evidence of lipofuscin 
Reagents: 
 Sudan Black B (SBB) 
 Ethanol 
 Formaldehyde  
Methods: 
Methods were adapted from Evangelou and Gorgoulis (2017). 
Preparation of SBB solution:  
0.7g of SBB (BDH, Athens, Greece) was dissolved in 70% ethanol, covered with 
parafilm, and thoroughly stirred overnight at room temperature. This was then 
filtered through filter paper and then filtered again using a frittered glass filter of 
medium porosity with suction. Throughout the process it was important to avoid 
ethanol evaporation, which results in precipitation of the stain and so the solution 
was stored in an airtight container. 
Staining Procedure:  
Frozen muscle sections were mounted onto SuperFrost slides prepared as described 
in Section 2.3.3, were fixed in 1% (wt/vol) formaldehyde/PBS for 1 min at room 
temperature and then washed three times at room temperature with PBS. Tissue was 
then incubated for 5 min in 50% ethanol and then for another 5 min into 70% ethanol. 
Coverslips with fixed tissue were incubated for 2 min in 70% ethanol. In order to avoid 
precipitation of SBB on tissue the following two steps were crucial:  
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1) A drop from freshly prepared SBB was placed on a clean slide. The slide with the 
tissue was placed face down on the SBB. Staining was observed under the 
microscope. 
2) Either the coverslip or the slide was carefully lifted and any SBB present on the 
edges of the tissue-slide was removed manually with tissue paper.  
The tissue sections were then washed with 50% ethanol and counterstained with 
0.1% Nuclear Fast Red (NFR) (Sigma, Athens, Greece) for 10 min., and mounted into 
40% Glycerol/TBS mounting medium. SBB staining was considered positive when 
perinuclear and cytoplasmic aggregates of blue-black granules were evident inside 
the tissue. 
For autofluorescence imaging, unstained muscle sections were imaged under a Zeiss 
LSM 800 confocal microscope at 20x magnification between 530 nm to 660 nm.  
2.3.6 Immunohistochemical analysis of muscle sections for senescence markers 
Reagents: 
• PBS (0.01% tween 20) for washes 
• PBS  
• Tween 20 (Sigma Aldrich, Dorset, UK) 
• Bovine Serum Albumin (Sigma Aldrich, Dorset, UK) 
• 4% PFA (Sigma Aldrich, Dorset, UK) 
• PBS (0.1% Triton) 
• Goat Serum (Sigma Aldrich, Dorset, UK) 
• Primary antibodies 
o Anti p21 [EPR3993] (ab109199) (Abcam, Cambridge, UK) 
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o Anti p16 [2D9A12] (ab54210) (Abcam, Cambridge, UK) 
• Secondary antibody 
o Alexa Fluor® 488 Goat anti-rabbit (Sigma Aldrich, Dorset, UK) 
• Rhodamine wheat germ agglutinin (WGA) (Sigma Aldrich, Dorset, UK) 
• Vector Shield mounting media with DAPI (Sigma Aldrich, Dorset, UK) 
• Cover slips (Sigma Aldrich, Dorset, UK) 
Methods: 
Muscle sections were prepared on microscopes slides, as described in 2.3.3. Muscle 
sections were washed once with ice cold PBS for 5 mins. Sections were then fixed 
with ice cold 4% PFA for 10 mins at RT. Sections were washed three times for 5 mins 
with PBS (0.01% Tween 20). Sections were permeabilised with 0.1% Triton (0.1%) in 
PBS for 10 mins at RT, followed by another 3x5 mins wash. Sections were then 
incubated with 10% goat serum, 1% BSA, and 0.1% tween 20 in PBS, at RT for an hour. 
Sections were then incubated overnight at 4°C in 1% BSA, 0.1% tween 20 in PBS, 
containing either anti-p21 or anti-p16 antibodies, at a 1 in 100 dilution.  
Following the overnight incubation, sections were washed 3x5 mins and incubated 
with a 1:1000 dilution of Alexa Fluor® 488 Goat anti-rabbit secondary antibody in 1% 
BSA, 0.1% tween 20 in PBS for 1 hr at RT. Sections were washed 3x5 mins and stained 
with Rhodamine WGA diluted 1 in 1000 for 10 mins at RT. Sections were was washed 
3x5 mins as previously described, then finally with sterile water. Sections were 
mounted with VectaShield Hardset medium containing DAPI (Sigma Aldrich, Dorset, 
UK).  
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2.4 Protein Quantification 
2.4.1 Generation of tissue homogenates 
Frozen mouse tissue was ground into a fine powder using a pestle and mortar under 
liquid nitrogen. C2C12 cell pellets or ground tissue powder was then lysed in 100µL 
RIPA lysis buffer, on ice for 30 mins. The cell debris was then centrifuged out at 
10,000g for 10 mins, at 4°C. The protein content was then determined using a protein 
assay.  
2.4.2 Bicinchoninic acid assay of tissue or cell homogenates 
The Bicinchonic acid (BCA) assay is used in the detection of the concentration of 
proteins in a sample via a standard curve of protein of a known concentration. The 
BCA assay is based on the method originally described by Smith et al. (1985). The 
assay works by exploiting Cu2+ protein complex formation. First, the peptide bonds in 
protein reduce Cu2+ ions from the copper (II) sulphate to Cu+ (a temperature 
dependent reaction). The amount of Cu2+ reduced is proportional to the amount of 
protein present in the solution. Next, two molecules of BCA chelate with each Cu+ 
ion, forming a purple-coloured complex that strongly absorbs light at a wavelength 
of 562 nm. The reduction of Cu2+ to Cu+ is proportional to the protein content of the 
sample in question. This results in the formation of purple coloured salt complex with 
Cu+, which can be quantified using a spectrophotometer (Olson and Markwell, 2007). 
 Pierce™ BCA Protein Assay Kit (Sigma Aldrich, Dorset, UK) containing: 
o BCA Reagent A - containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide 
o Reagent B - 4% cupric sulphate  
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o Albumin Standard Ampules, 1mg/mL, bovine serum albumin (BSA) in 0.9% 
PBS and 0.05% sodium azide 
Vial 
Volume of Diluent 
(µL) 
Volume and Source of BSA 
(µL) 
Final BSA Concentration 
(µg/mL) 
A 0 200 of Stock 1000 
B 100 100 of vial A 500 
C 100 100 of vial B 250 
D 100 100 of vial C 125 
E 100 100 of vial D 62.5 
F 100 100 of vial E 31.25 
G 100 100 of vial F 15.625 
H 100 0 0 = Blank 
Table 2.3 Preparation of Diluted Albumin (BSA) Standards 
Method: 
The BCA assay was performed by generating a standard curve of protein to use as a 
standard from a stock solution of BSA (1mg/mL) (Table 2.3). 
Twenty microliters of protein standard or tissue homogenates were loaded in 
triplicate into a 96 well plate. One hundred and eighty microliters of Reagent B, 
diluted 1 in 50 in Reagent A, was added to each well, and was incubated at 37°C for 
30 minutes. Absorbance was measured using a spectrophotometer (SPECTRO-star 
Nano, BMG Labtech, Offenburg, Germany) at 570nm. The protein standard curve was 
used to quantify the protein content of the samples.  
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2.4.3 Bradford Assay of tissue or cell homogenates 
The Bradford protein assay is a colorimetric protein assay based on the use of the dye 
Coomassie Brilliant Blue G-250 (Coomassie G-250 or Coomassie Blue). The dye exists 
in three forms: 
 Cationic (doubly protonated, red) 
 Neutral (green) 
 Anionic (stable, unprotonated, blue) 
Under normal conditions, the dye is predominantly in the doubly protonated red 
cationic form (Amax = 470 nm). However, when the dye binds to protein, it is converted 
to a stable unprotonated blue form (Amax = 595 nm) (Figure 2.1 Coomassie Brilliant 
Blue G-250 reaction). 
The blue protein bound dye form is detected at 595 nm using a spectrophotometer. 
The neutral, green form of the does not interfere with measurement in the Bradford 
assay since it has an Amax of 650 nm. 
Reagents: 
 Bovine Serum Albumin (BSA) (Sigma Aldrich, Dorset, UK) in H2O 
 Bradford Reagent (B6916) (Sigma Aldrich, Dorset, UK) 
Figure 2.1 Coomassie Brilliant Blue G-250 reaction. 
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Method: 
The Bradford assay was performed first by generating a standard curve of protein as 
a standard from a stock solution of BSA (1mg/mL) (Table 2.3). 
Twenty microliters of protein standard or tissue homogenates were loaded in 
triplicate into a 96 well plate. One hundred and eighty microliters of room 
temperature, Bradford reagent was added to each well. Absorbance was measured 
using a spectrophotometer (SPECTRO-star Nano, BMG Labtech, Offenburg, Germany) 
at 595 nm. The protein standard curve was used to quantify the protein content of 
the samples.  
2.5 Western blotting of tissue homogenates for detection of senescence markers 
The western blot (sometimes called the protein immunoblot) is a widely used 
technique to detect specific proteins in a sample homogenate, extract, or lysate 
(Section 2.4.1). 
In brief, the sample undergoes protein denaturation, followed by gel electrophoresis. 
A synthetic or animal-derived primary antibody was generated that recognises and 
binds to a specific target protein. The electrophoresis membrane is washed in a 
solution containing the primary antibody before excess antibody is washed off. A 
secondary antibody is added which recognises and binds to the primary antibody. 
The secondary antibody is tagged with a fluorescent protein and is visualised using 
immunofluorescence in this case, allowing detection of the specific target protein. 
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2.5.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS PAGE) 
Reagents: 
 Resolving Acrylamide Gel 
o 4x ProtoGel Resolving Buffer (Tris/SDS) (Geneflow, Litchfield, UK) 
 1.5 M Tris-HCl, 0.4% SDS; pH 8.8 
o ProtoGel Acrylamide (30% Solution at 37.5:1 acrylamide/methylene 
bisacrylamide solution ratio 10% ammonium persulphate (APS) (Sigma 
Aldrich, Dorset, UK) in H2O 
o N,N,N′,N′-tetramethylethylene-diamine (TEMED) (BioRad, Hertfordshire, 
UK) 
 Stacking Acrylamide Gel 
o ProtoGel Stacking Buffer (Tris/SDS) (Geneflow, Litchfield, UK) 
o ProtoGel Acrylamide (30% Solution at 37.5:1 acrylamide/methylene 
bisacrylamide solution ratio) 
o 10% ammonium persulphate (APS) (Sigma Aldrich, Dorset, UK) in H2O 
o N,N,N′,N′-tetramethylethylene-diamine (TEMED) (BioRad, Hertfordshire, 
UK) 
 Running Buffer 
o Tris-Glycine 10x Stock 
 250 mM TRIZMA® base (Sigma Aldrich, Dorset, UK) 
 2 M Glycine (Sigma Aldrich, Dorset, UK) 
 1% (w/v) SDS (Sigma Aldrich, Dorset, UK) 
o 4x sample loading buffer 
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o 20 mM Tris pH 6.8 
o 10% (v/v) glycerol 
o 2% (w/v) SDS 
o 10% (v/v) β-mercaptoethanol 
 PageRuler™ Plus Prestained Protein Ladder, 10 to 250 kDa (ThermoFisher, 
Massachusetts, US) 
Method 
Protein content of samples was been determined as described in Section 2.4. The 4x 
sample loading buffer was added to the samples at a 1 in 4 dilution. Samples were 
then denatured at 95°C for 5 minutes using heating block. Following this, samples 
thoroughly vortexed and were briefly centrifuged at 12,000 g for 2 minutes to collect 
to the bottom of the tube.  
Table 2.4 SDS PAGE formula 
Resolving and stacking gels were prepared using the formula described in Table 2.4. 
Gels were cast using Mini-PROTEAN Tetra Cell Casting Stand & Clamps (BioRad, 
Hertfordshire, UK). Ten millilitres resolving gel was added to 1.5 mm glass plates to 
set and 100% ethanol was added on top of the resolving gel to prevent air bubble 
 10% Resolving Gel 4% Stacking Gel 
H2O 4.1 mL 6.1 mL 
Acrylamide 3.4 mL 1.3 mL 
Resolving Buffer/Stacking Buffer 2.5 mL 2.5 mL 
10% APS 100 µL 100 µL 
TEMED 10 µL 10 µL 
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formation. Ethanol was removed and 5 mL 4% stacking gel was added and a well 
comb was inserted.  
Gels were placed into a Mini-PROTEAN® Tetra Electrode Assembly (BioRad, 
Hertfordshire, UK). The tank was filled to the appropriate level with 1x running buffer. 
Fifty micrograms of samples were loaded into each well of the gel, 3 µL protein 
ladders was added to a separate well. Electrophoresis was carried out at 60V for 
approximately 20 minutes or until samples had reached resolving gel. The voltage 
was then increased to 120V and electrophoresis continued for an hour or until the 
loading dye had reached the bottom of the gel. Gels were then transferred onto a 
nitrocellulose membrane for western blotting, as described in Section 2.5.2. 
2.5.2 Western Blotting 
Reagents: 
 Anode 1 Buffer (pH 10.4) 
o 0.3M Tris (Sigma Aldrich, Dorset, UK) 
o 20% (v/v) Methanol (Sigma Aldrich, Dorset, UK) 
o dH2O 
 Anode 2 Buffer (pH 10.4) 
o 25mM Tris (Sigma Aldrich, Dorset, UK) 
o 20% (v/v) Methanol (Sigma Aldrich, Dorset, UK) 
o dH2O 
 Cathode Buffer (pH 7.6) 
o 40mM 6-amino n hexanoic acid (Sigma Aldrich, Dorset, UK) 
o 20% (v/v) Methanol 
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 10x Tris-Buffered PBS (TBS) (pH 7.6) Stock 
o 200 mM TRIZMA® base (Sigma Aldrich, Dorset, UK) 
o 1.4 M NaCl (Sigma Aldrich, Dorset, UK) in dH2O 
o dH2O 
 Wash Buffer (pH 7.6) 
o 1 in 10 dilution of 10x TBS Stock  
o 0.1% (v/v) polyoxyethylene-sorbitan monolaurate (Tween-20) (Sigma 
Aldrich, Dorset, UK) 
o dH2O 
Method: 
The Geneflow blotting system (Gene flow, Litchfield, UK) comprises of two graphite 
panels containing electrodes. Whatman No1 filter paper was used as a buffer 
reservoir. Following electrophoresis, the SDS PAGE gels were removed from the Mini-
PROTEAN® Tetra Electrode Assembly (BioRad, Hertfordshire, UK), removed from 
glass plates; and the stacking gel was discarded. The resolving gel, the filter paper, 
and the nitrocellulose membrane were assembled as described in Figure 2.2, placed 
Figure 2.2 Schematic of western blot semi dry transfer assembly. 
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between the electrode plates and exposed to a current of 0.8mA/cm2 gel, for 75 
minutes. Following transfer, the gel was discarded, and the nitrocellulose membrane 
was stained with Ponceau S solution (Sigma, Dorset, UK) to ensure equal loading and 
transfer of proteins. Images of the membrane were recorded using the ChemiDoc 
imaging system (BioRad, Hertfordshire, UK). The Ponceau S solution was thoroughly 
removed from the membrane with liberal washes of wash buffer. Membrane could 
then be used for analysis for specific proteins.  
2.5.3 Analysis of membranes for specific proteins 
Reagents: 
 10x Tris-Buffered PBS (TBS) (pH 7.6) Stock 
o 200 mM TRIZMA® base (Sigma Aldrich, Dorset, UK) 
o 1.4 M NaCl (Sigma Aldrich, Dorset, UK) in dH2O 
o dH2O 
 Wash Buffer (pH 7.6) 
o 1 in 10 dilution of 10x TBS Stock  
o 0.1% (v/v) polyoxyethylene-sorbitan monolaurate (Tween-20) (Sigma 
Aldrich, Dorset, UK) 
o dH2O 
 Blocking buffer 
o 5% milk powder in Wash Buffer  
 Primary antibody 
o anti-p21 antibody [EPR3993] (ab109199) (Abcam, Cambridge, UK) 
 Secondary antibody 
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o IRDye® 800CW Goat anti-Rabbit (LI-COR, Cambridge, UK) 
Method: 
Following a transfer and removal of the Ponceau S staining described in Section 2.5.1, 
the membrane was then blocked for 1 hour at room temperature using 10 mL 
blocking buffer containing milk powder. Following this, the membrane was incubated 
overnight at 4°C with the primary antibodies listed in Section 2.5.5. After this 
incubation, the membranes were washed 3x5 minutes with wash buffer. The species-
specific secondary antibody was added as listed in Section 2.5.5 to the membranes in 
blocking buffer, for 1 hour at room temperature. After another 3x5 minutes washes 
with wash buffer, images of the membranes were captured on the LI-COR Odyssey® 
CLx Imaging System (LI-COR, Cambridge, UK) at the 800nm wavelength. 
2.5.4 Western blotting analysis  
Following imaging of the membrane, the intensity of each protein band on the 
membrane was measured using ImageJ software (US National Institutes of Health, 
Maryland, USA).  
2.5.5 List of Primary antibodies 
2.5.5.1  H2AX 
Rabbit polyclonal antibody to gamma H2A.X (phospho S139) (Abcam, Cambridge, UK) 
in 0.021% PBS, 1.764% Sodium citrate, 1.815% Tris; 0.1% Sodium azide. Detects a 
band of approximately 15 kDa. Used at 1 in 1000 dilution.  
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2.5.5.2  IKBα 
Rabbit monoclonal [E130] antibody to IKBα (Abcam, Cambridge, UK) in 40% Glycerol, 
0.05% BSA, 0.01% Sodium azide; pH 7.2. Detects a band of approximately 35 kDa. 
Used at 1 in 1000 dilution. 
2.5.5.3  p65 
Rabbit monoclonal (D14E12) antibody to NF-κB p65 (Cell Signalling Technology, 
London, UK) in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% 
glycerol; <0.02% sodium azide. Detects a band of approximately 65 kDa. Used at 1 in 
1000 dilution. 
2.5.5.4  Phosphorylated p65 
Rabbit monoclonal (93H1) antibody to Phosphorylated NF-κB p65 (Ser536) (Cell 
Signalling Technology, London, UK) in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 
100 µg/ml BSA, 50% glycerol; <0.02% sodium azide. Detects a band of approximately 
65 kDa. Used at 1 in 1000 dilution. 
2.5.5.5  p21CIP1 
Rabbit monoclonal [EPR3993] antibody to p21 (Abcam, Cambridge, UK) in 40% 
Glycerol, 0.05% BSA, 0.01% Sodium azide; pH 7.2. Detects a band of approximately 
21 kDa. Used at 1 in 1000 dilution. 
2.5.5.6  p53 
Mouse monoclonal (D14E12) antibody to p53 (Cell Signalling Technology, London, 
UK) in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol; 
<0.02% sodium azide. Detects a band of approximately 53 kDa. Used at 1 in 1000 
dilution.  
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2.6 Quantitative PCR for senescence markers 
2.6.1 RNA Extraction 
Reagents: 
 TRIzol™ Reagent (Life technologies, Warrington, UK) 
 Chloroform (Sigma Aldrich, Dorset, UK) 
 Isopropanol (Sigma Aldrich, Dorset, UK) 
 Ethanol (Sigma Aldrich, Dorset, UK) 
 RNase-free water (Sigma Aldrich, Dorset, UK) 
Method: 
To extract RNA, frozen muscle samples were ground into a fine powder under liquid 
nitrogen using a pestle and mortar. One millilitre of TRIzol™ was added per 50–100 
mg of ground tissue to the sample and lysed by passing through a needle and syringe. 
Samples were then incubated for 5 minutes to permit complete dissociation of the 
nucleoproteins complex. Chloroform (0.2 mL) was added per 1 mL of TRIzol™ Reagent 
used for lysis. The tubes were securely capped and incubated for 3 minutes.  
Samples were centrifuged for 15 minutes at 12,000g at 4°C. The mixture separates 
into a lower red phenol-chloroform, and interphase, and a colourless upper aqueous 
phase. The aqueous phase containing the RNA was transferred to a new tube.  
In order to isolate the RNA, 0.5 mL of isopropanol was added to the aqueous phase, 
per 1 mL of TRIzol™ Reagent used for lysis. Samples were then incubate for 10 
minutes followed by centrifugation for 10 minutes at 12,000g and 4°C. Total RNA 
precipitate forms a white gel-like pellet at the bottom of the tube. Supernatant was 
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discarded. To wash the RNA, the pellet was resuspended in 1 mL of 75% ethanol per 
1 mL of TRIzol™ Reagent used for lysis. The sample was briefly vortexed then 
centrifuged for 5 minutes at 7500g at 4°C. The supernatant was discarded, and the 
RNA pellet was left to air dry for 5–10 minutes. Finally, the pellet was resuspended in 
20–50μL of RNase-free water heated to 40°C in a heating block. Sample RNA 
concentration and purity was determine using a Nanodrop (Thermoscientific, 
Cheshire, UK). 
2.6.2 cDNA Synthesis  
Reagents: 
 iScript cDNA Synthesis Kit (BioRad, Cambridge UK) containing: 
o 5x iScript Reaction Mix 
o iScript Reverse Transcriptase 
o Nuclease free water 
Methods: 
Component Volume per reaction (µL) 
5x iScript Reaction Mix 4 
iScript Reverse Transcriptase 1 
Nuclease free water <15 
Sample RNA (1µg) Variable 
Total Volume 20 
Table 2.5 cDNA synthesis reaction 
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RNA was isolated and quantified as described in Section 2.6. Samples and reagents 
were thawed on ice when necessary. CDNA synthesis reactions were generated as 
described in Table 2.5. 
Complete reaction mixes containing RNA template were incubated in a thermal cycler 
using Table 2.6: 
Table 2.6 cDNA thermal cycler settings 
2.6.3 Quantitative PCR 
Reagents: 
 cDNA  
 Sybrgreen master mix (Thermoscientific, Cheshire, UK)  
 Primers (Invitrogen, Cheshire, UK) 
Methods 
cDNA was diluted 1 in 40 with RNAse free water and 3μl of diluted cDNA was added 
into 96 well plates. A master mix consisting of 5 μL of Sybrgreen, 1μL of forward 
primer and 1 μL of reverse primer was prepared for each sample and 7 μL were added 
to cDNA). Plates were then sealed, pulse centrifuged for 5 seconds and placed in the 
Step Duration /Temperature (minutes/°C) 
Priming 5 min/25°C 
Reverse transcription 20 min/46°C  
RT inactivation 1 min/95°C 
Hold Hold/4°C 
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thermal cycler (Starlab, Hertfordshire, UK) for thermo cycling (Table). Forty cycles 
were performed. 
2.7 Multiplex Cytokine Analysis 
For multiplex cytokine analysis, the Luminex Bio-Plex Multiplex immunoassay kit 
(BioRad, Hertfordshire, UK) was used. The Luminex is a colour coded, magnetic bead 
based multiplex assay that measures multiple cytokines, chemokines, and growth 
factors in a single sample.  
The basic principle behind the technique is the same as those use in normal sandwich 
ELISAs or western blotting. The beads used in the assay are fused to a specific primary 
antibody. The biomarker or target of interest is bound by the specific primary 
antibody, which in turn is bound by a biotinylated secondary detection antibody. This 
complex is then detected by a streptavidin-phycoerythrin (PE) conjugate (Figure 2.3).  
The magnetic, fluorescent 5.6 µm beads on which all these complexes form are 
detected by the Bio-Plex 200 system (BioRad, Hertfordshire, UK). The flow cytometry-
based system uses dual lasers: one at 635 nm to classify the beads unique fluorescent 
coating and determine which analyte is being detected. The second laser set at 525 
nm defines the magnitude of the PE-derived signal, which is directly proportional to 
the amount of analyte bound (Figure 2.3).  
The beads are coloured using a proprietary mix of an infrared and a red coloured dye. 
The distinct colouring can readily generate bead sets with a unique combination of 
the dyes used. Fluorescent excitation of the beads with one wavelength of light 
generates two observable emissions wavelengths, which differ between the different 
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bead’s sets used. By combining each unique bead set with a specific antibody, the 
assay allows for high throughput multiplexing.
 
Figure 2.3 Overview of Luminex Assay.  
(A) A visual representation of how the beads capture specific analytes and 
complexes with them to yield a fluorescent signal. (B) The dual lasers of the flow 
cytometer analyse the bead profile and fluorescence intensity, yielding a specific 
target and concentration. Reproduced from BioRad product information page.  
Page 117 of 300 
 
Reagents: 
 Bio-Plex® Pro™ Mouse Cytokine 23-plex Assay (#M60009RDPD) containing:  
o Coupled magnetic beads (10x) 
o Detection antibodies (10x) 
o Lyophilised cytokine standards 
o Detection antibody diluent HP 
o Standard diluent 
o Assay buffer 
o Wash buffer (10x) 
o Streptavidin-PE (100x) 
o 96 well, flat bottom, black assay plate  
Method: 
Senescent C2C12 myoblast was prepared as described in Section 2.2.1. The media 
was collected from the myoblasts and stored at -80°C. Lyophilised standards provided 
were reconstituted in 250 µL cell culture medium. Standard was vortexed for 5 
seconds then incubated on ice for 30 minutes. A seven-point standard curve was 
prepared as described in Table 3.4. Culture medium was used as a diluent to match 
the samples. The 10x magnetic beads were vortexed thoroughly for 30 seconds. For 
a 96 well plate, 570 µL of the 10x magnetic coupled beads was diluted 1 in 10 in assay 
buffer. The 1x magnetic bead solution was stored on ice in foil. The 1x bead solution 
was vortexed for 30 seconds and 50 µL was added to each well. The plate was placed 
onto the magnetic plate holder and washed twice by adding 100 µL of 1x wash buffer 
to each well. Fifty microliters of the standards, blank, and samples were loaded on to 
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the plate, vortexing thoroughly throughout. The plate was sealed and placed on a 
plate shaker at 850 ± 50 RPM for 30 minutes at room temperature. The Detection 
antibodies (10x) were prepared by vortexing the 10x detection antibody stock bottle 
for 20 seconds followed by a 30 second centrifugation to collect the entire reagent. 
For a 96 well plate, 300 µL of the 10x detection antibody stock was diluted 1 in 10 in 
detection antibody diluent. The plate was washed three times and 25 µL of the 1x 
detection antibody solution was added to each well. The plate was placed on the 
shaker at 850 ± 50 RPM for a further 30 minutes at room temperature. The 1x 
Streptavidin-PE (SA-PE) solution was prepared by vortexing the 100x SA-PE stock 
solution for 5 seconds followed by a 30 second centrifugation to collect the entire 
solution. Sixty microlitres of the 100x SA-PE stock was diluted in 1 in 100 in assay 
buffer; and kept away from light. The plate was washed three times and 50 µL of the 
1x SA-PE solution was added to each well. The plate was placed on to the shaker at 
850 ± 50 RPM for a further 10 minutes at room temperature. Finally, the SA-PE was 
discarded, and the plate was washed three times and 125 µL of Assay buffer was 
added to each well. The plate was placed back on a plate shaker at 850 ± 50 RPM for 
30-seconds before absorbance was determined on the Bio-Plex 2000 system (BioRad, 
Hertfordshire, UK). 
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Table 2.7 Preparing a fourfold dilution series for the Luminex 
2.8 Electromobility Shift Assay (EMSA) for NF-κB transcription factor activity 
An electrophoretic mobility shift assay (EMSA) (AKA: mobility shift electrophoresis, 
gel shift assay, gel mobility shift assay, band shift assay, or gel retardation assay) is 
an electrophoresis technique used to study protein/DNA or protein/RNA 
interactions. EMSAs can be used to identify sequence-specific, DNA-binding proteins 
(such as transcription factors) in crude lysates and, in conjunction with mutagenesis, 
to identify the important binding sequences within the upstream regulatory region 
of a given gene.  
The current, modern form of the assays differs little from the original protocols 
described by Fried and Crothers (1981), and Garner and Revzin (1981). There are also 
precursors to this technique in earlier literature (Eisinger, 1971, Chelm and 
Geiduschek, 1979, Varshavsky et al., 1976).  
Reagents: 
Standard Volume of Diluent (µL) Volume and Source (µL) 
S1 0 250 of reconstituted standard 
S2 150 50 from S1 
S3 150 50 from S2 
S4 150 50 from S3 
S5 150 50 from S4 
S6 150 50 from S5 
S7 150 50 from S6 
Blank 150 0 
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 Extraction buffer (pH 7.9): 
o 25% (v/v) glycerol 
o 0.42M NaCl 
o 1.5mM MgCl2 
o 0.2mM EDTA 
o 0.5mM dithiothreitol (DTT) 
o 0.5mM Phenylmethylsulphonyl fluoride (PMSF)  
o 20mM HEPES (N-2-hydroxyethylpiperazine -N’-2-ethanesulfonic acid) 
 EMSA Gel Solution 
o 5 mL 40% Acrylamide: bis-Acrylamide (29:1) solution (BioRad, 
Hertfordshire, UK) 
o 2 mL, 1 M Tris, pH 7.5 
o 7.6 mL 1 M Glycine 
o 160 µL 0.5 M EDTA, pH 8.0 
o 26 mL dH20 
o 200 µL 10% APS 
o 30 µL TEMED 
 Binding Reactions 
o 10x binding buffer 
 100 mM Tris, 500 mM KCl, 10 mM DTT; pH 7.5 
o 25 mM DTT, 2.5% Tween-20 
o Poly (dI-dC) 1 µg/µL in 10 mM Tris, 1mM EDTA; pH 7.5 
o 100 mM MgCl2 
o 200 mM EDTA, pH 8.0 
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o 50% Glycerol 
o 50 nM NF-κB Oligo (IRDye® 700) (LI-COR, Cambridge, UK) 
o dH2O  
 10x Orange loading dye (LI-COR, Cambridge, UK) 
 10x TBE Stock 
o 1 M Tris base 
o 0.9 M Borate  
o 10 mM EDTA (pH 8.0) 
o dH20 
Method: 
Protein extracts of cells were prepared according to the method described Mosser et 
al. (1988). C2C12 cell pellets or ground muscle powder (Section 2.4.1) were lysed in 
the extraction buffer, sonicated, and centrifuged at 10,000g for 10 minutes at 4°C 
(Eppendorf Centrifuge 5402, London, U.K.). The supernatants were then removed, 
rapidly frozen in liquid nitrogen and stored at -80°C for future analysis. The protein 
content of supernatants was determined via Bradford assay as DTT interferes with 
the BCA assay (Brown et al., 1989). 
The EMSA was performed using the Hoefer® SE400 Air-Cooled Vertical Protein 
Electrophoresis Unit (ThermoFisher, Manchester, UK). EMSA gel solution was 
prepared and was poured between two glass plates (18x16 cm) in clamp assemblies, 
a 1.5 mm thick comb was placed between the plates and the gels set.  
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Sample lysates were mixed with an equal volume of EMSA binding reaction, 
described in Table 2.8. Samples were incubated with the binding reaction at room 
temperature in the dark for 30 minutes. Following the incubation, 2 µL Orange 
loading dye was added to each sample and loaded into the EMSA gel. The 
electrophoresis chamber was covered in foil to prevent bleaching of the 
fluorophores. Electrophoresis was performed at 160V for 90 minutes, at 4°C. The 
bands were imaged on the LI-COR Odyssey® CLx Imaging System (LI-COR, Cambridge, 
UK).  
 Volume (µL) 
10x binding buffer 2 
25 mM DTT, 2.5% Tween-20 2 
Poly (dI-dC) 1 µg/µL in 10 mM Tris, 1mM EDTA; pH 7.5 1 
100 mM MgCl2 1 
200 mM EDTA, pH 8.0 1 
50 nM NF-κB Oligo (IRDye 680) 1 
dH2O  2 
Protein extract + dH2O 10 
Table 2.8 EMSA binding reaction 
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2.8.1 Competition and Supershift experiments 
To verify that the results from gel shift mobility assay do not arise from non-specific 
binding of probes to protein/DNA complexes, competition experiments and 
supershift assays were performed. 
Figure 2.4 illustrates the potential bands detected during an EMSA and supershift 
assays. In supershift experiments, the addition of antibodies to the reaction is used 
to determine the identity, as well as the specificity of the binding protein. If the 
antibody recognizes the DNA-protein complex, the antibody can bind and produce a 
‘heavier’ labelled band (supershift band). Since the extra mass of the antibody will 
result in slower migration in the gel than the original DNA-protein complex, thus 
“shifting” the band up the gel. Competition analyses take two forms: specific and 
non-specific. In the specific reactions, the unlabelled competitor DNA is an identical 
sequence as the original labelled probe. For non-specific reactions, DNA fragments 
or oligonucleotides with different sequences from the original probe are used. Thus, 
if the band is specific, the addition of the unlabelled, specific competitor should 
decrease the intensity of the band. The addition of the unlabelled, non-specific 
competitor should leave the specific band unchanged. 
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Figure 2.4 Overview of the gel shift assay method. 
Protein/DNA complexes are detected using fluorescent DNA probes for specific transcription factors. Addition of antibody specific to protein 
complex of interest increases the mass of the sample, reducing its ability to migrate through the gel. 
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2.9 Gene Ontology Term Analysis 
WebGestalt (2019 release) was used to perform the Overrepresentation Enrichment 
Analysis for each of the gene ontology categories (Biological Process, Cellular 
Component and Molecular Function). The list of mouse genes was analysed against 
the reference option of genome. The significance level was FDR<0.05 and the 
multiple test adjustment was done using the Benjamini–Hochberg method. 
To help better visualize the GO terms obtained from the analysis above described, 
the tool REViGO was used. The p-values here considered were the FDR values 
obtained previously, with the mus musculus database option used for the GO terms. 
2.10 Statistics 
Graphs were plotted and statistics were calculated with GraphPad Prism® Version 
6.5. Data are expressed as mean ± standard error of the mean (SEM). *P < 0.05. 
Grubbs test was used when appropriate to identify outliers within the sample 
population. Column statistics were then used on the data set to identify normality. 
  










3 Chapter 3: An In vitro Model of Cellular Senescence in C2C12 Muscle Myoblasts 
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3.1  Introduction 
3.1.1 Cellular Senescence 
The first introduction to, and demonstration of cellular senescence was led by 
Hayflick and Moorhead (1961), describing Replicative Senescence (RS), one of the 
methods of inducing cellular senescence in cells. There are several ways of inducing 
cellular senescence, not linked to proliferation dependent telomere shortening 
demonstrated by Hayflick and Moorhead (1961). Many proliferative cell types can 
undergo stress-induced premature senescence (SIPS) upon exposure to damaging 
but non-lethal stresses (UV light, ionizing radiation, H2O2, hyperoxia, etc.) (Toussaint 
et al., 2000b), and oncogene-induced senescence (OIS) which is a senescent 
phenotype that depends on the activation and/or overexpression of oncogenes 
(Serrano et al., 1997).  
This study focuses on the use of etoposide (Section 1.1.3.2) to induce a stress-induced 
premature senescence (SIPS) (Section 1.1.3.3) via DNA damage, triggering a DNA-
damage response (DDR) (Section 1.1.3.3) (von Zglinicki, 2002).  
3.1.2 Etoposide and the DNA Damage Response 
Etoposide induces of senescence (Section 1.1.3.2). Etoposide forms complexes with 
DNA and the topoisomerase II enzyme, used to unwind DNA during mitosis. 
Complexes of etoposide/topoisomerase II prevents unwinding and the subsequent 
re-ligation of the DNA strands; causing DNA strands to break (Pommier et al., 2010). 
The resulting DNA damage response results in a permanent cell cycle arrest and 
cellular senescence (Section 1.1.3.3). 
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DNA damage can be in the form of single or double strand breaks (DSBs) which 
activates the DDR and triggers DNA repair or cell cycle arrest (Zou, 2007). DNA DSBs 
have been shown to both indirectly and directly promote the phosphorylation and 
activation of p53, a key protein in cell cycle arrest (Saito et al., 2002). 
3.1.3  The Role of Cell dependant Kinase Inhibitors in Cell Cycle Arrest 
One of the hallmarks of a senescent cell is that they enter a metabolically active state 
of permanent growth arrest, triggered by the p53/p21 and/or p16INK4A/Rb tumour 
suppressive pathways; downstream of the DDR pathway (Section 1.1.3.3). 
Tumour protein 53 (TP53, or p53), is a gene that codes for a protein that regulates 
the cell cycle and functions as a tumour suppressor. The p53 protein has been shown 
to increase during cellular senescence (Serrano et al., 1997). When phosphorylated, 
p53 stimulates the expression of numerous genes that regulate cell cycle arrest 
and/or promote cellular senescence. An example of which is p21, which p53 
transcriptionally upregulates by direct promoter binding of the CDKN1A gene (Tahara 
et al., 1995).  
p21Cip1, also known as p21Waf1, cyclin-dependent kinase inhibitor 1, or CDK-
interacting protein 1; is a cyclin-dependent kinase (CDK) inhibitor (CDKI) triggers G1-
phase cell cycle arrest by inhibiting the cell cycle regulatory kinases CDK4 and CDK2 
(He et al., 2005).  
Phosphorylation of p53 also results in increased transcription of p16INK4A (Serrano et 
al., 1997). Upregulation of p16INK4A leads to the prevention of Retinoblastoma (Rb) 
phosphorylation, resulting in inhibition of E2F-dependent transcription. E2F are a 
group of genes that encode a family of transcription factors in mammalian cells, all 
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of which are involved in the cell cycle regulation (Serrano et al., 1997). The cell does 
not progress from G1 phase into S phase, resulting in cell cycle arrest.  
Furthermore, to ensure the stable repression of E2F-target genes and cell cycle 
arrest, Rb promotes heterochromatin formation at E2F-regulated gene promoters. 
The E2F gene promoters are epigenetically silenced, in a process called Senescence-
Associated Heterochromatin Foci (SAHF) formation (Narita et al., 2003); a marker of 
senescence. 
3.1.4 Markers of cellular senescence 
Senescent cells are diverse; dependant on the cell type of methods used to induce 
senescence, and the cell type (Wiley et al., 2017). None of the current markers are 
completely specific for senescence and are used in combination to characterise 
cellular senescence. Several markers of senescence were described in Section 1.1.1, 
which include: 
 Changes in morphology  
 Cell cycle arrest/absence of proliferative markers 
 Expression of Senescence-associated β-galactosidase (SA-β-gal) activity 
 Changes in Chromatin structure (Senescence Associated Heterochromatin Foci 
[SAHF]) 
 Production of Senescence associated secretory phenotype (SASP). 
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3.1.5 The Senescence Associated Secretory Phenotype (SASP) produced by 
senescent cells in vivo: role in the development of sarcopenia 
Senescent cells can have both a positive and negative role in vivo; primarily 
implemented via the senescence associated secretory phenotype (SASP), which has 
also been called the senescence messaging secretome (SMS) (Section 1.1.5). 
The SASP can have a detrimental effect on normal physiology and results in 
pathology, an example of which may be sarcopenia. Studies show that senescent cells 
can induce senescence in neighbouring cells through paracrine mechanisms: (Acosta 
et al., 2013, Nelson et al., 2012, Faggioli et al., 2012). This SASP mediated effect has 
been called the bystander effect (Nelson et al., 2012, von Zglinicki et al., 2020). 
Muscles from both old mice and humans have been shown to accumulate p16INK4a 
and SA-β-gal positive cells (Sousa-Victor et al., 2014, von Zglinicki et al., 2020), with a 
reduced regenerative capacity (Bernet et al., 2014). Inactivation of p16INK4a in 
transgenic mice rejuvenates aged satellite cells and promoted muscle regeneration 
upon injury (Cosgrove et al., 2014) (Section 1.1.7). Clearance of p16INK4a expressing 
satellite cells also ameliorated sarcopenia in a mouse model (Baker et al., 2011) 
(Section 1.1.7). This highlights that senescent satellite cells may be detrimental in the 
context of sarcopenia. 
3.1.6 The role of NF-κB in the Senescence Associated Secretory Phenotype of 
senescent cells 
Several studies have clearly demonstrated that NF-κB plays a significant role in the 
mRNA expression of most SASP factors (e.g. IL-6 and CXCL1) in several models of 
senescence (Reviewed by Malaquin et al. (2016)). In normal, stress-free conditions, 
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NF-κB is inhibited by its interaction with cytoplasmic IκB, preventing nuclear 
translocation. In stressed conditions, IκB kinase (IKK) initiates the degradation of IκB, 
allowing for nuclear accumulation and post translational modifications (e.g. 
phosphorylation, acetylation) of NF-κB. Ultimately resulting in NF-κB activation 
(Karin, 1999). The molecular mechanisms leading to NF-κB activation in the context 
of senescence remain poorly defined. Work by Acosta et al. (2008) suggests that the 
SASP may act in an autocrine feedback loop to reinforce growth arrest.  
3.1.7 Hypothesis 
The hypothesis was that senescent cells accumulate in muscle during ageing. The 
proinflammatory SASP activates NF-κB in old muscles which then contribute to the 
pro-inflammatory phenotype of the mouse. The nature of senescent cells in unclear 
but it was hypothesised that mononuclear myoblasts present in muscles can express 
senescence markers and that these cells have a detrimental effect on mature muscle 
cells.  
This hypothesis was tested by inducing and characterising senescence in C2C12 
myoblasts as a proof of principle. Furthermore, C2C12 myotubes will be treated with 
the conditioned media containing the SASP from the senescent cells to investigate 
the effect on activation NF-κB activity in multinuclear myotubes. 
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3.2 Methods 
3.2.1 Inducing cellular senescence in C2C12 myoblasts  
C2C12 myoblasts were seeded into 12 well plates and treated as described in Section 
2.2.1. Briefly, myoblasts were seeded into 12 well plates at 5x103 cells per well and 
incubated at 37°C in a humidified 5% CO2/95% air incubator overnight to adhere. 
Etoposide powder (Sigma, E1383) was reconstituted in Dimethyl Sulfoxide (DMSO) to 
a concentration of 100 mM, and this was diluted 1 in 10 to a stock concentration of 
10mM in growth media. Myoblasts were then treated with different concentrations 
(30-3.75µM) of etoposide or DMSO carrier control in growth media for 24 hours and 
incubated appropriately. Etoposide or DMSO control containing media was then 
removed and replaced with standard growth media and further incubated for up to 
5 days. Cells were monitored daily to check for progression of senescent morphology, 
using a light (Nikon Diaphot, Tokyo, Japan) microscope.  
3.2.2 Viability of etoposide treated C2C12 myoblasts 
C2C12 myoblasts were seeded into 12 well plate and treated as described in Section 
2.2.1. Cell viability was determined using a LIVE/DEAD© reduced Biohazard 
Viability/Cytotoxicity Kit (Molecular Probes, UK) as described in Section 2.3. Cells 
were counted in 3 fields of view, in 3 unique wells, at a 10x magnification for each 
treatment, and quantified.  
3.2.3 Proliferation of etoposide treated C2C12 myoblasts 
C2C12 myoblasts were seeded into 6 well plate and treated as described in Section 
2.2.1. Treated C2C12 myoblasts in a 6 well plate well were aspirated from the well 
using trypsin as described in Section 2.2.5, 1-5 days post treatment. The initial 
Page 133 of 300 
 
number of seeded cells was used to signify day 0 (1x104). Cells were counted using 
Trypan blue and the cell number plotted over time.  
3.2.4 Senescence Associated β-Galactosidase staining of cells 
C2C12 myoblast were seeded and treated as described in Section 2.2.1. SA-β-gal 
detection was performed using the Senescence β-Galactosidase Staining Kit (Cell 
Signalling Technologies, #9860) (Section 2.3.2). C2C12 myoblasts were immersed and 
incubated at 37°C overnight, in a low CO2 environment. The staining solution was 
then removed, cells were rinsed with DPBS and imaged under a light microscope 
(Nikon Diaphot, Tokyo, Japan). Cells were counted in 3 fields of view, in 3 unique 
wells, at a 10x magnification for each treatment, and quantified. 
3.2.5 Western blotting for markers of senescence in C2C12 myoblasts 
C2C12 myoblasts were seeded into 6 well plates and treated as described in Section 
2.2.1. The cells were aspirated form the wells using trypsin and lysed as described in 
Section 2.4.1 and protein concentrations quantified as described in Section 2.4.2. 
Samples were then denatured and loaded onto acrylamide gels and proteins 
resolved, as described in Section 2.5.1. Following transfer of proteins to a 
nitrocellulose membrane using the Geneflow blotting system (Section 2.5.2), 
membranes were blocked in 5% milk and incubated with primary antibodies (Table 
3.1) at 4°C overnight. Membranes were washed 3x5 minutes and incubated with the 
secondary antibody (Table 3.1) for 1 hour at room temperature. Membranes were 
then washed for 3x5 minutes and images of the membranes were captured on the LI-
COR Odyssey® CLx Imaging System (LI-COR, Cambridge, UK) at a wavelength of 
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800nm. 
3.2.6 Immunofluorescent analysis of senescence markers in etoposide treated 
C2C12 myoblasts 
C2C12 myoblasts were seeded into 12 well plate and treated as described in Section 






Secondary antibody Secondary 
antibody 
dilution 
P65 1 in 1000 IRDye® 800CW Goat anti-Rabbit 
(LI-COR, Cambridge, UK) 
1 in 15,000 
p53 1 in 1000 IRDye® 800CW Goat anti-Mouse  
(LI-COR, Cambridge, UK) 
1 in 15,000 
p21 1 in 1000 IRDye® 800CW Goat anti-Rabbit 
(LI-COR, Cambridge, UK) 
1 in 15,000 
p16 1 in 1000 IRDye® 800CW Goat anti-Rabbit 
(LI-COR, Cambridge, UK) 
1 in 15,000 
IKBα 1 in 1000 IRDye® 800CW Goat anti-Rabbit 
(LI-COR, Cambridge, UK) 
1 in 15,000 
Table 3.1 Antibody dilutions for western blotting of senescence markers in C2C12 
cells 
Page 135 of 300 
 
3.2.7 Multiplex cytokine analysis of the media from etoposide treated C2C12 
myoblasts 
C2C12 myoblasts were seeded into 6 well plates and treated as described in Section 
2.2.1. The media from these cells were collected and analysed for cytokine content 
by Luminex, as described in Section 2.7. Cytokine values were normalised to the 
protein content of the wells, which was analysed by protein quantification (Section 
2.4). 
3.2.8 Analysis of myotubes treated with SASP from senescent myoblasts: effect on 
Electromobility Shift Assay (EMSA) for NF-κB transcription factor activity and 
myotube diameter 
C2C12 myoblasts and myotubes were seeded into several plates as described in 
Section 2.2.3. Myotubes were treated with media collected from senescent and 
control myoblasts. The treated myotubes were analysed by EMSA, as described in 
Section 2.8. The bands were quantified as described in Section 2.5.4. for 
determination or myotube diameter, images of myotubes were taken at 10x 
magnification using a light microscope (Nikon Diaphot, Tokyo, Japan). Myotubes in 
the field of view were analysed using Image J (US National Institutes of Health, 
Maryland, USA). For each image, myotubes were traced and the minimum Ferets 
diameter was measured. Measurements for approximately 20 single myotubes from 
6 wells were pooled to give an average value per condition. 
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3.3 Results 
3.3.1 Viability of etoposide treated C2C12 myoblasts 
Figure 3.1 shows fluorescent images of C2C12 myoblasts treated with 3.75 µM (B), 
7.5 µM (C), 15 µM (D), and 30 µM (E) etoposide; as well as those treated with DMSO 
vehicle control (A) for 24 hours. C2C12 myoblasts treated with etoposide showed a 
dose dependant loss of viability following treatment with increasing concentrations 
of etoposide for 24 hours. Quantification of viable cells (F) showed a significant loss 
of viability when cells were treated with 15 µM and 30 µM etoposide, when 
compared with DMSO treated control cells (P<0.05). No significant effect on viability 
was seen when cells were treated with the lower concentrations of etoposide (3.75 
µM and 7.5 µM) when compared to the DMSO treated control cells. 
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Figure 3.1 LIVE/DEAD viability assay of etoposide treated myoblasts.  
C2C12 myoblasts treated with 3.75 µM (B), 7.5 µM (C), 15 µM (D), 30 µM (E) etoposide, or DMSO 
vehicle control (A). Viable cells (Green); non-viable cells (Red). (F) Percentage of viable cells, from 
3 unique fields of view (10x magnification). Data are expressed as mean ± SEM (N=3). ANOVA 
(P<0.05) with Tukey's test. # compared with control, P<0.05. * Compared with 3.75μM 
etoposide, P<0.05. Scale bar represents 100 µm. 
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3.3.2  Proliferation of etoposide- and DMSO-treated C2C12 myoblasts 
Figure 3.2 shows the cell number of C2C12 myoblasts treated with 3.75 µM etoposide 
or DMSO vehicle control for 24 hours, analysed for a further 5 days of culture. 
Myoblasts treated with DMSO increased in cell number, peaking at 3 days of culture. 
The myoblasts treated with etoposide did not increase in cell number following 
treatment. Treatment of myoblasts with etoposide for 24 hours appeared to halt 
cellular division permanently when compared with DMSO treated controls since cell 
division did not return following removal of etoposide. Thuds, a significant difference 
in total cell number were seen at 3 days following-etoposide treatment when 
compared with the equivalent time point in the DMSO control cells (P<0.05).  
  
Figure 3.2 Cell number of C2C12 myoblasts treated with etoposide.  
C2C12 myoblasts treated with 3.75 µM etoposide or DMSO for 24, and cell number 
was measured across 5 days of culture. Data are expressed as mean ± SEM. ANOVA 
(P<0.05) with Tukey's test. * P<0.05. 
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3.3.3  SA-β-gal activity of etoposide- and DMSO- treated C2C12 myoblasts  
Figure 3.3 shows representative bright field images of DMSO treated control C2C12 
myoblasts and myoblasts stained for SA-β-gal activity after 5 days after treatment 
with 3.75 µM (B), 7.5 µM (C), 15 µM (D), and 30 µM (E) etoposide. Blue pigments 
show positive staining. Quantified number of SA-β-gal positive cells are shown in (F).  
Treatment with etoposide resulted in a substantial increase in SA-β-gal staining, 
whereby approximately 35% of the etoposide treated cells showed SA-β-gal staining, 
whereas the DMSO control cells showed no detectable activity. Little difference in 
the number of positive cells was seen between the different concentrations of 
etoposide treatment used. Furthermore, changes in the morphology of etoposide 
treatment myoblasts, compared with DMSO treated, or untreated control cells were 
evident in Figure 3.1 and Figure 3.3. The etoposide treated cells had a flatter 
appearance and covered a larger surface area. 




Figure 3.3 SA-β-Gal staining of etoposide treated myoblasts.  
C2C12 myoblasts at 5 days after treatment with 3.75 µM (B), 7.5 µM (C), 15 µM (D), 30 µM (E) 
etoposide, compared with DMSO vehicle control treated for 24 hours (A). SA-β-Gal positive 
cells (Blue). Percentage of SA-β-Gal positive cells following treatment with different 
concentrations of etoposide, from 3 unique fields of view (10x magnification). Data are 
expressed as mean ± SEM. ANOVA (P<0.05) with Tukey's test. Scale bar represents 100 µm. 
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3.3.4 Detection of senescence markers in etoposide treated C2C12 myoblasts 
Figure 3.4 shows the protein levels of the senescence markers: p53, p21, and p16; in 
untreated C2C12 myoblasts and in cells at 1, 3, or 5 days after 24‐hours of treatment 
with 3.75 µM etoposide, or DMSO treated controls. Inflammation markers p65 and 
IKBα were also investigated. Etoposide treated myoblasts showed elevated levels of 
p21 following treatment, at 3 days following treatment. The IKBα protein levels 
decreased following etoposide treatment, suggesting this as a mechanism of NF-κB 
activation. The proteins p65, p53, and p16 were not consistently detected in any 
sample (positive control was excluded, data not shown).  
Figure 3.5 shows the localisation of p21 in the nuclei of etoposide treated C2C12 
myoblasts, which was absent in the untreated control cells. Some localization of p21 
was also seen in the DMSO treated control cells. Etoposide treated cells showed an 
altered morphology, a larger flattened shape compared with the untreated or DMSO 
control myoblasts. The etoposide treated cells also showed a larger nuclear space, 
with punctate DAPI staining, which was absent in untreated or DMSO treated cells. 
In agreement with the western blot analysis, control untreated cells contain low 
levels of p21 and evidence of positively stained cells was rare by immunostaining. In 
contrast, DMSO treatment resulted in some non-significant increase in p21 levels 
(Figure 3.4) and some increased p21 staining; particularly in the cells that seem to 
have begun to fuse into myotubes at the 5 day time point (Figure 3.5), although this 
was not as evident as the increase seen in etoposide treated myoblasts. 
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A 
Figure 3.4  
(A) Protein levels of p65, IKBα, p53, p21, and p16, of C2C12 myoblasts 1, 3, or 5 days after 24‐hour treatment with 3.75 µM etoposide, 
DMSO treated and untreated actively proliferating myoblasts. (B) Quantification of the relative intensity of p21 levels within etoposide 
treated, DMSO treated, or untreated, proliferating C2C12 myoblasts (n=3). ANOVA (P<0.05) with Tukey's test 
B 
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Figure 3.5  
C2C12 myoblasts 5 days after 24-hour treatment with 3.75 µM etoposide, DMSO treated, and untreated, proliferating C2C12 myoblasts. Cells 
were stained for p21 (Red), phalloidin (Green), and DAPI (Blue). Scale bar represents 100 μm. 
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3.3.5 Analysis of the SASP from etoposide- and DMSO-treated C2C12 myoblasts. 
Figure 3.6 shows the cumulative cytokine content of the SASP secreted into the media 
of etoposide treated myoblasts after either 1, 3, or 5 consecutive days incubation, 
compared with DMSO treated, and untreated myoblasts. The media contained the 
cytokines produced across the entire incubation period and so has the limitation that 
the value represents the whole time and so may both mask larger acute release but 
also does not account for degradation of released proteins. Media from etoposide 
treated cells showed significantly increased IL-2, IL-6, IL-12(p40), IL-17, Eotaxin, KC, 
MCP-1 and RANTES, when compared with untreated controls when collected over 
the full time period Of interest is that this increased production of SASP by etoposide 
treated myotubes was accompanied by decreased levels of Iκ-B in myotubes, 
inferring increased activation NF-κB (Figure 3.4). IL-2, IL-6 IL-12(p40) were 
significantly higher in media collected at each time point than the corresponding 
DMSO treated control. Media from DMSO treated cells showed also significantly 
higher levels of Eotaxin, KC, and MCP-1 when compared to untreated actively dividing 
myoblasts, particularly at later time points when myoblasts had reached contact 
inhibition.  
To investigate the potential issue of cytokine degradation in the media over time, 
one-hour samples were also analysed at each time point. Figure 3.7 shows the acute 
cytokine content of the SASP secreted into the media of etoposide treated myoblasts 
for 1 hour at 1-, 3-, or 5-days incubation, compared with media from DMSO treated 
and untreated, actively dividing myoblasts. The increase in a number of the values 
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over the full time period was reflected in those measured acutely for one hour at 
each time point, particularly for IL-2, Eotaxin and RANTES.  
3.3.6 Effects of treating C2C12 myotubes with SASP enriched media from senescent 
C2C12 myoblasts on NF-κB DNA binding activity. 
Figure 3.8 shows representative images of C2C12 myotubes after 24-hour treatment 
with SASP conditioned media from senescent C2C12 myotubes, or DMSO vehicle 
treated myoblasts. DMEM differentiation media was used as a control. An untreated 
control was added as the quantification of the cytokines produced by DMSO treated 
myoblasts showed increased levels of the cytokines Eotaxin, KC, and MCP-1 when 
compared to untreated controls. No significant differences were seen in myotube 
fibre diameters between etoposide- and DMSO-treatment. 
Figure 3.9 shows a representative EMSA of NF-κB/p65 transcription factor activity in 
C2C12 myotubes after treatment with the SASP enriched media from senescent 
C2C12 myoblasts. Quantification of the EMSA bands showed that the myotubes 
treated with media from the senescent myoblasts had increased NF-κB/p65 activity 
when compared with the myotubes treated with media from DMSO treated 
myoblasts, as well as untreated myotubes and myotubes with a media change alone.
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Figure 3.6 Cytokine analysis of the total SASP from senescent compared with 
proliferating C2C12 myoblasts. 
The cumulative cytokine content of the media from C2C12 myoblasts treated with 
3.75 µM etoposide collected after 1, 3, or 5 days following treatment, compared 
with DMSO treated and untreated, proliferating C2C12 myoblasts. Data are 
expressed as mean ± SD (N=3-6). ANOVA (P<0.05) with Tukey's test. * compared 
with control, P<0.05. 
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Figure 3.7 Cytokine analysis of the acute SASP from senescent compared with 
proliferating C2C12 myoblasts. 
The acute cytokine content of the media from C2C12 myoblasts treated with 3.75 
µM etoposide collected for 1 hour at 1, 3, or 5 days after treatment, compared 
with DMSO treated and untreated, proliferating C2C12 myoblasts. Data are 
expressed as mean ± SD (N=3-6). ANOVA (P<0.05) with Tukey's test. * compared 
with control, P<0.05. 
 




Figure 3.8  
Representative images of C2C12 myotubes treated with conditioned media for 24 hours, from 
etoposide treated C2C12 myoblasts 3, 5, or 7 days past etoposide treatment (B-D), compared with 
untreated myotubes (A). Conditioned media from DMSO treated myoblasts (E-G) and 
differentiation media (H) were used as controls. (I) Minimum Ferets diameter of myotubes fibres 
after 24-hour treatment with conditioned media from etoposide treated or DMSO treated 
myoblasts. Data are expressed as mean ± SEM. ANOVA (P<0.05) with Tukey's test. Scale bar 
represents 100 µm. 
I 
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Figure 3.9 EMSA for NF-κB/p65 transcription factor DNA binding activity in C2C12 
myotubes cultured in SASP enriched media. 
(A) Representative EMSA of C2C12 myotubes treated with SASP enriched media 
collected, from senescent (etoposide treated) or DMSO vehicle treated C2C12 
myoblasts. Myotubes were treated for 24 hours and the fibres collected for EMSA, 
looking for NF-κB/p65. Arrows represent migration of supershifted bands. (B) 
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3.4  Discussion  
The aims of this study were to establish a model of senescence in C2C12 myoblasts and 
examine the effect of SASP produced by the cells on the activity of NF-κB in myotubes, as a 
potentially bystander effect of senescent cells on myotubes. Data presented here 
demonstrated that treatment of C2C12 myoblasts with etoposide resulted in increased 
evidence of several hallmarks of senescence; including altered morphology, permanent 
arrested cell growth, increase in senescence markers particularly p21, and the production of 
an inflammatory SASP detectable in the cell media. Treatment of C2C12 myotubes with media 
from senescent myoblasts resulted in an increased NF-κB DNA binding activity, suggesting 
that the presence of such cells is likely to have a detrimental effect on multinuclear myotubes.  
3.4.1 Treatment C2C12 myoblasts with etoposide induced senescence  
There are a significant number of small molecules which are widely used to induce senescence 
in experimental models, extensively reviewed by Petrova et al. (2016). As discussed in Section 
3.1.2, etoposide is a topoisomerase II inhibitor widely used as a chemotherapeutic agent. Like 
other topoisomerases, etoposide treatment has been used in several other tissue culture 
models to induce senescence. Five days of etoposide treatment has been shown to be 
sufficient to generate a senescent phenotype in other cell types (Nagano et al., 2016). Probin 
et al. (2006) treated WI38 cells with 20 µM etoposide for 24 hours and identified a senescent 
phenotype, with an increase in p53 and p21 signalling; as well as γH2AX phosphorylation. 
Litwiniec et al. (2013) treated A549 cells with 0.75–3 µM etoposide for 72 hours and saw a 
senescent like morphology, positive SA-β-gal activity as well as increased p21 expression.  
The decrease in myoblast viability following the treatment with relatively high concentrations 
of etoposide can be attributed to cytotoxic effects; the DNA damage caused by etoposide 
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results in DNA double strand breaks (Pommier et al., 2010), and data suggests that higher 
doses of etoposide caused a significant loss in viability, and subsequent death.  
In this study, trypan blue was used to determine cell number at different time points following 
treatment to identify whether the etoposide treated C2C12 myoblasts were in growth arrest. 
The cell numbers of etoposide treated myoblasts remained the same over 5 days of culture 
despite the removal of the etoposide after 24 hours, unlike the DMSO vehicle treated cells. 
This demonstrated growth arrest, for up to 5 days after etoposide treatment, suggesting 
potential permanent growth arrest.  
Several studies have induced senescence in C2C12 myoblasts through various means: (Chen 
et al., 2020) (Hwang et al., 2018), (Sosa et al., 2018), (Jadhav et al., 2013), (D'Orazi et al., 2000). 
However, this is the first demonstration of the use of etoposide to induce senescence in 
C2C12 myoblasts.  
3.4.2  C2C12 myoblasts demonstrated characteristic features of senescence 
There is not a single universal biomarker that identifies senescence in cells. Therefore, 
researchers have identified several common indices of senescence, as described in Section 
3.1.4, that are used in tandem to identify cellular senescence. 
SA-β-gal staining is a common marker for senescence in tissue. C2C12 myoblasts treated with 
etoposide displayed positive β-gal staining when compared with untreated or DMSO vehicle 
control cells (Section 3.1.4). Similar staining was seen in a study by Jadhav et al. (2013), where 
C2C12 myoblasts were treated with 50 μM C2-ceramide for 8 hours; resulting in higher β-gal 
staining when compared with controls. The limitation of this assay is that whilst increased SA-
β-gal activity is associated with cellular senescence, the assay is not completely specific for 
senescence. For example, cells at confluence can show increased β-gal activity, as can some 
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differentiated cells, such as adult melanocytes (Dimri et al., 1995) and maturing tissue 
macrophages (Bursuker et al., 1982).  
As previously discussed, one biomarker alone is not sufficient to confirm that cells were 
senescent. Previous studies have shown increased p21 staining in the nuclei of C2C12 cells 
(Wang and Walsh, 1996). In this study, we also examined the levels of p21 in control and 
treated cells. Etoposide treated myoblasts had higher protein levels of p21 than the cells 
treated with DMSO vehicle control, at 3 days following etoposide treatment (Figure 3.4). The 
levels of p21 protein appeared to be increasing from day 1-3 and decreasing by day 5. 
Previous studies have shown that 3–5 days of p21 overexpression can induce senescence in 
tumour cells (Chang et al., 1999). Transcriptional silencing of E2F genes responsible for cell 
cycle progression could result in the upregulation of p21, reinforcing cell cycle arrest (Narita 
et al., 2003).  
The quantification of p21 protein content by western blotting or immunohistochemistry in 
etoposide treated cells compared with DMSO treated cells is complicated. Senescent cells 
demonstrate growth arrest and an increase in cell volume. In contrast, DMSO treated cells 
continue to replicate, finally resulting in temporary growth arrest when confluent, where they 
begin to terminally differentiate into myotubes. Thus, the numbers of etoposide treated cells 
plateaued following the 24-hour treatment, whilst the DMSO treated cells carried on dividing 
and reached a plateau once they had reached confluence within the plate at 5 days of culture. 
Indeed, p21 may have played a role in establishing permanent cell cycle arrest following 
etoposide treatment, but may not be crucial in the maintenance of growth arrest since only 
minor effect of confluence was seen in p21 immunohistochemical identification when DMSO 
treated cells reached confluence at the 5 day time point (Narita et al., 2003). During 
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myogenesis, precursor cells irreversibly withdraw from the cell cycle as they differentiate into 
mature myotubes and this complicates the measurement of indices of senescence, 
particularly p21. Upregulation of p21 is a critical regulatory event that establishes the post-
mitotic state with additional development of resistance to apoptosis; such coordinated 
regulation of cell proliferation and cell death provides a mechanism to deposit muscle mass 
during embryonic development (Walsh, 1997).  
The changes in morphology of the C2C12 myoblasts demonstrated characteristic senescent 
morphology. Senescent myoblasts in vitro present with a larger, flatter morphology than their 
original, non-senescent shape (Jadhav et al., 2013). Thus, etoposide treated myoblasts were 
significantly larger than the untreated and DMSO treated control cells. This, accompanied by 
altered DAPI staining, resembling senescence associated heterochromatin formations 
(SAHFs) within the etoposide treated cells was not evident in the untreated or DMSO treated 
control cells (Narita et al., 2003). This further complicated the quantification of the content 
of proteins such as p21 since levels are normalised to total protein content. However, in this 
instance, each cell may contain significantly more total protein. Thus, higher levels of p21 per 
unit protein in the nucleus then reflects more p21 per nuclei in a larger cell and so 
considerably more per cell. The effects of this are unclear. 
From the findings described, we can conclude the etoposide treatment of C2C12 myoblasts 
resulted in a senescent phenotype, and that DMSO treated cells did not induce senescence, 
although some minor evidence of increased p21 staining was evident, likely due to contact 
inhibition at confluence. It is intriguing that little evidence of p16 or p53 were evident in these 
cells despite changes in other indices suggesting that the cells were senescent.  
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3.4.3 Characterising the SASP produced by senescence C2C12 cells 
To characterise the secretory profile of the senescence C2C12 myoblasts, media was collected 
at 1, 3, and 5 days after etoposide treatment and examined by multiplex ELISA system. Data 
showed that etoposide treated, senescent C2C12 myoblasts produce a proinflammatory 
secretory profile that contained cytokines that have been reported as part of the SASP in 
other cells (Coppe et al., 2010a). 
The levels of IL-2, IL-6, IL-12(p40), IL-17, Eotaxin, KC, MCP-1, and RANTES were significantly 
increased in the media of etoposide treated, senescent myoblasts collected at specific time 
points following treatment. Since it was possible that cytokines may have degraded during 
incubation in the media over a 5-day period, we also examined the acute release of cytokines 
in the media for 1 hour at each of the time points and these data confirmed increases in a 
number of these cytokines. Eotaxin, KC, and MCP-1 were also increased in the media of DSMO 
treated myoblasts compared with untreated actively proliferating myoblasts. One 
explanation for this is similar to the discussion of p21 above, that the DMSO treated cells were 
capable of dividing to confluence, where cells may start to differentiate to form myotubes. 
Ge et al. (2013) have shown that cytokines play a role in the differentiation process of C2C12 
cells from myoblast to myotubes and the increase in cytokine levels seen in the media of 
DMSO treated myoblasts could be due to normal differentiation programming of C2C12 
myoblasts, potentially ruling out a direct role of these cytokines in senescence per se.  
3.4.4 Treatment of C2C12 myotubes with media containing the SASP from senescent C2C12 
myoblasts promoted inflammation.  
To examine the effect of the presence of senescent cells on mature muscle myotubes in vivo, 
C2C12 myotubes were treated with the media containing the SASP from senescent C2C12 
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myoblasts at 3, 5, and 7 days after etoposide treatment. The 1-day time point was excluded 
and replaced with the 7-day time point to capture any longer-term effects on myotubes (as 
the 1-day time point contained etoposide and so would complicate interpretation). Increased 
activation of canonical p65/NF-κB transcription factor was seen in the myotubes treated with 
SASP containing media compared with media from the DMSO-treated, fresh DMEM, or from 
untreated control cells. However, this was not accompanied by any significant changes in fibre 
diameter, although a significantly longer period may be needed to detect atrophy. 
These findings are supported by other studies. A systematic review and meta-analysis by Bano 
et al. (2017), highlights the role inflammation on the development of muscle atrophy and 
sarcopenia. Muscle from old mice and humans have been shown to accumulate p16INK4a and 
SA-β-gal positive senescent satellite cells (Sousa-Victor et al., 2014), and this is proposed to 
reduce regenerative capacity of the muscle (Bernet et al., 2014). Inactivation of p16INK4a 
rejuvenated satellite cells of old mice and promoted muscle regeneration following injury 
(Cosgrove et al., 2014). Clearance of p16INK4a expressing satellite cells has also been shown to 
ameliorate sarcopenia in a mouse model (Baker et al., 2011). Highlighting that the presence 
of senescent satellite cells in muscle may play a role in the development of sarcopenia, 
beyond inhibiting regeneration. Studies in our laboratory and others (McArdle et al., 2019) 
have shown that the muscles of old mice and humans demonstrate a chronic increase in NF-
κB activation (Vasilaki et al., 2003). The activation of NF-κB in myotubes by SASP from 
senescent cells provides compelling proof-of-principle that the local effects of SASP may be a 
mechanism by which NF-κB is chronically activated in old mice and humans (Vasilaki et al., 
2003).  
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3.5 Conclusions  
The aims of this chapter were to develop and validate a model of senescence in C2C12 
myoblasts and further, to investigate if senescent cells produced a proinflammatory SASP that 
contributed to the increased NF-κB activity evident in muscle of old mice. Data suggest that 
treatment of C2C12 myoblasts with etoposide resulted in evidence of several the hallmarks 
of senescence and could provide insight into how senescent myoblasts may affect mature 
myotubes in vivo. This in turn provides an explanation as to why a chronic inflammatory 
profile and increased NF-κB activity is seen in skeletal muscle of old mice and humans. Thus, 
it is evident that at least C2C12 myoblasts can become senescent and that SASP produced by 
the senescent cells can activate NF-κB in C2C12 myotubes. Whether such effects are evident 
in vivo is unclear. 
  










4 Chapter 4: Characterising senescence in skeletal muscle of adult and old mice in vivo 
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4.1 Introduction 
The presence of senescent cells in skeletal muscle of old rodents and humans is currently 
unresolved. Several studies have suggested that skeletal muscle contains senescent cells or 
indeed that terminally differentiated muscle fibres can demonstrate evidence of increased 
indices of senescence (da Silva et al., 2019), potentially induced by the presence of non-
muscle senescent cells (the bystander effect) (Nelson et al., 2012, da Silva et al., 2019, von 
Zglinicki et al., 2020). Others have suggested that although muscle fibres themselves do not 
‘senesce’, the detrimental effects of an increase in the local presence of non-muscle 
senescent cells play a major role in the development of sarcopenia. 
4.1.1 The role of senescence in inflammation-mediated sarcopenia 
The mechanisms by which sarcopenia occurs are unclear, but there is evidence that a chronic 
inflammation has a detrimental effect on muscle mass and function (Reviewed by Bano et al. 
(2017)). Muscle strength (Visser et al., 2002), muscle mass (Schaap et al., 2006), muscle 
protein synthesis and catabolism (Jo et al., 2012) have all been shown to be affected by 
inflammation. However, there is no consensus as to the source of this systemic inflammation. 
The elevated level of low-grade, chronic systemic inflammation, called inflammaging, seen in 
old mammals is characterised by increased serum levels of proinflammatory cytokines 
including the components of the SASP, IL-6 and TNFα (Franceschi and Campisi, 2014). The 
source of these cytokines is unclear but it is hypothesised that the presence of increasing 
numbers of senescent cells in old age contributes to this chronic systemic inflammation 
(Campisi and d'Adda di Fagagna, 2007) and so to sarcopenia. Studies where senescent cells 
were transplanted into muscle showed that the presence of senescent cells had a detrimental 
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effect on muscle (da Silva et al., 2019), supporting a role for the increased presence of 
senescent cells in the development of sarcopenia. 
Chronically activated NF-κB is evident in the skeletal muscle of old mice (Vasilaki et al., 2006). 
The mechanism by which this occurs are not clear. Evidence suggests that increased 
extracellular levels of pro-inflammatory cytokines can activate NF-κB in muscle (Lightfoot et 
al., 2014), possibly via increased mitochondrial production of ROS (Lightfoot et al., 2014). The 
chronic activation of NF-κB can lead to activation of degenerative pathways (Thoma and 
Lightfoot, 2018) and so play a direct role in the development of sarcopenia. Skeletal muscle 
has also demonstrated an ability to be a potential source of cytokines, called myokines 
(Nielsen and Pedersen, 2008). Examples of myokines include IL-6, IL-8, and IL-15, which have 
also been reported to be secreted as part of the senescence associated secretory phenotype 
(SASP) in other cell types (Coppe et al., 2010a),potentially further contributing to the 
circulating levels of pro-inflammatory cytokines.  
There are two primary possibilities for senescence in skeletal muscle in vivo, 1) that the 
chronic systemic inflammation from a local or distant site resulted in the activation of NF-κB 
in muscle cells and the muscle production of cytokines contributes further to the systemic 
inflammatory cytokines or 2) that muscle cells themselves demonstrate some indices of 
senescence in old age.  
4.1.2 Evidence of senescence in skeletal muscle fibres 
Several markers of senescence have been identified and are routinely used to identify the 
presence of senescent cells in tissues. However, not all indices are evident in all senescent 
cells and some are notoriously difficult to identify (Hernandez-Segura et al., 2018).  
Page 160 of 300 
 
Whilst skeletal muscle contains a range of different cell types such as fibroblasts and 
adipocytes, muscle fibres are terminally differentiated, multinucleated post-mitotic tissue. 
Due to the terminally differentiated nature of the muscle fibres, there has been little interest 
in investigating cellular senescence. However, there is emerging albeit confusing evidence of 
the presence of senescent-like cells within skeletal muscle tissue. Such evidence for the 
presence of senescent cells in skeletal muscle is however unclear. Few studies have examined 
the expression of senescence markers in other terminally differentiated cells, but the 
implication of such changes is also confusing. Studies have demonstrated increases in some 
indices of senescence in skeletal muscle, but others demonstrate no change (see von Zglinicki 
et al. (2020) for current review).  
Increased expression of senescence marker such as p53 and p21 have been detected in whole 
lysates of skeletal muscles of old mice (Edwards et al., 2007), monkeys (Kayo et al., 2001), and 
humans (Welle et al., 2004). However, detection of senescence in skeletal muscle is 
complicated due to the composition of the tissue and a muscle lysate will undoubtedly 
contain several other cell types. Mature multinuclear skeletal muscle fibres comprise much 
of the tissue, but resident ‘stem’ or satellite cells are also present in the tissue where they are 
responsible for successful regeneration of muscle fibres following muscle damage (Sousa-
Victor et al., 2014). The number of satellite cells present in muscle declines during ageing (Day 
et al., 2010).Indeed, the cell composition of muscle can change with age, complicating any 
whole tissue homogenate analysis.  
Sousa-Victor et al. (2014) investigated satellite cell regeneration in wild-type mice of 2–3 
(young), 5–6 (adult), 20–24 (old) and 28–32 (geriatric) months of age, and hypothesised that 
the environment of the satellite cells may induce irreversible changes that inhibit muscle 
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maintenance in ageing. The authors demonstrated that the number of satellite cells 
decreased in old mice versus adult, but did not decrease further in geriatric mice. Satellite 
cells from mice of different ages or the SAMP8 accelerated ageing model (Section 1.1.7.1) 
were transplanted in to young mice, which resulted in decreased muscle fibre number and 
size with increasing age of the donor/SAMP8 mice.  These results indicate that geriatric age 
induces intrinsic alterations in muscle stem-cell regenerative functions, which cannot be 
rejuvenated by a young host environment. In order to identify these intrinsic alterations, 
global gene expression changes were investigated. Whilst there was divergent gene 
expression between young, adult and old mice, the satellite cells from geriatric mice had a 
cluster that was enriched for genes associated with cellular senescence, including CDKN2A 
(p16). To investigate the role of p16 in satellite cells, Bmi1-/- premature ageing mice were 
also investigated via gene expression analysis and showed increased senescence gene 
expression. Silencing of p16 via shRNA in geriatric satellite cells downregulated p16 
expression and significantly restored activation early after injury, whilst reducing the 
expression of senescence-associated genes. Silencing p16 in transplanted geriatric cells also 
restored the cells ability to self-renew. The shift in these geriatric satellite cells from quiescent 
to senescent is called ‘geroconversion’, and is explained by an imbalance in the 
p16INK4a/Rb/E2F axis, as described in Section 1.1.3.3. Forced p16 expression promoted 
geroconversion of young satellite cells during regeneration and in vitro myogenesis whilst 
depletion of p16 prevents geroconversion from occurring. 
Muscle tissue also contains a number of other cell types due to the presence of blood vessels 
containing immune and other cells as well as fibroblasts, endothelial cells, adipose tissue 
neuronal tissue etc. (Berry et al., 2013), and these cell types have been shown to senescence 
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(von Zglinicki et al., 1995, Akbar et al., 2016, Jurk et al., 2012, Imamura et al., 1983). Studies 
show that senescent cells can induce senescence and tumorigenesis in neighbouring cells 
through paracrine mechanisms: (Acosta et al., 2013, Nelson et al., 2012, Faggioli et al., 2012, 
Coppe et al., 2010a). This SASP mediated effect has been called the bystander effect (Nelson 
et al., 2012) and is evident in transplantation of senescent cells into mice (Xu et al., 2017, da 
Silva et al., 2019). These senescence cells, as well as potentially ‘senescent’ muscle fibres may 
contribute to the pro-inflammatory phenotype and chronic NF-κB activation seen in muscles 
of old mice (Vasilaki et al., 2006). 
4.1.3 Hypothesis and aims 
The hypothesis was that there is an increase in senescence cells near or within skeletal muscle 
of old mice, when compared with adult mice. Further, that these senescent cells are 
producing a proinflammatory SASP driving increased NF-κB activity within the muscle fibres 
of old mice.  
The aim of this chapter was to determine the presence of senescent cells within muscle of 
adult and old mice including the potential of muscle of adult and old mice to produce pro-
inflammatory cytokines as SASP. 











Figure 4.1 A brief overview of the methodology used for this chapter. 
Adult (8-12 months-old) and old (24 months-old) mice were culled, and their blood and hind limbs muscles collected. The plasma of 
these mice was used for multiplex cytokine analysis. The skeletal muscle was prepared for either immuno-histological sectioning and 
staining, or the whole muscle was lysed for protein and mRNA content and assayed for senescence markers.  
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4.2.1 Western blotting for senescence markers 
Gastrocnemius muscle from adult and old mice were ground under liquid nitrogen, lysed, and 
homogenised as described in Section 2.4.1 and protein concentrations quantified as 
described in Section 2.4.2. Samples were then denatured and loaded into acrylamide gels and 
proteins resolved, as described in Section 2.5.1. Following transfer of proteins to a 
nitrocellulose membrane using the Geneflow blotting system (Section 2.5.2), membranes 
were blocked in 5% milk and incubated with primary antibodies (Table 4.1) at 4°C overnight. 
Membranes were washed 3x5 minutes and incubated with the secondary antibody (Table 4.1) 
for 1 hour at room temperature. Membranes were then washed for 3x5 minutes and, images 
of the membranes were captured on the LI-COR Odyssey® CLx Imaging System (LI-COR, 






Secondary antibody Secondary 
antibody dilution 
p53 1 in 1000 IRDye® 800CW Goat anti-Mouse  
(LI-COR, Cambridge, UK) 
1 in 15,000 
p21 1 in 1000 IRDye® 800CW Goat anti-Rabbit 
(LI-COR, Cambridge, UK) 
1 in 15,000 
p16 1 in 1000 IRDye® 800CW Goat anti-Rabbit 
(LI-COR, Cambridge, UK) 
1 in 15,000 
Table 4.1 Antibody dilutions for western blotting of senescence markers in skeletal muscles of 
adult and old mice 
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4.2.2 Quantitative PCR for senescence markers 
Gastrocnemius muscle from adult and old mice were ground into a fine powder under liquid 
nitrogen (Section 2.4.1), lysed in TRIzol™ Reagent (Life technologies, Warrington, UK) and the 
mRNA was extracted (Section 2.6.1). The mRNA was then reverse transcribed and quantified 
as described in Section 2.6.2. Qualitative PCR was performed as described in Section 2.6.3, 
using primer sequences specific for p53, p21, and p16 (Table 4.2). Ct values were normalised 
to the housekeeper gene PPIA (Gong et al., 2016).  
Target Forward Sequence Reverse Sequence 
p53 AGGGTCCATATCCTCCA AATGCAGACAGGCTTTGC 
p21 ATTCCATAGGCGTGGGACCT TCCTGGGCATTTCGGTCAC 
p16 AATCTCCGCGAGGAAAGC GTCTGCAGCGGACTCCAT 
PPIA GGCAAATGCTGGACCAAAC CATTCCTGGACCCAAAACG 
Table 4.2 Primer sequences for senescence markers 
4.2.3 Senescence Associated β-Galactosidase staining of muscle sections 
Gastrocnemius muscle from adult and old mice were cryosectioned as described in Section 
2.3.4. SA-β-gal detection was performed using the Senescence β-Galactosidase Staining Kit 
(Cell Signalling Technologies, #9860) (Section 2.3.2). Muscle sections were immersed and 
incubated at 37°C overnight, in a low CO2 environment. The staining solution was then 
removed, muscle sections were rinsed with DPBS and imaged under a light microscope (Nikon 
Diaphot, Tokyo, Japan). 
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4.2.4 Sudan Black B staining of muscle sections for lipofuscin  
Gastrocnemius muscle from adult and old mice were cryosectioned as described in Section 
2.3.4. Sudan Black B staining was performed on muscle sections as described in Section 2.3.5. 
Muscle sections were imaged under a light microscope (Nikon Eclipse Ci, Tokyo, Japan). 
4.2.5 Immunohistochemistry for senescence markers in etoposide- and DMSO-treated 
C2C12 myoblasts 
Gastrocnemius muscle from adult and old mice were cryosectioned as described in Section 
2.3.4. Muscle sections incubated with primary antibodies (Table 4.3) at 4°C overnight. Muscle 
sections were washed 3x5 minutes and incubated with the secondary antibody (Table 4.3) for 
1 hour at room temperature.  
4.2.6 Multiplex Cytokine Analysis 
Adult and old mice were sacrificed by cervical dislocation and blood was collected from the 
descending aorta. Blood was centrifuged at 10,000g for 10 mins at 4°C, and the plasma 
Primary Antibody 
Target 
Dilution Secondary antibody Dilution 
p53 1 in 100 Alexa Fluor® 488 Goat anti mouse 
(Sigma Aldrich, Dorset, UK) 
1 in 10, 000 
p21 1 in 100 Alexa Fluor® 488 Goat anti rabbit 
(Sigma Aldrich, Dorset, UK) 
1 in 10,000 
p16 1 in 100 Alexa Fluor® 488 Goat anti rabbit 
(Sigma Aldrich, Dorset, UK) 
1 in 10,000 
Table 4.3 Immunohistochemistry antibody dilutions of senescence markers 
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collected. Gastrocnemius muscle from the same mice were collected and the plasma were 
analysed using a Bio-Plex® Pro™ Mouse Cytokine 33-plex Assay (#12002231) (Section 2.7).  
4.2.7 Gene Ontology Term Analysis 
WebGestalt (2019 release) was used to perform the Overrepresentation Enrichment Analysis 
for each of the gene ontology categories (Biological Process, Cellular Component, and 
Molecular Function). The list of mouse genes was compared against the reference option of 
genome. The significance level was FDR<0.05 and the multiple test adjustment was 
performed using the Benjamini–Hochberg method. 
To help better visualize the GO terms obtained from the analysis above described, the tool 
REViGO was used. The p-values here considered were the FDR values obtained previously, 
with the mus musculus database option used for the GO terms. 
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4.3 Results
4.3.1 Molecular markers of senescence in muscle of adult and old mice. 
No statistically significant differences were seen in the abundance of p53, p21, and 
p16 proteins between muscles of adult and old mice (Figure 4.2). A significant 
decrease in p53 mRNA expression was seen in muscles of old when compared with 
adult mice. Although no significant difference was seen in p21 and p16 mRNA levels 
in muscles of old compared with adult mice, mean levels of these indices also 
appeared to be <50% of levels in muscles of adult mice (Figure 4.2). 
4.3.2 Detection of senescence markers in histological sections of muscle from adult 
and old mice.  
Figure 4.3 shows SA-β-Gal staining of 12µm thick sections of gastrocnemius muscle 
from adult and old mice. No detectable evidence of positive staining for β-Gal was 
seen in any of the serial sections from a number of biological replicates (n=4) of 
samples from muscles of mice of both ages. Both sudan black staining and auto-
fluorescence was used to examine muscle for the presence of lipofuscin. Figure 4.4 
shows Sudan Black B staining of gastrocnemius muscle sections from adult and old 
mice for evidence of the accumulation of lipofuscin. No detectable staining of 
lipofuscin was seen in the serial muscle sections from biological replicates (n=4) using 
this method. Figure 4.5 shows sections of gastrocnemius muscle of adult and old mice 
that were analysed for fluorescent lipofuscin granules by auto-fluorescence. In this 
instance, the muscle from old mice showed significantly more auto-fluorescence 
than the muscle from adult mice. No significant differences in the presence of p21 
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(Figure 4.6) and p16 (Figure 4.7) content of old mice muscle sections was seen when 
compared with muscle sections from adult mice.  
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Figure 4.2  
Relative protein levels of p53 (A), p16 (B), and p21 (C), in gastrocnemius muscles of adult (10 months) or old (24 months) WT mice. Relative 
expression of p53 (D), p16 (E), and p21 (F), in gastrocnemius muscles of adult (10 months) or old (24 months) C57BL6 mice. Data are presented 
as mean ± SEM (N=4), *P > 0.05, Student’s T‐Test. 
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Figure 4.3  
Representative transverse muscle sections (12µm) of gastrocnemius muscle 
stained for SA-β-Gal activity, adult (left) and old (right) WT mice. Liver was used as 
a positive control (bottom). Positive staining is blue, negative is brown. Scale bar 
represents 100 μm.  
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Figure 4.4 Sudan Black B staining of gastrocnemius muscle from adult and old 
mice. 
Representative transverse (12µm) sections of gastrocnemius muscle stained with 
Sudan Black B for lipofuscin from adult (left) and old (right) WT mice. 
Counterstained with Nuclear Fast Red (pink). Positive staining is black/blue, 
negative is pink/purple. Scale bar represents 100 μm. 
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Figure 4.5 Detection and quantification of lipofuscin particles by autofluorescence 
within the gastrocnemius muscle from adult and old mice. 
Transverse (12µm) sections of gastrocnemius muscles imaged for lipofuscin auto-
fluorescence from adult (left) and old (right) WT mice.  
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4.3.3 Immunohistochemical staining for the senescence marker p21 
Figure 4.6  
Transverse sections of anterior tibialis muscle sections (12µm) stained for p21 (green), WGA (red), and DAPI (blue) from adult (bottom) and 
old (top) WT mice.  
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Figure 4.7  
Transverse sections of anterior tibialis muscle sections (12µm) stained for p16 (green), WGA (red), and DAPI (blue) from adult (bottom) and 
old (top) WT mice.  
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4.3.4 Multiplex cytokine analysis of plasma and muscle from adult and old mice 
Data from the multiple cytokine analysis of plasma and muscle lysate from adult and 
old WT mice are shown in Figure 4.8 and Figure 4.9. 
Of the 33 cytokines measured, 12 were significantly increased in plasma of old mice 
compared with adult mice (Figure 4.8). In contrast, cytokine analysis of lysates from 
gastrocnemius muscle of adult and old mice (Figure 4.9) showed that GM-CSF and 
MIP-2 were the only two cytokines with significantly higher levels in muscles of old 
compared with adult mice.  
Gene ontology (GO) term analysis on biological process was performed for the 
cytokines significantly higher in old mouse plasma compared to adult plasma (Figure 
4.10).  
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Figure 4.8  
Plasma cytokine/chemokine concentrations (pg/ml) from adult (red) and old (blue) WT mice (A-AG). Data are presented as mean ± SEM. 
*P>0.05 
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Figure 4.9  
Tissue cytokine/chemokine concentrations normalised to gastrocnemius protein (µg/µg) from muscles of adult (red) and old (blue) WT mice. 
Data are presented as mean ± SEM. *P>0.05 
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Figure 4.10  
GO term analysis of the cytokines significantly increased in the plasma of old WT mice compared with adult WT mice. Box size was based on 
FDR values (<0.05) from gene ontology analysis using Web Gestalt. Figure produced using Revigo.  
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4.4 Discussion 
The aims of this chapter were to examine skeletal muscles of adult and old mice for evidence 
of senescence. This was achieved by examination of muscles for common markers of 
senescence including: SA-β-Gal activity, senescence markers (e.g. p21), as well as the 
evidence for the increased production of SASP.  
4.4.1 Characterisation of senescence markers in the skeletal muscle of adult and old mice 
4.4.1.1 Protein and mRNA levels of p16 and p21 in the muscles of adult and old mice. 
Both p16 and p21 play a key role in the development of cellular senescence (Coppe et al., 
2010a). No significant differences were seen in p16 and p21 protein abundance in the skeletal 
muscle from adult and old mice. The mRNA from skeletal muscle of adult and old mice was 
also examined. The level of p53 mRNA was significantly decreased in muscles of old mice 
compared with adult mice. Jeyapalan et al. (2007) reported no differences in p53 levels in 
skeletal muscle nuclei comparing young and very old baboons (Jeyapalan et al., 2007). There 
was also a significant decrease in the mRNA levels of both p21 and p16 in muscles of old 
compared with adult mice. Feng et al. (2007) demonstrated decreased p53 and p21 
transcriptional activity in various tissues in aging C57BL/6 female mice, from 6 to 20 months 
old in several tissues including skeletal muscle. Sousa-Victor et al. (2014) performed qPCR on 
muscle satellite cells (SCs) from adult and old mice to investigate the effects of ageing on SCs. 
These authors reported no significant changes in p16 mRNA levels in the SCs from 20-24 
months old C57BL/6 mice compared with 5-6 months old adult mice, and only saw a 
significant increase in p16 mRNA levels in 28-32 months old geriatric mice. Edwards et al. 
(2007) reported increased p53, p21, p16 expression within the gastrocnemius muscle of 25 
months old mice compared with 5 months old adult mice. In contrast to Jeyapalan et al. 
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(2007), (da Silva et al., 2019) did indeed find increased p53 levels within skeletal muscles of 
32-months old mice. Thus, there is little consensus on the evidence of changes in these 
proteins in muscle of mice with increasing age. There are several potential reasons for these 
discrepancies. The differences may be due to methodological approaches. Both Sousa-Victor 
et al. (2014) and Edwards et al. (2007) performed qPCR to analyse p53 and p21 expression in 
old mice. For both studies, old mice were approximately 24/25 months old. Edwards et al. 
(2007) prepared samples from whole muscle lysates whilst Sousa-Victor et al. (2014) used 
isolated SCs. As previously mentioned, muscle tissue contains a range of other cell types that 
contribute to the muscle bulk and its cellular composition may change during ageing. Indeed, 
p16 is not specific to senescent cells and positive p16 staining has been reported in normal 
healthy T-cells (Akbar and Henson, 2011). Other tissues (e.g., adipocytes or immune cells) may 
in fact be senescent and contributing to the p53 and p21 mRNA levels and thus the senescent 
profile of the whole muscle analysed although that was not evident in our studies. In addition, 
other studies in our laboratory have demonstrated that, during ageing, the mRNA levels do 
not always reflect the protein levels of specific proteins (Owen et al, unpublished).  
4.4.1.2 Immunohistochemistry for SA-β-Gal and Lipofuscin 
Another canonical marker of cellular senescence is the lysosomal enzyme, beta-galactosidase, 
which is proposed to be specific to senescent cells and not evident in quiescent cells or 
terminally differentiated cells (Debacq-Chainiaux et al., 2009). However, Debacq-Chainiaux et 
al. (2009) have proposed that SA-β‐Gal staining may occur in quiescent cells induced by 
confluency or serum starvation, in immortalized cells (Cristofalo, 2005). 
No evidence of SA-β-Gal activity was seen in any of the muscle sections from either adult or 
old mice (Figure 4.3). There have been limited studies to date examining the SA-β-Gal activity 
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in skeletal tissue. Since skeletal muscle is mainly post-mitotic, it is a poor target for examining 
cellular senescence. Sousa-Victor et al. (2014) performed SA-β-Gal analysis of isolated 
satellite cells from adult, old and geriatric (28-32 months old) C57BL6 mice. Their data showed 
no positive SA-β-Gal staining in the satellite cells of adult and old mice, but positive staining 
as evident in the geriatric mice. However, these analyses were performed on isolated satellite 
cells, and do not describe whether multinucleated muscle fibres themselves were positive for 
SA-β-Gal.  
Lipofuscin can be detected by using the natural auto-fluorescent properties, or it can also be 
detected using Sudan Black B staining (Glees and Hasan, 1976). Sudan Black B is a highly 
lipophilic agent that exhibits high affinity to the lipid compartment of lipofuscin (Gatenby and 
Moussa, 1949). Lipofuscin is an aggregate of oxidised proteins, lipids, and metals, and is 
considered a hallmark of ageing (Brunk and Terman, 2002). Lipofuscin accumulates in various 
tissues and species with age, particularly post mitotic tissues such as the brain and cardiac 
and skeletal muscle (Brunk and Terman, 2002) although this isn’t consistently seen (Ikeda et 
al., 1985). An explanation for the latter may be that the pathways which drive senescence and 
the accumulation of lipofuscin, functions independently of the ability of a cell to divide, as 
demonstrated in neurons (Jurk et al., 2012) and adipocytes (Minamino et al., 2009). Lipofuscin 
has also been shown to accumulate during replicative senescence of cells such as human 
fibroblasts (von Zglinicki et al., 1995) and in resident satellite cells in muscles of older humans 
(Roth et al., 2000). Increased granular deposits of lipofuscin were evident by auto-
fluorescence in muscle sections from old mice compared with muscles of adult mice although 
no difference was evident when Sudan Black B staining was used. The difference in findings 
using the two different methods is unclear. An increase in deposits of lipofuscin in muscles of 
old mice is in agreement with current literature, where lipofuscin granules accumulate with 
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ageing (Kakimoto et al., 2019) and particularly in skeletal muscle (Tohma et al., 2011). 
However, the potential increase in lipofuscin granules due to the increased presence of 
senescent cells is in contrast to the other findings in this Chapter, showing little evidence of 
changes in other indices of senescence... Change in fibre type, as seen in muscles of old mice 
can also result in changes in lipofuscin content of muscles (Roth et al., 2000). The positioning 
of the granules in the transverse sections of muscles also suggests that it may be outside of 
the muscle cells in some instances, possibly evident in satellite cells, although this was not 
examined in detail. In conclusion, in the absence of any more specific indices of senescence, 
it is likely that that the increase seen in this instance is due to a non-specific increase in 
oxidation with advancing age, evident in muscles of old mice. There is significant evidence to 
indicate that there are fundamental changes in redox signalling and homeostasis, which occur 
during ageing (Jackson and McArdle, 2011). Skeletal muscles of old mice demonstrate 
significant oxidative damage to DNA, lipids, and proteins (Vasilaki et al., 2006). The imbalance 
in ROS homeostasis may ultimately initiate the upregulation of proinflammatory signals, 
resulting in chronic inflammation (Meng and Yu, 2010). Oxidative stress, such as muscle 
derived ROS, is proposed to activate NF-κB and up-regulate the inflammatory response (Meng 
and Yu, 2010). 
4.4.2 Characterisation of the inflammatory cytokine profiles of adult and old mice 
Figure 4.10 shows gene ontology (GO) term analysis of the cytokines shown to be significantly 
elevated in the plasma of old mice compared with adult mice, showing common motifs in the 
functions of the cytokines. GO terms are descriptors that assigns terms to genes, allowing for 
hierarchically classification. The logical structuring of these hierarchies allows queries to be 
performed, looking for similar terms between groups of genes. Through GO term analysis, 
several common motifs were identified: 
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4.4.2.1 Chemotaxis and the immune system 
The largest field, with the highest FDR (false discovery rate) values and most overlapping 
functions was “leukocyte migration”, “response to chemokines”, and “positive regulation of 
cytokine production”. Chemotaxis, as the name suggests is when an organism moves in 
response to a chemical stimulus of some kind. An example of which are bacteria, that make 
use of chemotaxis to move towards nutrients and away from hazards. In the context of 
multicellular organisms, cytokines, and chemokines; chemotaxis refers to the movement and 
migration of immune cells.  
Immune cells such as neutrophils migrate in response to chemoattractant. Neutrophils 
release proteases, such as neutrophil elastase, damaging healthy tissue in the process, 
resulting in inflammation (Wilson et al., 2017). The efficiency of chemotaxis decreases with 
age, resulting in greater inflammation and damage when compared with adults (Wilson et al., 
2017). 
4.4.2.2 Skeletal muscles as a source of cytokines 
Skeletal muscle comprises approximately 40% of total body mass, and has been shown to be 
a source of cytokines, called myokines (Nielsen and Pedersen, 2008, Janssen et al., 2000). 
Indeed, IL-6 expression increases significantly in skeletal muscle following exercise where it is 
proposed to have beneficial effects (Steensberg et al., 2000). However, a chronic increase in 
IL-6, for example in plasma results in increased ubiquitin protein and mRNA expression in 
muscle, resulting in muscle degradation (DeJong et al., 2005). IL-6 binds to the glycoprotein 
130 (gp130) or CD130 receptor, and shares several functions with other cytokines such as IL-
11, leukaemia inhibitory factor (LIF), oncostatin M (OSM), granulocyte colony-stimulating 
factor (G-CSF), and IL-12 (Ohtani et al., 2000). 
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Data in this study show an increase in a number of cytokines/chemokines in the plasma of old 
compared with adult mice, but a limited number elevated in the muscle of old mice, where 
significant increases were seen only in GM-CSF and MIP-2, with MIP-2 only common to 
increases seen in these in plasma of old compared with adult mice. Cytokines are produced 
by tissues and rapidly released. It may therefore be possible that this results in little difference 




































Summary table of the cytokines significantly 
increased in the plasma and/or muscle of old mice 
compared with adult mice. Green, increased; Grey, 
no difference.  
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determination of protein levels of cytokines alone in muscle tissue is a limitation of this study. 
Indeed, mRNA analysis of muscle from old versus adult mice from our laboratory supports 
this possibility for IL-6 (Owen et al, unpublished) where muscle levels of mRNA for IL-6 were 
also increased in old compared with adult mice, although a full range of cytokine/chemokines 
was not assessed. Cytokines/chemokines may be produced by cells within the muscle and 
result in altered local concentrations, for example at the location of the peripheral nerve, but 
may not alter plasma levels of these molecules. Thus, further data from our laboratory has 
also demonstrated an increase in the release of several cytokines from isolated muscle fibres 
from old compared with adult mice, including Eotaxin and MCP-1 (Owen at al, unpublished)  
Data from Chapter 3 suggests that myoblasts have the capability of senescence and release 
increased levels of cytokines/chemokines including IL-2, IL-6, Eotaxin, KC and MCP-1. 
However, although these cytokines/chemokines are released by senescent cells (Chapter 3), 
such release in not exclusive to senescent cells and data presented in this Chapter suggest 
that resident senescent cells in muscle tissue are not a major source of these cytokines since 
no evidence of the presence of local senescent cells was seen. However, data suggest that the 
source of some cytokines may still be the muscle fibres themselves in a so-called bystander 
effect although the release is limited and non-muscle cells in the muscle bulk cannot be ruled 
out as an alternative source.  
The chemokines, MIP-1α, MIP-1β, and MIP-2, belong to the MIP (Macrophage Inflammatory 
Proteins). MIP-1α and -1β, have been shown to be secreted as part of the SASP (Coppé et al., 
2010). MIP-2 is transcriptionally controlled by NF-κB (Burke et al., 2014). MIP-2 levels were 
significantly higher in the muscle lysates of old mice when compared with adult mice 
suggesting that muscle may in part be a source of this cytokine. MIP-2, as well RANTES and 
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MCP-1, have been shown to increase in the plasma of aged rats on a high-fat diets, when 
compared with control diet rats, due to greater deposits of long-chain fatty acid esters 
creating inflammatory cross-talk with the sarcopenic muscles (Laurentius et al., 2019). Zhu et 
al. (2019) have also proposed that peri-muscular adipose tissue (PMAT), an ectopic fat deposit 
surrounding muscle, may drive muscle wasting.  
Granulocyte–macrophage colony stimulating factor (GM‐CSF) functions to activate and 
recruit granulocytes to sites of tissue damage (Hammond et al., 1995, Francisco-Cruz et al., 
2014) and is proposed to play a major role in tissue remodelling (Sacramento et al., 2009). A 
study examining the effect of transient expression of GM-CSF shows an increase in the 
number of ‘healing’ M1-like macrophages immediately after traumatic muscle injury 
promoting muscle recovery (Martins et al., 2020). Skeletal muscle of old mice accumulates 
focal areas of damage and so increased production of GM-CSF by skeletal muscle may be a 
response by the muscle to promote efficient muscle repair.  
Data showed significant changes in a number of other cytokines in plasma of old compared 
with adult mice although the source of these cytokines is unclear. The effect of these on 
muscle mass and function is also unclear, but the individual cytokines may have specific 
effects. TNFα has been shown to directly upregulate the NF-κB pathway via IκB kinase (IKK). 
Activation of the transcription factor NF-κB in muscle results in myofibre atrophy and 
activation of the ubiquitin-proteasome pathway (Li and Reid, 2000, Ladner et al., 2003, Cai et 
al., 2004). Furthermore, treatment of mice with TNFα caused suppression of the Akt-mTOR 
pathway, resulting in decreased protein synthesis (Pijet et al., 2013).  
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Fractalkine structure differs from typical cytokines. The soluble version is a potent chemo-
attractant of T-cells and monocytes, whilst the cell-bound form promotes the strong adhesion 
of leukocytes (Bazan et al., 1997). In an effort to identify new biomarkers of ageing, Deng et 
al. (2019) investigated the cytokine profile of the serum from young and old mice. From their 
panel Fractalkine, amongst others, was significantly higher expressed in the plasma of old 
mice when compared to young, which agrees with the data presented in this Chapter. 
IL-10 was also significantly higher in the plasma of old compared with adult mice. IL-10 was 
first discovered in 1991 by de Waal and colleagues (de Waal Malefyt et al., 1991a, de Waal 
Malefyt et al., 1991b), IL-10 was initially reported to suppress cytokine secretion, antigen 
presentation, and CD4+ T cell activation. As an anti-inflammatory cytokine, it inhibits the 
synthesis of IFN-γ, IL-2, IL-3, TNF-α, and GM-CSF by cells such as macrophages and Th1 cells 
(Moore et al., 1993). However, it has also been shown to stimulate thymocytes, mast cells 
and B cells (Moore et al., 1993). IL-10 has also been shown to be a myokine, and is increased 
in plasma following exercise (Ostrowski et al., 2000). The role in plasma of old mice is unclear 
but it may be an attempt by muscle to counteract the pro-inflammatory environment.  
The transcription factor NF-κB plays a significant role in the expression of inflammatory 
cytokines and the SASP (Malaquin et al., 2016, Lopes-Paciencia et al., 2019). Elevated levels 
of NF-κB have been shown in the skeletal muscle of old mice and humans, when compared 
with adults (Vasilaki et al., 2006, Cuthbertson et al., 2005). Senescent cells accumulate in 
other tissues throughout the body with age throughout the body and may be a source of the 
SASP (Baker et al., 2016). Indeed, There is evidence to suggest that the SASP secreted by 
senescent cells within adipose tissue reduces the expression of contractile proteins and 
induces insulin resistance in human muscle cells (Sachs et al., 2019).  
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The pro-inflammatory cytokines produced as SASP can contribute to the plasma cytokine pool 
of old individuals and can promote further NF-κB activation in several tissues, producing more 
inflammatory cytokines , creating a vicious feedback loop. This SASP mediated feedback loop 
has been described as the bystander effect (Nelson et al., 2012). Whereby senescent cells can 
induce senescence like behaviour in neighbouring cells through paracrine mechanisms 
(Acosta et al., 2013, Nelson et al., 2012, Faggioli et al., 2012). As skeletal muscle is a source of 
cytokines (myokines), such a bystander effect may also have a substantial effect on circulating 
cytokine levels since muscle comprises a substantial proportion of the body (Lutz and Quinn, 
2012, Nielsen and Pedersen, 2008), creating a vicious circle. 
4.5 Conclusion 
In summary, analysis of muscles of adult and old mice has provided little evidence of classical 
senescence in any cell types present in muscle tissue. Data examining protein levels of 
cytokines in muscle of old compared with adult mice suggest that muscle may partially 
contribute to the increase in plasma cytokines evident in plasma of old mice, but suggest that 
the source of the majority of cytokines seen in plasma is not primarily muscle tissue. It may 
be that muscle rapidly produces and secretes cytokines and so changes in intracellular protein 
levels will not be evident, but such cytokines produced by muscle may still have a local effect 
on peripheral nerves for example.  
To elucidate the role of the presence of senescent cells distant to the muscle on plasma 
cytokine profiles and changes in muscle function during ageing, models are required to 
eliminate senescent cells form the whole body.  
 
 









5 Chapter 5: Removal of senescent cells in p16-3MR mice: effect on age-related loss of 
skeletal muscle 
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5.1 Introduction 
The ability to eliminate senescent cells in transgenic mouse models has allowed the 
examination of the effect of the presence or accumulation of senescent cells distant to tissues 
during ageing on tissues such as skeletal muscle. Most senescent cells express the tumour 
suppressor p16INK4a, which prevents cell cycle progression from the G1 to S phases by 
inhibiting two cycle-dependent kinases, CDK4 and CDK6 (Section 1.1.3.1). The expression of 
this protein has been exploited to develop transgenic mouse models aimed at eliminating 
p16-positive senescent cells (Demaria et al., 2014, Baker et al., 2016).  
5.1.1 The p16-3MR mouse model 
The p16-3MR mouse model (Section 1.1.7.3) allows the investigation of the role of the 
presence of senescence cells in ageing in several tissues, allowing the selective elimination of 
senescent cells in vivo. The model was first described by Demaria et al. (2014) in order to 
investigate the role of cellular senescence in wound healing. A Bacterial Artificial 
Chromosome (BAC) was used to inactivate the original p16INK4a gene and drive 3MR 
expression instead. The P16-3MR mice have genes, which contain functional domains of 
Figure 5.1 Schematic of the p16-3MR transgene. 
Adapted from Demaria et al. (2014). 
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Renilla luciferase (LUC), monomeric red fluorescent protein (mRFP), and a truncated herpes 
simplex virus (HSV)-1 thymidine kinase (TK) under control of the full p16ink4a promoter (Figure 
5.1). The LUC and mRFP are both fluorescent reporter proteins, which allow for detection of 
3MR expressing. HSV-TK allows for selective elimination of p16ink4a expressing cells by 
ganciclovir (GCV), a nucleoside analogue. GCV has a high affinity for HSV-TK but low affinity 
for the cellular TK (Laberge et al., 2013). HSV-TK converts GCV into a toxic DNA chain 
terminator in 3MR expressing cells which competes with deoxyguanosine triphosphate for 
incorporation into nascent DNA chains, leading to DNA synthesis termination (Laberge et al., 
2013). Production of toxic GCV-P by HSV-TK results in damage to nuclear and mitochondrial 
DNA, causing caspase-dependent apoptosis of p16 expressing cells, and so loss of these cells 
(Laberge et al., 2013). The P16-3MR mice provided novel insight in to the role of senescent 
cells in wound healing (Demaria et al., 2014). Data from this study showed that the presence 
of senescent cells increased with age in many tissues (visceral fat, kidneys, and lungs), 
evidenced by an increased level of luminescence, starting ~18 months of age. GCV treatment 
of old (20–24 months) mice efficiently eliminated senescent cells as determined by reduced 
total body luminescence, SA-β-gal staining, and p16 mRNA levels in biopsies of visceral fat 
(Demaria et al., 2014). These data demonstrate that the model was effective in removal of 
senescent cells. However, the effects of elimination of p16 expressing senescent cells on the 
musculoskeletal system was not examined in this study. 
A loss of skeletal muscle mass is seen in old mice, with a 20-30% loss of muscle mass and 
function by 24-26 months of age (Brooks and Faulkner, 1991, McArdle et al., 2004). Similar 
rates of loss of motor units are observed in electromyography studies in ageing (Campbell et 
al., 1973). The mechanisms by which sarcopenia occurs are unclear, but the role of 
senescence in this muscle loss has received some attention recently.  
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Senescent cells produce a proinflammatory cytokines via the SASP (Coppe et al., 2010a).  
Muscle strength (Visser et al., 2002), muscle mass (Schaap et al., 2006), muscle protein 
synthesis and catabolism (Jo et al., 2012) have all been shown to be affected by inflammation, 
suggesting a potential mechanism by which sarcopenia develops. Age-related loss of muscle 
mass and function is associated with an increased chronic activation of NF-κB in muscles of 
old mice (Vasilaki et al., 2006). The mechanisms by which this occurs are unclear, but 
activation would undoubtedly contribute to further local increases in the production and 
concentrations of pro-inflammatory cytokines and proteolytic processes leading to loss of 
muscle mass and function (Lightfoot et al., 2014).  
The role of the presence of senescence cells distant to muscle on muscle function have been 
examined using a similar transgenic mouse model, known as INK-ATTAC mouse model 
(Section 1.1.7.2). Briefly, when exposed to the synthetic molecule AP20187, p16 expressing 
cells in these transgenic mice undergo caspase-induced apoptosis (Baker et al., 2011). 
AP20187 is a ligand, which induces the homodimerisation of fusion proteins, which contain a 
specific mutant of the FKBP domain (Mabe et al., 2014). In order to examine the role of 
senescence in ageing, the INK-ATTAC mice were crossed with another mouse line with 
accelerated ageing, BubR1H/H mice (Baker et al., 2008). BubR1H/H mice have been 
characterised and display accelerated onset of age-related phenotypes such as a shortened 
lifespan, lordokyphosis (abnormally excessive curvature of the spine), and sarcopenia, 
amongst others; within 3-5 months (Baker et al., 2004). BubR1H/H;INK-ATTAC mice treated 
with AP20187 from weaning age until 10-months old showed significantly larger mean 
gastrocnemius fibre diameter and exercise ability, when compared with vehicle treated mice 
(Baker et al., 2011). To investigate the effect of senescent cell clearance later in life when age-
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related phenotypes are apparent in BubR1H/H mice, Baker et al. (2011) started AP20187 
treatment of BubR1H/H;INK-ATTAC mice at 5 months instead of weaning age and analysed the 
mice at 10 months old. Ten-month-old AP20187 treated mice had larger mean gastrocnemius 
fibre diameter and exercise ability, when compared with vehicle treated mice (Baker et al., 
2011). The same authors later performed similar experiments with older cohorts of mice, but 
the INK-ATTAC model was bred into a C57BL/6 WT background rather than the model of 
accelerated ageing. In this study, gastrocnemius fibre diameter was preserved in 18-month-
old female mice following AP20187 treatment compared with untreated WT mice (Baker et 
al., 2016). 
These data suggest that senescent cells may play a role in age-related decline of skeletal 
muscle mass and function, and that removal of senescent cells from the mice may preserve 
muscle mass and function.  
5.1.2 Hypothesis and aims 
The hypothesis was that the presence of senescent cells distant to the muscle during ageing 
contributes to the development of sarcopenia by the increased production of pro-
inflammatory cytokines (SASP). Removal of p16 positive senescent cells in old P16-3MR mice 
during ageing will result in a reduction in the number of senescent cells in the whole body, 
reduced plasma cytokine concentrations and preserve muscle mass and function.  
This hypothesis was investigated by determining the effects of removal of P16 positive 
senescent cells in P16-3MR mice on plasma cytokine concentrations and indices of skeletal 
muscle function and inflammation in mice.  
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5.2 Methods
 
Figure 5.2 Overview of methodology used for Chapter 5 
Following GCV treatment, muscle force measurements were recorded. The mice were then culled for plasma and tissue collection. The plasma 
and the skeletal muscles were analysed for cytokine levels. 
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5.2.1 GCV treatment of P16-3MR mice 
This was a collaborative study with Dr Brooks at the University of Michigan and Drs Richardson 
and Van Remmen at Oklahoma. The mice were treated with GCV at Oklahoma and analysis of 
muscle function was carried out at the University of Michigan. This allowed additional muscle 
analyses although sample collection was limited and a mixed sex cohort was used.  
Twenty-one 20-month-old P16-3MR mice of both genders were treated with 25mg/kg 
Ganciclovir by intraperitoneal (I.P) injection in PBS, or with PBS only as control, using a regime 
of 5 days of injections with 2 days of rest (Laberge et al., 2013). Following I.P injection, mice 
were treated every 4 weeks with a 5-day course of GCV, until 26 months old where the mice 
were sacrificed for tissue harvest and muscle force measurements.  
5.2.2 Measurements of force generation of muscles in situ and ex vivo 
Muscle force measurements were performed in situ at the University of Michigan. 
Gastrocnemius stimulation, both nerve and by direct muscle activation, were performed in 
vivo. Muscle force measurements of the extensor digitorum longus (EDL) and soleus were also 
performed ex vivo. Muscles were carefully dissected and placed at resting length into a 
Mammalian Ringer’s solution at 37oC and gassed with O2/CO2. Muscles were attached to a 
force transducer and maximum tetanic tension determined (Brooks et al., 1995). The in situ 
Figure 5.3 Experimental design for treatment of P16-3MR mice with GCV. 
P16-3MR mice received repeated doses of GCV or PBS to ablate senescent cells.  
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analysis of gastrocnemius function allows determination of maximum muscle contractile 
forces when activated by nerve stimulation compared with activation by electrodes placed 
across the muscle surface, bypassing neural stimuli. Any difference between the two 
measures provides information regarding a reduced nerve function, potentially 
demonstrating a proportion of denervation of the muscle. Analysis of both EDL and soleus 
muscle function ex vivo provides muscle stimulation only but will demonstrate differential 
effects on muscles that are primarily comprised of type I or type II fibres.  
5.2.3  qPCR of inflammatory markers 
Quantitative PCR for cytokines was performed at the University of Michigan and so the nature 
of cytokines analysed was limited to those that had been shown to be reduced in previous 
studies (Baker et al., 2016). Data were normalised to 18S.  
5.2.4 EMSA for NF-κB transcription factor activity 
EMSA was performed on the gastrocnemius muscles of GCV and PBS treated P16‐3MR mice. 
The samples and protocol were performed as described in Section 2.8, and 100µg of muscle 
lysate was used.  
5.2.5 Multiplex cytokine analysis 
Blood samples from P16-3MR mice were collected into EDTA coated microcentrifuge tubes 
from the descending aorta. Samples were centrifuged at 10,000g for 10 mins at 4° and the 
plasma collected. Multiplex cytokine analysis for pro-inflammatory cytokines was performed 
as described in Section 2.7.  
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5.3 Results 
5.3.1 Effects of GCV treatment of p16-3MR mice on muscle mass and morphology.  
Data are presented either as separate sexes or pooled (Figure 5.4). No significant 
difference was seen in the body weight of GCV treated compared with PBS treated 
P16-3MR mice, when either presented as separate sexes or pooled. Treatment of 
P16-3MR mice with GCV resulted in preservation of muscle mass in male, but not 
female mice (Figure 5.4) whereby the masses of the TA, soleus, and GTN of GCV 
treated male mice were significantly higher than those of PBS treated P16-3MR mice, 
and the masses of the EDL and quadriceps just failed to reach statistical significance. 
Although some evidence of increased muscle mass in male mice was seen, this was 
due to the cohort of mice being larger, since no significant differences in muscle 
masses were seen when normalised to body weight (Figure 5.4G-L). 
No significant differences in fibre size distribution were seen between the GCV and 
PBS treated groups of either sex (Figure 5.5A and B). No significant differences were 
seen in fibre type composition of GTN muscles between GCV and PBS treated P16-
3MR mice (Figure 5.5C). 
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Figure 5.4 Hind limb muscle mass of GCV or PBS treated p16-3MR mice 
Mass (mg) of the hind limb muscles: EDL (A), SOL (B), AT (C), GTN (D), PLN (E), and QUAD (F) of male, female, and pooled GCV and PBS treated 
(control) P16‐3MR mice. Muscle weights of EDL (G), SOL (H), AT (I), PLN (K), GTN (J), and QUAD (L); normalised to body weight (mg/mg) of male, 
female, and pooled GCV and PBS treated (control) P16‐3MR mice. Body weight (g) of male, female, and pooled GCV and PBS treated P16‐3MR mice 
(M). Data are presented as mean ± SEM. Significance determined using Student’s T‐Test.  
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Figure 5.5 Fibre size and type analysis of PBS treated (control) or GCV treated p16-3MR mice. 
 
Fibre size distribution in GTN muscles of GCV and PBS treated male (A), female (B) or mixed sex (C) P16‐3MR mice. Data are presented as 
mean ± SEM, N=3‐6.  
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5.3.2 Effects of GCV or PBS treatment of P16-3MR mice on muscle force generation.  
Treatment of P16-3MR mice with GCV had no effect on force generation by several 
muscles of male or female mice compared with PBS treated P16-3MR mice. Thus, no 
significant differences in absolute tetanic force (P0 (mN)) (Figure 5.7) or specific force 
(kN/m2) (Figure 5.6) were seen in either male or female GCV treated mice when 
compared with PBS treated mice.  
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Figure 5.7 Absolute tetanic force generation by hind limb muscles of GCV and PBS 
treated P16-3MR mice.  
Absolute force (mN) of EDL (A), Soleus (B), and nerve (C) or muscle (D) stimulated 
GTN of male and female GCV or PBS treated P16‐3MR mice. Data are presented 
as mean ± SEM, N=3‐6. Student’s T‐test.  
Figure 5.6 Specific force generation by hind limb muscles of GCV and PBS treated 
P16-3MR mice. 
Specific force (kN/m2) of EDL (A), Soleus (B), and nerve (C) or muscle (D) stimulated 
GTN of male and female GCV and PBS treated P16‐3MR mice. Data are presented 
as mean ± SEM, N=3‐6. Student’s T‐test.  
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5.3.3 Effects of GCV or PBS (control) treatment of P16-3MR mice on the 
inflammatory cytokine profile of plasma and muscle.  
Figure 5.10 and Figure 5.11 show the cytokine profile of the plasma of GCV or PBS 
treated P16-3MR mice. Since no effect of sex on muscle function was seen, samples 
were combined. There was a tendency for several cytokines to be decreased in the 
plasma from GCV treated compared with PBS treated mice although only the values 
for G-CSF reached significance when compared with PBS treated control mice. 
Surprisingly, DNA binding of the NF‐κB/p65 transcription factor was significantly 
increased in GTN muscle of GCV treated P16‐3MR mice when compared with muscle 
from PBS treated control mice (Figure 5.8). 
No significant differences were seen in the mRNA levels of IL-6 or TNF-α in the AT 
and GTN muscles of PBS treated and GCV treated P16-3MR mice (Figure 5.9).   
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Figure 5.9 Cytokine mRNA levels in muscle of PBS or GCV treated p16-3MR mice.  
Fold changes in expression of IL‐6 and TNF‐α, in TA and GTN from GCV or PBS 
(control) treated p16‐3MR mice, normalised to 18S. Data are mean ± SEM, N=3‐6. 
Significance tested with ANOVA.  
 
A 
Figure 5.8 NFκB/p65 activity in muscles of GCV treated p16-3MR mice. 
(A) EMSA for NFκB/p65 transcription factor binding in the gastrocnemius of GCV 
and PBS treated P16‐3MR mice. (B) Densitometry. SP, Specific competitor. N‐SP, 
Non‐specific competitor. SS, Supershift. Data are mean ± SEM. *P<0.05, Student’s 
T Test. Top red arrow displays supershifted band from bottom red arrow. 
B 
Page 205 of 300 
  
Figure 5.10 Multiplex cytokine 
analysis of plasma from GCV and 
PBS treated p16-3MR mice. 
 (n=4). Data are presented as mean 
± SEM, N=4‐8. *, p<0.05 compared 
with PBS treated control data. 
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 Figure 5.11 Heatmap and Dendritic Clustering of cytokines from the plasma of GCV and PBS treated p16-3MR mice. 
Cytokine concentrations plotted on a log10 scale. (n=4 per group).  
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5.4 Discussion 
The aims of this study were to determine the effects of the whole body removal of senescent 
cells on plasma cytokine concentrations and indices of skeletal muscle inflammation and to 
examine whether removal of senescent cells from old P16-3MR mice following treatment 
with ganciclovir resulted in preservation of skeletal muscle including mass and function 
compared with that of PBS (control) treated P16-3MR mice.  
5.4.1 Effects of elimination of p16 expressing cells from p16-3MR mice on skeletal muscle 
mass and function. 
Male p16‐3MR mice treated with GCV showed a small but significant preservation of mass of 
most muscles measured; with others, just missing significance compared with muscles of PBS 
treated p16‐3MR mice (Figure 5.4). This preservation was not seen in female p16‐3MR mice 
treated with GCV compared with PBS treated p16‐3MR mice. However, when data were 
normalised to body weight, there were no significant differences in muscle mass, in either 
gender of p16‐3MR mice suggesting that the mice in the GCV-treated group were generally 
larger than the PBS-treated control mice. Since body weight was not recorded prior to 
treatment, it was not possible to determine whether the treatment was responsible for this. 
Treatment of female p16‐3MR mice with GCV resulted in no significant differences when 
compared with the PBS treated p16‐3MR mice. These data show that GCV treatment and so 
removal of p16 cells provides little protection from the age-related loss of muscle mass in 
either sex. A characteristic of sarcopenia is an age-related loss of muscle fibres (Lexell et al., 
1988) and an atrophy of the remaining fibres, with type II (fast-twitch) fibres demonstrating 
a greater reduction in cross-sectional area, when compared with the size of type I fibres (slow-
twitch) fibres (Lexell et al., 1988). Data showed that there was no significant difference in 
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fibre size between the GCV treated and the PBS treated mice. Therefore, elimination of p16 
expressing cells did not preserve fibre number or size in old mice. No effect of GCV treatment 
was seen on force generation (Figures 5.6 and 5.7) and little effect was seen on fibre size 
distribution, suggesting that the increase in body mass seen was not relevant and that 
depletion of P16 positive cells in old mice had little effect on muscle function.  
5.4.2 Effects of elimination of p16 expressing cells from p16-3MR mice on plasma cytokine 
levels. 
The findings from this study are in contrast to other studies. Demaria et al. (2014) treated of 
p16-3MR mice with GCV via daily intraperitoneal (IP) injections for 5 consecutive days at 25 
mg/kg in PBS. In the study presented in this Chapter, p16-3MR mice were treated with the 
same dosing regimen used by Demaria et al, but across the longer period of 4 months. 
Supplemental Figure 2E from Demaria et al (Figure 5.12) shows the time course of total body 
luminescence for p16 in p16-3MR mice at 12, 18, 20, and 24 months of age, indicative of the 
Figure 5.12 Total body luminescence of p16 expressing cells of p16-3MR mice with increasing 
age.  
Adapted from supplemental figure 2E of Demaria et al. (2014).  
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accumulation of p16 positive senescence cells. Significant increases in luminescence, 
reflecting a concomitant increase in senescent cells were seen. Luminescence was 
significantly increased in 24-month old p16-3MR mice when compared with 12-month old 
p16-3MR mice. GCV treatment of 24-month-old p16-3MR mice decreased total luminescence 
to that of 12-month-old untreated p16-3MR mice.  
The current study in this Chapter did not examine luminescence in these mice. GCV treatment 
results in the acute removal of senescent cells although the time course of removal and 
repletion is unclear. It is unlikely although possible that the treatment did not result in 
complete and persistent removal of senescent cells in our model. It may also be possible that 
prolonged treatment of mice with GCV has a detrimental effect on mice and unfortunately, 
no untreated control mice or GCV treated old WT mice were included in this study. 
Whilst the effect of removal of senescent cells on skeletal muscle mass and function was not 
investigated in the Demaria et al. (2014) study, decreased concentrations of SASP factors 
interleukin-6 (IL-6), interleukin-15 (IL-15), and MMP-3 were reported in the fat of GCV-treated 
p16-3MR mice. It is well documented that senescent cells produce a SASP (Baker et al., 2016). 
The SASP is proposed to contribute to the altered cytokine profile of the plasma in old age 
and the levels of a substantial number of cytokines are elevated in plasma of old mice (Section 
4.4.2). The levels of some of these cytokines are also changed in muscles of old mice, (Section 
4.4.2) and it is proposed that this occurs via activation of NF-κB in muscle, (Vasilaki et al., 
2006), potentially by the bystander effect. GCV-mediated elimination of senescent cells 
should therefore reduce the levels of SASP-related cytokines in the plasma and muscle with 
normalisation of the level of activation of NF-κB. However, in the current study, GCV 
treatment of p16‐3MR mice had little effect on the plasma cytokine levels compared with PBS 
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treated mice, except for G-CSF, which was significantly decreased when compared with PBS 
treated old p16‐3MR mice. Although mRNA analyses were limited in this study, GCV 
treatment had no significant effect on IL-6 and TNF-α mRNA levels in the AT or GTN muscles 
when compared with PBS treated p16‐3MR mice. These data contradict other studies where 
senescent cells have been eliminated from whole mice. The inflammatory SASP makers, 
including IL-6, IL-1α, and TNFα were examined in the gastrocnemius of INK-ATTAC mice (Baker 
et al. (2016). IL-6 increased significantly from 12- to 18-months of age, and AP20187 
treatment resulted in reduced expression to levels similar to that of 12-month-old mice (Baker 
et al. (2016). IL-1α and TNFα did not change in expression with age, however, administration 
of AP20187 also resulted in significantly lower expression of IL-1α and TNFα in muscles of 
these mice. Such changes in IL-6 were not reproduced in the study presented here (Baker et 
al. (2016). 
In contrast to the hypothesised normalisation of NF‐κB activation, treatment of p16‐3MR mice 
with GCV resulted a large and significant increase in DNA binding activity of NF‐κB although 
this was not accompanied by a major change in muscle cytokine production. A comparison of 
plasma cytokine levels in mice with P16 positive senescent cells removed, with cytokines 
shown to be modified in old WT mice in Chapter 4 (Table 5.1) shows no effect of removal of 
senescent cells on any of the cytokines elevated in plasma of old compared with adult mice. 
Together, these data suggest that elimination of senescent cells in old mice had little effect 
on plasma cytokine levels with the exception of G-CSF, muscle production of cytokines or 
muscle mass and function suggesting no major role for P16 positive senescent cells in age-
related loss of muscle mass and function.  
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Table 5.1 
Summary of the cytokines measured in the 
plasma of old compared with adult mice, and the 
plasma of GCV treated P16-3MR compared with 
PBS treated mice. Green, significantly increased; 
Red, significantly decreased; Grey, no difference; 
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5.4.3 The effects of G-CSF on skeletal muscle 
Despite no evidence of an effect of elimination of P16 positive cells from old mice on cytokines 
known to be elevated in plasma of old compared with adult WT mice. The effect of elimination 
of p16 positive cells on granulocyte-colony stimulating factor (G-CSF) is intriguing. G-CSF is 
also known as colony-stimulating factor 3 (CSF3). G-CSF is a 25kD secreted glycoprotein 
encoded by the CSF3 gene. G-CSF has a significant role in the regulation of neutrophils, as G-
CSF receptor-deficient mice are characterised by neutropenia; a reduced capacity to respond 
to infection with neutrophils (Liu et al., 1996). G-CSF has not been identified as a member of 
SASP for any other cell. G-CSF is secreted by almost all tissues in response to a number of 
inflammatory stimuli such as IL-1, LPS, and TNF-α (Roberts, 2005). G-CSF is used 
therapeutically to stimulate the bone marrow, resulting in the production and release of 
hematopoietic stem cells (HSCs) in to the blood (Deotare et al., 2015). Studies have shown 
that human myotubes that undergo cyclic mechanical strain secrete IL-6, IL-8, MCP-1, and G-
CSF (Peterson and Pizza, 2009). Furthermore, G-CSF has been shown to be asymmetrically 
expressed in satellite cells. G-CSF positively affects the satellite cell population during multiple 
stages of differentiation in fibres cultured ex vivo (Hayashiji et al., 2015). It may decrease bone 
mineral density in mice (Hayashiji et al., 2015). Thus, it is tempting to speculate that a 
decrease in G-CSF as seen in the current study denotes a potentially reduced production of 
HSCs, reducing the immune cell population and represents a potential detrimental effect of 
the treatment. Disruption of satellite cell growth may also deplete the cell pool, inhibiting 
muscle growth and repair, potentially contributing to sarcopenia in the longer term (Hayashiji 
et al., 2015) although no worsening of sarcopenia was seen in the current study.  
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5.4.4 Comparison with the INK-ATTAC mouse model  
Studies examining the effect of elimination of p16 positive cells on age-related loss of muscle 
mass and function are limited. A similar model that also made use of genetically modified 
mice to remove senescent cells was reported by Baker et al. (2016). These authors made use 
of the INK-ATTAC strain, as well as the P16-3MR mice (Section 1.1.7.2). The INK-ATTAC 
transgenic mouse model was also used to selectively eliminate p16 positive, senescent cells. 
The model has been used to investigate several senescence related pathologies. Examples 
include age-related bone loss (Farr et al., 2019, Farr et al., 2017, Kim et al., 2019), age-
dependent hepatic steatosis (Ogrodnik et al., 2017), neurogenesis (Ogrodnik et al., 2019), 
kidney disease (Valentijn et al., 2018), heart regeneration (Lewis-McDougall et al., 2019), 
adipogenesis (Xu et al., 2015a), diabetes, (Aguayo-Mazzucato et al., 2019), and 
atherosclerosis (Roos et al., 2016). 
Baker et al. (2016) showed that INK-ATTAC mice bred onto two different backgrounds, 
C57BL/6 and C57BL/6-129Sv-FVB (a model of different white fat depots) show a loss of 
spontaneous movement and exploratory behaviour from 12 to 18 months of age (Baker et 
al., 2016). Abnormal movement and behaviour were rescued to levels equal to 12-month-old 
mice by the administration of AP20187 (Section 1.1.7.2) with the concomitant removal of 
senescent cells. In contrast, exercise time, distance, and work were not improved in 18-
month-old INK-ATTAC treated with AP20187 , when compared with 18 month old control 
mice (Baker et al., 2016). Physiological measures of the fitness and gastrocnemius weight of 
18-month-old INK-ATTAC mice was not significantly increased with AP20187 treatment, in 
both genders (Baker et al., 2016). Gastrocnemius fibre diameter was significantly greater in 
18-month-old female AP20187 treated INK-ATTAC mice when compared with untreated 
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controls, however, male AP20187 treated INK-ATTAC mice were not significantly affected 
(Baker et al., 2016).  
There are some differences between Baker et al. (2016), and the study performed in this 
chapter in addition to the use of different transgenic animal models (INK-ATTAC versus p16-
3MR).The published work of Baker only examined 18-month-old mice whilst 26-month-old 
mice were used in this current study. With that in mind, the data presented in Baker et al. 
(2016) contrast with our own. Data presented in the current study show no effect on tetanic 
force generation by GTN muscles using either nerve or direct muscle stimulation (Figure 5.7), 
when compared with PBS treated (control) p16-3MR mice. Furthermore, SASP and 
inflammatory markers IL-6 and TNFα were measured in the gastrocnemius of both studies via 
qPCR. Baker et al. (2016) reported an approximately 50% decrease in IL-6 and TNFα 
expression within the muscle of 18-month-old female INK-ATTAC mice. In the current study, 
no significant differences were reported in IL-6 or TNFα mRNA levels within the muscle of 26-
month-old p16-3MR mice compared with muscles of PBS treated control mice. The reasons 
for these differences are unclear. It may be due to the difference in protocols or the nature 
of the samples used for the qPCR in this study. In the current study, surprisingly, the EMSA 
for NF-κB transcription factor activity showed increased activity in muscles of GCV treated 
compared with PBS treated control mice. This increase may be due to a direct effect of chronic 
treatment of mice with GCV or an effect of removal of senescent cells although the 
mechanism by which this is acting is unclear. Such increases in NF-κB transcription factor 
activity may therefore be potentially masking any changes seen from removal of p16 positive 
senescent cells. One drawback of the study was the lack of a control old WT group receiving 
ganciclovir alone.  
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5.4.5 The use of P16-3MR mice in other studies 
P16-3MR mice have been used for several other studies investigating senescence and age-
related pathologies. Examples of these include senescent chondrocytes and osteocyte in the 
development of osteoarthritis (OA) (Jeon et al., 2017, Kim et al., 2019), Acute myeloid 
leukaemia (AML) (Abdul-Aziz et al., 2019), intervertebral disc degeneration (IDD) (Patil et al., 
2019), immune-senescence in irradiated mice (Palacio et al., 2019), and the role of senescent 
astrocytes in cognitive decline (Yabluchanskiy et al., 2020). None of these studies investigated 
the effects of removing senescent cells on muscle mass and function. However, some have 
reported a decrease in the expression of pro-inflammatory cytokines such as: IL-6, IL-1β (Jeon 
et al., 2017) (anterior cruciate ligament), IL-1α, IL-6, TNFα (Kim et al., 2019) (bone marrow‐
derived macrophages), IL-6, IL-8, MIP-3a (Abdul-Aziz et al., 2019) (bone marrow stem cells), 
and plasma levels of IL-1α, IL-6, IL-10, KC, MCP-1, VEGF (Palacio et al., 2019). The decrease in 
the expression of the pro-inflammatory cytokine IL-6 is the most common result following 
GCV treatment in these varying studies. These effects were not seen in the current study, 
both at the mRNA level and at the protein level in circulating plasma. These differences may 
have occurred due to the different GCV treatment regimens utilised by this study. 
Furthermore, not only were the ages of the mice studies different, but they were also subject 
to unique experimental procedures to investigate each of the authors’ hypotheses.  
5.4.6 Limitations of this and other studies 
The lack of study of females is a major limitation in a large number of studies. Women and 
non-human female mammals are underrepresented in studies, whereby researchers assume 
results from males apply to females (Beery and Zucker, 2011). Researchers avoid the inclusion 
of females because of concerns that hormonal cycles decrease the homogeneity of study 
populations and confound effects of experimental manipulations (Beery and Zucker, 2011). 
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Many drug studies using males often generate different results from those for women (Soldin 
and Mattison, 2009). The study presented in this Chapter contained mixed sex groups and it 
was not possible to separate sexes in most analyses due to the small sample number. 
Experimental designs should include batches of sex and aged matched males/females as 
females differ from males at a cellular, molecular, and whole organism level. A recent analysis 
of gene expression in mice demonstrated substantially sexual dimorphic expression in the 
brain, liver and adipose tissue and whilst both sexes make the same steroid hormones they 
are inevitably found in different quantities (Yang et al., 2006). 
Another limitation to the study is that all p16 expressing cells of the P16-3MR mice would be 
eliminated with GCV treatment. T-cells express high levels of p16 (Liu et al., 2009), and highly 
differentiated T-cells show some similarities with senescent cells (Pangrazzi and Weinberger, 
2020). It is proposed that removal of p16 positive cells in an effort to remove senescent cells 
may also influence T-cell populations and removal of p16 expressing T-cells would have an 
impact on the plasma cytokine profile of the GCV treated mice. Baker et al. (2016) Examined 
CD4+, CD8+, CD44hi/CD4+, and CD44hi/CD8+ T-cell populations in peripheral blood 
mononuclear cells in INK-ATTAC mice. However, this study showed that removal of p16 
expressing cells had little effect on T cell populations. CD4+ T-cell populations decreased with 
age, but clearance of senescent cells at 18 months of age had no effect on T-cell population 
size when compared with the untreated controls. Examination of T-cell populations was out 
of the scope of the current study. 
Despite the obvious benefits of removing proinflammatory senescent cells, there may 
negative consequences to the organism. Grosse et al. (2020) investigated cellular senescence 
in organismal ageing with two different strains of transgenic mice. The first line (p16-Cre/R26-
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DTA) acted as a reporter and identified that age-induced p16 senescence is a slow process 
that manifests around 10–12 months of age in mixed C57BL/6J and 129/SvJ background mice. 
Furthermore, the majority of these p16 reporter cells were vascular endothelial cells mostly 
in liver sinusoids (LSECs), and to lesser extent macrophages and adipocytes. The second strain 
examined by these authors was the INK-ATTAC strain discussed previously, whereby 
continuous or acute elimination of p16 expressing senescent cells disrupted the blood-tissue 
barriers. Senescent liver sinusoids (LSECs) removal via INK-ATTAC were not replaced with 
healthy LSECs but instead resulted in fibrosis. This ultimately resulted in liver and perivascular 
tissue fibrosis and health deterioration of the mice. Of interest is that when ex vivo isolated 
LSECs were treated with the senolytics Dasatinib and Quercetin, there was no significant 
effects reported. Furthermore, when 10-month-old p16-Cre/R26-mTmG mice were treated 
with these senolytics for 5 weeks, a significant difference in p16 expressing macrophages was 
reported when compared with vehicle control mice, but LSECS and adipocytes were not 
affected. These differences may have arisen from the fact that senescent cells are 
heterogeneous, and that each method of senescent cell removal may have specificity for a 
subset of senescent cells.  
5.5 Conclusion 
In summary, removal of p16 expressing, senescent cells from P16-3MR mice by GCV 
treatment had no effect on preserving muscle mass or on muscle function. Furthermore, the 
GCV treatment to remove p16 positive senescent cells had very specific effects on the plasma 
pro-inflammatory cytokine G-CSF and no effect on tissue expression of inflammatory 
cytokines. There were some limitations to the current study. , The differences reported 
between this study and other reported findings may be attributed to the nature of the GCV 
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treatment, the age and sex of the mice, and the experimental protocol. Data are complicated 
by the need to include a number of control groups in such transgenic studies and, whereas 
genetic intervention to remove and investigate cellular senescence remains a powerful tool, 
this does not translate to an immediate treatment for humans. Pharmacological intervention 
with molecules designed to eliminate senescent cells provides a simpler model and could 
prove to be an effective tool in removing senescent cells and identifying their contributions 
to age-related pathologies such as sarcopenia and inflammaging.  









6 Chapter 6: The effects of intervention with the senolytic fisetin on muscle mass and 
function in old mice 
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6.1 Introduction 
6.1.1 Senolytics 
Senolytics (from the words “senescence” and “lytic” – destroying) are small molecule 
compounds that selectively induce the death/clearance of senescent cells (Xu et al., 2018). 
The aim of senolytics are to reverse the negative effects of senescence cells on ageing (Xu et 
al., 2018). The mechanisms by which the presence of senescent cells are deleterious are 
thought to be at least in part to the previously described senescent associated secretory 
phenotype (SASP), which includes pro-inflammatory cytokines, chemokines, and matrix 
remodelling proteins (Section 1.1.5) (Coppe et al., 2008). Several reviews have identified the 
potential role of senescent cells and the SASP in aging-related conditions (Munoz-Espin and 
Serrano, 2014, LeBrasseur et al., 2015, da Silva et al., 2019). Studies that have removed 
senescent cells in vivo via inducible removal of p16 expressing senescent cells have shown 
enhanced health span and delays in the development of multiple age-related phenotypes in 
genetically modified progeroid mice, including age-related loss of muscle mass and strength 
(Baker et al., 2016, Baker et al., 2008, Baker et al., 2011).  
Thus, pharmacological interventions that target senescent cells and/or the SASP provide a 
potential therapeutic approach to ameliorate age-related chronic diseases, disabilities and 
possibly extend health span. Zhu et al. (2016) used a bioinformatics-based approach to 
identify potent senolytic agents that would activate cell death pathways and trigger apoptosis 
preferentially in senescent cells without damaging non-senescent, proliferating, quiescent, or 
differentiated cells throughout the body. From this bioinformatic screen, two compounds 
were selected as candidate senolytics, and were tested in vivo: The tyrosine kinase inhibitor 
Dasatinib and the polyphenol Quercetin (see Section 1.1.8).  
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In a related study, Xu et al. (2018), where senescent cells were transplanted into mice, both 
of these drugs were shown to have a positive effect on muscle loss. Even a small number of 
senescent preadipocytes (0.2-1x106 cells) were sufficient to cause significant decreases in grip 
strength, hanging endurance, maximal speed, and more when compared with control mice. 
Furthermore, mice with senescent cells transplanted into them showed significant decreases 
in lifespan when compared with untreated mice and experimental-control mice. Dasatinib 
and quercetin were administrated via oral gavage 1 month prior to analysis. The 
administration of senolytics to both senescent cell-transplanted younger and naturally aged 
mice alleviated physical dysfunction, with measures in grip strength, hanging endurance, 
maximal speed equalling or greater than control mice. Dasatinib and quercetin treatment also 
increased post-treatment survival and reversed the negative effects of the transplanted cells 
on lifespan compared to that of control mice.  
The senolytics dasatinib and quercetin have been used in human trials, and have resulted in 
significant improvement thus far (Hickson et al., 2019). The open label Phase 1 pilot study 
administered 3 days of oral dasatinib (100mg) and quercetin (1000mg) to subjects with 
diabetic kidney disease. Significant decreases in p16, p21, SA-β-gal activity, and circulating 
SASP factors (including IL-1α, IL-6, MMP-9, and MMP-12) were reported in adipocytes, 
epidermal cells within 11 days of treatment.  
6.1.2 Polyphenols as senolytics 
Polyphenols are small, water soluble compounds (Haslam and Cai, 1994). Several hundred 
different polyphenols are found in plant-based foods (Extensively reviewed by Tressera-
Rimbau et al. (2017)). Current research on the role of polyphenols in health and disease has 
focused on their antioxidant and anti-inflammatory properties (Hussain et al., 2016). Many 
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polyphenols are not absorbed in their native form but are instead metabolised by intestinal 
enzymes and/or colonic microflora. These metabolites are further modified to allow entry 
into the blood and tissues (Scalbert et al., 2002). Indirect evidence of the absorption of 
polyphenols through the gut barrier is the increase of the antioxidant capacity of the plasma 
following the consumption of polyphenol-rich foods (Scalbert et al., 2002). The effects of 
polyphenols in human health have been extensively reviewed by Serino and Salazar (2018), 
and reported improved cardiovascular disease (CVD) outcomes in humans with increased 
dietary polyphenol consumption; amongst other changes. This is part due to two reasons. The 
first is that polyphenols are reducing agents and thus scavenge free radicals, and participate 
in the regeneration of other antioxidants such as vitamin E (Scalbert et al., 2002). The second 
is that some polyphenols have shorter, more specific effects. For example, isoflavone 
phytoestrogens are associated with a lower risk of hormone-dependent diseases and have 
well-documented pseudo-estrogenic properties (Scalbert et al., 2002). 
6.1.3 Fisetin as a senolytic 
Fisetin (7, 3′, 4′-flavon-3-ol) is a plant based polyphenol from the flavonoid group, and can be 
found in a wide variety of plants (Arai et al., 2000). The concentration of fisetin in these 
sources ranged from 2-160 μg/g. Individuals typically consume approximately 0.4 mg of 
Fisetin per day (Arai et al., 2000). Like other polyphenols, fisetin is a sirtuin activating 
compound (Section 1.1.8) and has been shown to extend the life span of simple organisms 
like yeast, worms and flies (Baur, 2010). The effect appears to be derived from the ability of 
fisetin to block the PI3K/AKT/mTOR pathway (Syed et al., 2013), as well as interfere with cell 
cycle progression (Gupta et al., 2014). A number of studies have demonstrated that fisetin 
has the potential to prevent and/or inhibit various chronic inflammation-related conditions 
(Pal et al., 2016b).  
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Yousefzadeh et al. (2018) examined the effects of a range of polyphenols on senescent murine 
and human fibroblasts. In this study, the effects of fisetin on senescent cells was tested in 
INK-ATAC mice (Section 1.1.7.2), progeroid p16 reporter mice (C57BL/6 p16Luc/+; Ercc1+/− and 
FVB/n p16+/Luc; Ercc1+/∆), and old C57BL/6 WT mice. The publication is a little confusing since 
the mouse models, age, and methods of fisetin delivery vary throughout the study.  
The mice treated were either given a diet containing fisetin (500mg/kg) or an oral gavage 
(100mg/kg). Progeroid luciferase p16 reporter mice treated with fisetin as part of their diet 
over 10 weeks showed significantly less total body luminescence when compared with vehicle 
fed control mice. This treatment resulted in a decreased presence of senescent cells in 
internal organs (fat, spleen, liver, and kidneys) in fisetin fed mice when compared with control 
mice (Yousefzadeh et al., 2018). Furthermore, old C57BL/6 WT mice (22-24 months old) given 
fisetin by oral gavage showed reduced senescent cell content (SA-ß-gal) and pro-
inflammatory immune cells (T-cells, and natural killer (NK) cells) within the adipose tissue 
compared with vehicle treated mice and young mice (Yousefzadeh et al., 2018).  
To investigate the effects of fisetin on lifespan, 20-month old WT mice were fed a diet 
containing fisetin, which resulted in a substantial extension of median and maximal lifespan 
to approximately 32-months, when compared with vehicle treated mice. Several tissues 
(brain, kidneys, liver, and lungs) had reduced age-related pathology and reduced the 
expression of senescence and SASP markers in the fisetin treated group compared to the 
control mice (Yousefzadeh et al., 2018).  
Thus, fisetin has the potential to be a therapeutic agent to combat age-related pathologies, 
in mice at least. Indeed, a phase II trial has been initiated to determine whether fisetin may 
alleviate frailty, inflammation, and related measures in older adults (NCT03675724). 
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However, little is currently known about the effects of fisetin on skeletal muscle mass and 
function in old WT mice and humans.  
6.1.4 Fisetin treatment and cell signalling 
Fisetin has been proposed to modulate many signalling pathways. At lower doses (3.4-50 µM), 
fisetin targets Aurora B kinase by inhibiting kinetochore and centromere localization. This 
results in immature segregation of chromosomes, premature cessation of mitosis without 
cytokinesis, and ultimately aneuploidy (Gollapudi et al., 2014). At higher doses of fisetin (30-
100 µM), DNA replication enzymes, topoisomerase I and II, are inhibited which results in 
chromosomal breakage (Lopez-Lazaro et al., 2010, Olaharski et al., 2005).  
Much work has been undertaken to investigate the role that fisetin plays is cancer in studies 
both in vivo and in vitro. Treatment of cancer cells with fisetin resulted in: 
Inhibition of cell cycle progression by targeting cyclins and cyclin-dependant kinases (CDKs). 
Fisetin forms a complex with human CDK6 and inhibits its activity with an IC50 of 0.85 μM 
(Sung et al., 2007, Salmela et al., 2009).  
Inhibition of NF-κB DNA binding activity and signalling within several cancer cell lines (Pal et 
al., 2015, Pal et al., 2016a, Pal et al., 2014). Indeed, EMSA data has shown that 50 μM fisetin 
treated H1299 cells suppressed TNF-induced NF-κB activation within 6 hours (Sung et al., 
2007).  
PC3 cells were treated with 40, 80 and 120 μM of fisetin for 48 hours inhibited the activity of 
mTOR by 6, 11 and 25%, respectively (Suh et al., 2010). It also increased apoptosis via 
inhibition of the expression of PI3K, phosphorylation of AKT, expression and phosphorylation 
of mTOR, and mTOR complex formation (Suh et al., 2010, Chien et al., 2010). 
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Indeed, Fisetin was reported to reverse the acquired cisplatin-resistance in A549-CR lung 
cancer cells (Zhuo et al., 2015). Fisetin (40 μM) in combination with cisplatin (10 μM) showed 
intense suppression of cell viability and induction of apoptosis as compared to cells treated 
with fisetin and cisplatin alone, possibly via inactivating MAPK pathways as well as 
suppressing Survivin expression (Zhuo et al., 2015). 
6.1.5 Hypothesis 
Skeletal muscle mass and function is decreased in old mice and is accompanied by an increase 
in plasma cytokine levels and increased NF-κB activity in skeletal muscle. The hypothesis was 
that the polyphenol fisetin would reduce the burden of senescent cells in old mice, reducing 
pro-inflammatory cytokine levels in the plasma, and reduce the chronic NF-κB activation seen 
in skeletal muscle; ultimately preserving muscle mass and function.  
This was investigated by treating old WT mice with fisetin as part of their diet from 20 to 24 
months old, to investigate the pro-inflammatory cytokine levels in the plasma, and the NF-κB 
activity within the skeletal muscles and the effect on muscle mass and function. 
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6.2 Methods 
6.2.1 Senolytic intervention study 
This study was undertaken in the animal research facility at the University of Liverpool. 
Eighteen male C57BL/6 WT mice (20 months) were randomly divided in to two groups, one of 
was fed fisetin (500 mg/kg) as part of their normal chow (CRM(P), Special Diet Services, 
801722) ad libitum (approximately 2.5 mg/day/mouse or 8.7 µM/day/mouse). The second 
group were fed CRM(P) chow without fisetin. Mice were maintained on the diet for 16 weeks 
and monitored weekly to determine any changes in body weight. After 16 weeks, force 
generation of EDL muscle was determined and mice where then sacrificed for tissue and 
plasma collection.  
Figure 6.1 A brief overview of the methodology used for this chapter 
Eighteen 20-month-old C57BL/6 mice were treated with fisetin (500mg/kg) as part of their 
normal diet for 4 months. Following this, muscle force generation was determined. The 
mice were culled, and tissue and plasma removed and stored. The plasma was used for 
cytokine analysis whilst the muscle was weighed and then analysed for NF-κB activity. 
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6.2.2 Force measurements 
The protocol was adapted from McArdle et al. (2004). Mice were anaesthetised with 
isoflurane and maintained under anaesthesia throughout the procedure. The knee of the right 
hind limb was fixed. The distal tendon of the extensor digitorum longus (EDL) muscle was 
exposed and attached to the lever arm of a servomotor (Cambridge Technology, Cambridge, 
UK). The lever served as a force transducer. The peroneal nerve was exposed, and electrodes 
were placed across the nerve. The EDL muscle of the contralateral limb served as a non-
exercised control. Stimulation voltage and muscle length were each adjusted to produce 
maximum twitch force. The optimal length for maximum twitch force is also the optimal 
length (L0) for the development of maximum tetanic force (P0; (Brooks and Faulkner, 1988)). 
With the muscle at L0, the P0 was determined during 300msec of voltage stimulation at 8-10V. 
The P0 was identified by increasing the frequency of stimulation at 2-min intervals until the 
maximum force plateaued. The electrodes were then moved to provide direct activation of 
the muscle, the voltage increased to 30V and the maximum tetanic force was re-measured. 
Muscle fibre length (Lf) and cross-sectional area were calculated (Brooks and Faulkner, 1988).  
Following the final measurement, the mouse was removed from the platform, blood was 
collected from the descending aorta and mice were sacrificed by cervical dislocation. Mice 
were weighed, and all hind limb muscles and internal organs were removed post-mortem, 
weighed, and snap frozen in liquid nitrogen. Half of the anterior tibialis (AT) muscle was 
mounted on to a cork disk, surrounded with mounting medium (O.C.T., Merck, UK), frozen 
rapidly in liquid nitrogen cooled iso-pentane. EDL muscles were pinned and fixed using neutral 
buffered formalin (NBF), and later stored at 4°C in PBS + 0.1% sodium azide. The specific P0 
was calculated as the absolute P0/muscle cross-sectional area (Brooks and Faulkner, 2001). 
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6.2.3 EMSA for NF-κB activity in muscle 
EMSA was performed on the gastrocnemius (GTN) muscles of mice in both groups. The 
samples and protocol were performed as described in Section 2.8, and 100µg of muscle lysate 
was used. 
6.2.4 Luminex analysis of plasma cytokine content 
Blood from old mice was collected post-mortem from the descending aorta. The blood was 
centrifuged for 10 mins at 10,000g at 4°C, and the plasma collected. Luminex was performed 
as described in Section 2.7.
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6.3 Results 
6.3.1 Effect of Fisetin treatment on the survival and body weight of old mice 
Figure 6.2 shows percent weight change of mice treated with fisetin or on the normal control 
diet. No significant differences were seen in the body weight of the fisetin treated group (32.4 
± 1.0g), when compared with the control group (31.2 ± 1.2g) (Figure 6.2A). No significant 
differences were seen in the percent weight lost in the fisetin treated group (5.36±3.55%), 
when compared with the control group (5.45±4.24%) (Figure 6.2B). The survival plot of the 
two populations were not significantly different; between 20 and 24 months of age, one 
mouse died due to natural causes in each group over the time frame of the study (Figure 
6.2C).   
Figure 6.2 Effects of fisetin treatment on body weight and survival of mice 
(A) Body weight of mice after 4 months of treatment with fisetin or control diet. (B) The 
percent loss of body mass of mice after 4 months of treatment with fisetin or fed the 
control diet, when compared with initial body weight at 20 months. (C) Survival curve of 
mice in each group over 16 weeks of study. Data are presented as mean ± SEM. N= 8. 
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6.3.2 Effect of Fisetin treatment on the organ weights of old mice 
No significant differences were seen in the weight of the heart (2133 ± 158mg) (Figure 6.3A), 
lungs (2300 ± 89.55mg) (Figure 6.3B), kidneys (4965 ± 167.2mg) (Figure 6.3C), and spleen 
(783.3 ± 49.45mg) (Figure 6.3D), of fisetin treated mice, when compared with the heart (2080 
± 294mg) (Figure 6.3A), lungs (2241 ± 85.58mg) (Figure 6.3B), kidneys (4672 ± 126.0mg) 
(Figure 6.3C), and spleen (945.5 ± 95.72mg) (Figure 6.3D), of mice fed the control diet.   
Figure 6.3 Organ weights following fisetin treatment 
Weights of the heart (A), lung (B), spleen (C), and kidneys (D) of mice treated with fisetin 
or fed the control diet. Data are presented as mean ± SEM. N=8  
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6.3.3 Effect of fisetin treatment on the muscle mass of old mice 
Figure 6.4 shows the mean muscle mass (Figure 6.4A-E) or the muscle mass normalised to 
body weight (Figure 6.4F-J) of fisetin treated and control mice. No significant differences were 
seen in the absolute muscle or normalised weight of fisetin treated mice when compared with 
mice fed the control diet.  
6.3.4 Effect of Fisetin treatment on force generation of the EDL muscles of old mice 
No significant differences were seen in maximum tetanic force generation (Figure 6.5A) or 
specific force generation (Figure 6.5) of EDLs of fisetin treated mice when compared with 
control mice. This lack of difference was evident whether the EDL was activated by nerve 
stimulation or by direct muscle activation. 
6.3.5 Multiple cytokine analysis of the plasma from fisetin treated and control mice 
Figure 6.6 shows multiple cytokine data of the plasma collected from fisetin treated and 
control mice. MCP-1 was significantly decreased in plasma of fisetin treated mice compared 
with that of control mice. The plasma level of G-CSF approached significance (P=-0.0525) in 
fisetin treated mice compared with that of control mice, whereby the level was higher in 
plasma of fisetin treated mice.




Figure 6.4 Hind limb muscle weights of fisetin treated mice after 4 months of senolytic treatment compared with mice fed the control diet. 
The absolute weight (mg) and the muscle weight normalised to body weight (mg/mg) of: AT (A+F), EDL (B+G), GTN (C+H), SOL (D+I), and 
Quadriceps (E+J) of control or fisetin treated mice. Data are mean ± SEM.  
Page 233 of 300 
 
 
Figure 6.5 Force generation by EDL muscles of fisetin treated and control mice. 
The tetanic (A+C) and specific (B+D) force of the EDL muscle from fisetin treated and control mice. The specific Po was calculated as the 
absolute Po/muscle CSA. Data are presented as mean ± SEM. 
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Figure 6.6 Multiple cytokine analysis of plasma from mice after 4 months of treatment with fisetin compared with control mice. 
Plasma cytokine concentrations (pg/ml) of fisetin treated or control mice. Data are presented as mean ± SEM. Significance tested via Student’s 
T-test. 
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6.3.6 NF-κB activity in skeletal muscle of fisetin treated and control mice  
DNA binding of the NF-κB/p65 transcription factor was very variable in both groups 
but not different in GTN muscle of fisetin treated mice when compared with muscle 
from control old mice (Figure 6.7). 
  
Figure 6.7 NF-κB activity in muscles of fisetin treated and control mice. 
(A) Representative EMSA for NF-κB/p65 transcription factor DNA binding in the 
GTN of fisetin treated and control mice. (B) Quantification of the densitometry. 
SP, Specific competitor. N-SP, Non-specific competitor. SS, Supershift. Data are 
presented as mean ± SEM. Significance tested via Student’s T-Test. 
A 
B 
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6.4 Discussion 
 We hypothesised that the polyphenol fisetin would reduce the burden of senescent 
cells in old mice, reducing pro-inflammatory cytokine levels in the plasma, and 
reducing the chronic NF-κB activation seen in skeletal muscle; ultimately preserving 
muscle mass and function. This was investigated by treating old WT mice with fisetin 
as part of their diet from 20 to 24 months old, to investigate the pro-inflammatory 
cytokine levels in the plasma, and the NF-κB activity within the skeletal muscles and 
the effect on muscle mass and function. 
Age (months) 6 12 24 
Body Weight (g) Average 30.1  32.9 a  30.0  
SEM 0.8  0.8  0.7  
 
Heart (mg) Average 197.2  240.2  205.7  
SEM 13.4  30.8  8.8  
Lungs (mg) Average 208.3  240.9 a  228.5  
SEM 12.1  11.4  12.8  
Liver (mg) Average 1580.3  1758.4  1212.1 a,b  
SEM 76.2  130.9  127.7  
Kidneys (mg) Average 402.9  496.8 a  450.1  
SEM 12.5  23.9  35.5  
Spleen (mg) Average 70.8  100.3 a  66.9 b  
SEM 5.4  7.4  10.6  
Brain (mg) Average 388.4  386.7  383.1  
SEM 31.4  25.4  22.7  
 
Heart OW/BW Average 6.5  7.2  5.0 a,b  
SEM 0.3  0.8  0.6  
Lungs OW/BW Average 6.9  7.3  6.7  
SEM 0.3  0.3  1.4  
Liver OW/BW Average 52.3  53.3  39.1 a,b  
SEM 1.5  3.4  9.8  
Spleen OW/BW Average 2.3  3.0 a  5.6  
SEM 0.1  0.2  3.0  
Table 6.1 Body weight of C57BL/6 mice on a standard diet over time  
(Nye et al, unpublished)  
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6.4.1 The effect of fisetin treatment on body weight of old mice 
A decline in the body weight of mice is evident after 20 months of age (Vanhooren 
and Libert, 2013). Unpublished data from our laboratory have shown that C57Bl/6 
mice fed a standard diet lose body weight by 24 months old (Table 6.1, Nye et al, 
unpublished). The body weights of the control treated (31.2 ± 1.2g) and fisetin 
treated (32.4 ± 1.0g) old mice were not significantly different at the end of treatment. 
This suggests that inclusion of fisetin in the diet of the mice did not affect the 
palatability of the chow. Yousefzadeh et al. (2018) did not report body mass following 
dietary fisetin treatment of mice. However, no significant differences in body weight 
were reported in a 9 month long dietary fisetin treatment of mice from 3-12 months 
of age (Currais et al., 2014).  
6.4.2 Fisetin treatment, survival, and potential toxicity 
The survival plot of the two groups were also not significantly different suggesting no 
adverse effects of the diet on the lifespan at this age (20-24 months old). These 
findings suggest that fisetin appeared to have no immediate or long-term effects on 
the health of the mice that would result in increased mortality. Yousefzadeh et al. 
(2018) reported a significant improvement in median lifespan in a cohort of fisetin 
treated mice when compared with control mice. However, the median lifespan of the 
control group in their study was greater than 24 months of age, which was the 
endpoint for this current study. Fisetin (25 mg/kg) has not been shown to result in 
any signs of measurable toxicity, and is readily absorbed and distributed to blood 
vessels (Krasieva et al., 2015). Moreover, fisetin can be detected within the brain and 
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other distal organs at 40 minutes after oral administration (25 mg/kg) and remains 
detectable for up to 2 hours (Krasieva et al., 2015).  
Other studies have investigated the toxicity of fisetin over shorter periods of time. 
Mice were orally administered 2000 mg/kg body weight of fisetin, examined for 48 
hours and sacrificed; again, no indications of toxicity were observed (Maher, 2015). 
Effects of long-term feeding of fisetin on health were also evaluated and no 
significant differences in body weights were seen between control and fisetin-fed 
animals given fisetin (25 mg/kg body weight) in their diets for 9 months (Currais et 
al., 2014). Following sacrifice, Currais et al. (2014) examined lungs, spleen, liver, 
kidneys, heart, stomach, intestine, testes and ovary and no evidence of toxicity was 
seen following fisetin treatment.  
6.4.3 Fisetin treatment and organ weights 
Data from our laboratory have shown a significant reduction in the weights of a 
number of organs including heart, lung and kidneys and a significant increase in 
spleen mass with advancing age (Table 6.1). The weights of the organs of the fisetin 
treated mice were not significantly different when compared with the control mice, 
suggesting that treatment of mice with fisetin had no effect on age-related changes 
in weights seen in these tissues. The study by Yousefzadeh et al. (2018) did not report 
on internal organ weights but did report a decrease in senescence markers in the fat, 
spleen, liver, and kidneys of fisetin fed progeroid p16-reporter mice when compared 
with control progeroid p16-reporter mice. Jung et al. (2013) investigated the effects 
of fisetin treatment on a high fat, diet-induced obesity. Treatment of mice with 
fisetin, alongside the high fat diet, reduced weight gain and accumulation of white 
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adipose tissue, via suppression of mTORC1 signalling and reduced differentiation of 
pre-adipocytes (Jung et al., 2013). 
Fisetin has been shown to have no significant toxic effects on the lungs, liver, spleen, 
kidneys, heart, stomach, intestine, or reproductive organs; at doses as high as 2g/kg 
(Currais et al., 2014) and our current study. In models of diabetic rats, a month of 
fisetin treatment significantly decreased blood glucose levels, increased insulin 
levels, and reduced glycosylation of red blood cells (Prasath and Subramanian, 2011). 
In the liver and kidneys of these treated rats, fisetin restored the activity of glycolytic 
pathway enzymes and inhibited the activity of gluconeogenic pathways (Prasath and 
Subramanian, 2011).  
6.4.4 Fisetin treatment of old mice: effect on muscle mass and force generation of 
the EDL muscle  
The maximum tetanic force generated by muscles of 24 month old WT mice is 
generally decreased by 30-40%, specific force by 10-15% (McArdle et al., 2004) and 
muscle mass is decreased by 20-30% . The muscle masses or maximum tetanic and 
specific force generation of muscles of fisetin treated mice was not significantly 
different when compared with that of control mice whether the muscle was activated 
by nerve stimulation or direct muscle activation. These data suggest that fisetin did 
not provide any protection against age-related loss of muscle mass and function. 
Indeed, there was a trend to decrease in the absolute force generation in the EDL 
from the fisetin treated mice, when compared with the control mice.  
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These findings are contrary to the hypothesis that removal of senescent cells would 
improve muscle function by eliminating the SASP. Fisetin treatment and 
inflammation 
Data in Chapter 4 show that the plasma levels of a number of cytokines were elevated 
in old compared with adult mice. When comparing similar data from the fisetin 
treated group with the control group, the only significant effect on plasma cytokine 
levels was a decrease in Monocyte chemotactic protein-1 (MCP-1). Yousefzadeh et 
al. (2018) also saw a specific and significant decrease in plasma circulating MCP-1 in 
mice treated with fisetin compared with control mice. A comparison of changes in 
plasma cytokine levels in plasma in old compared to adult WT mice, and the fisetin 
treated mice together with their controls (Table 6.2).  
The source of plasma MCP-1 is unclear and since plasma MCP-1 levels were not 
affected by ageing, these effects are unlikely to be due to the removal of senescent 
cells. MCP-1 is a chemokine and member of the small inducible cytokine family, 
playing a crucial role in the recruitment of monocytes and T lymphocytes into tissues 
(Baggiolini, 1998); and is expressed by adipocytes (Gerhardt et al., 2001). MCP-1 was 
found to impair glucose uptake (Sartipy and Loskutoff, 2003) and was shown to 
impair insulin signalling in skeletal muscle at physiological levels (200 pg/ml); via 
ERK1/2 activation but does not involve activation of the NF-κB pathway (Sell et al., 
2006).  
  

















































Summary table of the cytokines 
measured in the plasma of old mice 
compared with adult mice, and fisetin 
treated mice compared with control 
mice. Green, significantly increased; Red, 
significantly decreased; Grey, no 
difference; White, not measured.  
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6.4.5 Comparison of the current study with published studies. 
Yousefzadeh et al. (2018) noted that the effect of fisetin treatment was greater on 
p16-expressing cells than on p21 expressing cells, at least in subcutaneous fat. 
Although the current study saw no increase in p21 or p16 in muscle tissue, the nature 
of senescent cells in non-muscle tissue of old mice was not examined. If p21 
expressing cells are dominant at 24-26 months old, this might explain the lack of 
effects in the current studies.  
In other studies, specific ablation of p16 expressing senescent cells had a profound 
effect on muscle. Whilst weight or force generation was not reported, an 
improvement in fibre diameter was reported and greater mobility was seen in the 
p16 ablated mice compared to the control mice (Baker et al., 2016, Baker et al., 2011).  
Data from Sousa-Victor et al. (2014) showed that there were no significant increases 
in p16 expression in satellite cells from old (24 months) mice, when compared with 
adult (12 months). von Zglinicki et al. (2020) reported significantly increased 
expression of p16 and p21 in the muscles of very old (32 months) mice when 
compared with adult (8 months) mice, and also saw significantly increased nuclear 
p21 in the old mice. These data, and more discussed in Section 4.4.1.1 suggest that: 
A) skeletal muscle show significantly increased markers of cellular senescence, but 
only once mice are classed as “geriatric” (32-months old); and B) cellular senescence 
in muscle may be based more on changes in p21 activity, rather than p16.  
6.5 Conclusion 
Fisetin treatment had no significant effects in preserving the loss of hind limb muscle 
mass and EDL function with age, when compared with control treated old mice. 
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Fisetin treatment resulted in a significant decrease in the plasma concentration of 
MCP-1 when compared with control treatment mice although this cytokine was not 
elevated in plasma of old WT mice. Fisetin treatment had no significant effect on NF-
κB transcription factor binding activity in muscle, when compared with that of control 
old mice. Overall, fisetin treatment had a no effect regarding preserving muscle mass 
and function in mice of this age, as well as little effect in reducing the pro-
inflammatory plasma cytokines. Recent studies suggest that skeletal muscle does not 
contain a significant population of senescent cells until the mice are significantly older 
(da Silva et al., 2019, von Zglinicki et al., 2020) despite showing sarcopenia by 24 
months old. The mice used in this study were 24 months old, and therefore would 
have a limited pool of senescent cells. Therefore, it may be that the effects of a 


















7 Chapter 7: General Discussion and Future Directions 
  




7.1 Hypothesis.  
The overall hypothesis of this thesis was that senescent cells accumulate in old mice, 
either locally to skeletal muscle or distally, and that they produce an inflammatory 
SASP which may contribute at least in part to the chronic NF-κB signalling and the loss 
of muscle mass and function seen in the muscles of old compared with adult mice.  
This programme of work tested this hypothesis by utilising different models of 
senescence in vitro and in vivo and using a senolytic and transgenic intervention. 
 
7.2 Aims of the thesis  
The aims of the work reported in this thesis were to: 
1. Establish an in vitro model of cellular senescence in muscle cells by inducing 
and characterising senescence in C2C12 myoblasts. Furthermore, C2C12 
myotubes were treated with the conditioned media containing the SASP from 
the senescent cells to investigate the effect of the SASP on activation of NF-
κB activity in mature multinucleated myotubes.  
2. To determine the presence of senescent cells within muscle of adult and old 
WT mice including the potential of muscle of adult and old mice to produce 
SASP. 
3. To determine the effects of senescent cell removal on plasma cytokine 
concentrations and indices of skeletal muscle inflammation, as well as muscle 
mass and function in old P16-3MR mice treated with gancyclovir to remove 
P16 positive cells compared with PBS treated old P16-3MR mice.  
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4. To determine the effects of pharmacological removal of senescent cells by 
treating old WT mice with the senolytic fisetin as part of their diet over several 
months and investigate muscle mass and function, the pro-inflammatory 
cytokine levels in the plasma, and the NF-κB activity within the skeletal 
muscles.  
7.3 Summary of the findings of the thesis 
The major findings of this work were: 
1. Treatment of C2C12 myoblasts with etoposide, a well-studied small molecule 
capable of causing DNA damage and inducing senescence, resulted in a dose 
dependant loss of cell viability. Low concentrations of etoposide induced 
senescence in C2C12 myoblasts, and these cells showed many hallmarks of 
senescence, including increased protein levels of p21, increased SA-β-Gal activity, 
SAHF, and altered morphology. Furthermore, the senescent myoblasts produced 
a proinflammatory SASP detectable in the cell media that was able to increase 
NF-κB transcription factor activity in mature C2C21 myotubes. These findings 
suggest that C2C12 myoblasts can become senescent and that the SASP produced 
can activate NF-κB in mature muscle myotubes. 
2. Muscles of old (24-months-old) WT mice did not show any significant change in 
indices of senescence (p16, p21, p53, SA-β-Gal) when compared with muscles of 
adult (8-12-month-old) mice. These findings provide little evidence of the 
presence of classical senescent cells in muscles of old mice. Old mice showed 
evidence of increased levels of potential SASP components in the plasma 
although the role of senescent cells in the production of these 
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cytokines/chemokines is unclear. Data examining levels of cytokines in muscle of 
old compared with adult mice suggest that muscle may partially contribute to the 
increase in some plasma cytokines evident in plasma of old mice but suggests that 
the source of many cytokines seen in plasma is not primarily muscle tissue. 
However, it may be that muscle rapidly produces and secretes cytokines and so 
changes in intracellular protein levels will not be evident, but such cytokines 
produced by muscle may still have a local effect on peripheral nerves for example. 
3. GCV treatment of old (20 to 24-months-old) P16-3MR mice to remove p16 
expressing senescent cells both local and distant to muscle showed no significant 
effect on muscle mass or function, compared with vehicle treated P16-3MR 
control mice. GCV treatment of P16-3MR mice resulted in a minor effect on the 
plasma cytokine/chemokine profile of old mice and had no effect of reducing the 
NF-κB transcription factor activity in muscle of these old mice.  
4. In a similar manner to the study using P16-3MR mice, treatment of old (20 to 24-
months-old) WT mice with fisetin as part of their diet had no significant effect on 
muscle mass or function, when compared with vehicle treated control mice. Only 
MCP-1 was significantly lower in the plasma of fisetin treated old mice compared 
with age-matched control mice, although this cytokine had not been identified as 
elevated in plasma of old compared with adult WT mice. No significant 
differences were seen in NF-κB transcription factor activity in the muscles of 
fisetin treated compared with control mice. 
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7.4 General discussion 
7.4.1 Senescence in a cell culture model.  
One of the major challenges of the current study was the establishment of a suitable 
cell culture model allowing accurate determination of cytokine release by senescent 
cells. The study described in Chapter 3 used a DNA damaging agent, etoposide to 
successfully induce senescence in myoblasts, providing proof-of-principle that 
myoblasts were capable of senescence. However, quantification of 
cytokine/chemokine release by cells proved challenging.  
The senescent cells demonstrated growth arrest and an increase in cell volume 
following treatment with etoposide. In contrast, DMSO treated cells continue to 
actively divide, finally resulting in temporary growth arrest when confluent at ~ 5 days 
following seeding in the current experiments, where they begin to terminally 
differentiate into myotubes. The indices of senescence may also be involved in this 
contact inhibition and differentiation process in muscle cells and so comparison of 
the levels of such indices in these ‘control’ cells with that of senescent cells may be 
misleading. In addition, there is considerable discussion on the method of 
normalisation of cytokine/chemokine release into the media from the different 
groups of cells. Wells of senescent cells will have less cells than those of DMSO-
treated control wells of cells, but the senescent cells are much larger. It is anticipated 
that a comparison of the expression of cytokine/chemokine release data will be 
different if expressed per unit of protein in each well or per cell. Both will be 
particularly informative but care in interpretation is recommended. 
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7.4.2 Senescence in skeletal muscle tissue 
The first introduction to, and demonstration of cellular senescence was led by the 
pioneering study from Hayflick and Moorhead (1961). Since then, cellular senescence 
has become far more widely studied, with a number of hallmarks of senescence being 
identified (Hernandez-Segura et al., 2018). However, senescent cells are diverse and 
their profiles are dependent on the cell type of origin and how senesce was induced 
(Wiley et al., 2017). Of these hallmarks, of interest is the senescence associated 
secretory phenotype (SASP), a cocktail of cytokines, chemokines, and proteases 
secreted by senescent cells (Coppe et al., 2010a). Indeed, the SASP has been 
hypothesised to be a contributor to the age-related increase in inflammation, termed 
inflammaging (Franceschi and Campisi, 2014). This increase in inflammation has a 
negative effect on tissue structure and function, increasing the development of 
several age-related pathologies, including sarcopenia.  
The mechanisms underlying the development of sarcopenia are not completely 
understood. It is likely that sarcopenia is a multi-factorial disease with a network of 
interacting, dysfunctional systems (Larsson et al., 2019). However, data has shown 
that increased inflammation that occurs with ageing is likely to play a major role 
(Bano et al., 2017).  
As part of this thesis, it was hypothesised that senescent cells accumulate with age in 
old mice, either locally or distant to skeletal muscle. These senescent cells produce 
an inflammatory SASP which contributes to the chronic NF-κB activation and 
inflammation seen in muscle ageing, contributing to the activation of degradation 
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pathways and loss of muscle mass and function seen in old mice (Lightfoot et al., 
2014).  
Similar studies have proposed a role for senescence in inflammation and the 
development of age-related pathologies, including the development of sarcopenia 
(Demaria et al., 2014, Baker et al., 2016). Despite these studies, the literature 
supporting the presence of senescent cells in skeletal muscle is heterogeneous 
(Jeyapalan et al., 2007, Edwards et al., 2007, Sousa-Victor et al., 2014, da Silva et al., 
2019). The differences between these data may be due to methodological 
approaches. Indeed, data presented as part of this thesis show that whilst muscle 
cells have the capability to senescence in vitro, there is little evidence of this occurring 
within muscle in vivo, at least up to the age of 24 months, when considerable loss of 
muscle mass is evident.  
Skeletal muscle is mainly comprised of post-mitotic multinucleated muscle fibres, and 
there has been limited interest in investigating senescence in post-mitotic tissue. 
However, von Zglinicki et al. (2020) investigated indices of senescence in several 
different post-mitotic tissues in geriatric mice and showed that post-mitotic tissue, 
including skeletal muscle fibres can display evidence of senescence. Studies using 
transgenic mice for whole body removal of senescent cells (Baker et al., 2016) or 
senolytic treatment (Yousefzadeh et al., 2018), have also demonstrated 
improvements in several measures of physical mobility in old mice. However, when 
muscle mass and function were investigated as part of this current thesis, using both 
transgenic mouse models (Chapter 5) and senolytic treatment (Chapter 6), no 
significant preservation of muscle mass and function were seen.  
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One potential reason for the difference between the current study and those 
discussed above may be due to the age of the mice used.  
7.4.3 Senescence may only be evident in very old (geriatric) mice.  
Studies that have demonstrated senescence within skeletal muscle, have commonly 
made use of geriatric (32-months-old) mice (Sousa-Victor et al., 2014, von Zglinicki et 
al., 2020, da Silva et al., 2019, Baker et al., 2016). Geriatric mice represent a human 
approximately in their 80th decade of life (Ackert-Bicknell et al., 2015). Skeletal 
muscle accounts for 40% of total body weight, and 50-75% of total body protein 
(Frontera and Ochala, 2015). A decrease of 30-50% in skeletal muscle mass and 
function had been reported in adult by approximately 80 years of age (Akima et al., 
2001). More recent studies have shown that after the age of 30, about 0.5–1% of 
skeletal muscle mass is lost per year, with the rate of loss accelerating after the age 
of 65 (Kyle et al., 2001, Melton et al., 2006). On average, 5–13% of individuals aged 
over 60 have low skeletal muscle mass, with the prevalence increasing to as high as 
50% in those over of 80 (Morley et al., 2014). Geriatric mice will also show 
substantially increased indices of cancer and so caution needs to be taken when 
interpreting data from such studies. 
The data, together with the data presented in this thesis suggest that the 
accumulation of senescent cells may only occur in very old (>32 month) mice. Loss of 
muscle mass and function occurs at ~18 months onward in mice and so the presence 
of senescent cells is only evident at a time point when substantial sarcopenia is 
evident, suggesting that senescence plays little role in the development of sarcopenia 
in mice. In contrast, data show substantial inflammaging at the time of the 
development of sarcopenia, suggesting an association between an elevation in 
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plasma cytokine/chemokine levels and the development of sarcopenia and this was 
not affected by removal of senescent cells. Muscle may contribute in part to these 
cytokines/chemokines but data suggest there are additional, likely non-senescent 
sources of cytokines/chemokines seen in plasma of old mice (Larsson et al., 2019, 
Bano et al., 2017). 
7.4.4 Use of transgenic mouse models to eliminate senescent cells 
Several landmark studies by Baker et al (2016, 2013, 2011, 2008, 2004) have 
investigate the role of senescence in the development of age-related pathologies 
using progeroid mouse models crossed with a transgenic mouse model that can both 
report and selectively eliminate senescence cells (Section 1.1.7.2). To summarise 
their findings in the context of sarcopenia and frailty, elimination of senescent cells 
from the whole organism result in delayed onset of age-related pathologies in 
adipose tissue, skeletal muscle, and eye. Increases in health span and several 
measures of fitness, as well increases in gastrocnemius mass were reported following 
senescent cell elimination. Furthermore, a decrease in the level of inflammatory 
cytokines was reported in the plasma and muscles of these mice following senescent 
cell elimination. The difficulty with interpreting these data are that mice of several 
different ages and genetic backgrounds are used throughout all of the studies. Whilst 
these findings are novel, they were again reported in geriatric mice, and as previously 
discussed, whilst the muscles of geriatric mice may show indices of senescence, old 
(24-months-old) do not appear to, particularly in skeletal muscle. Therefore, the 
effects of eliminating senescent cells from an old mouse with age-related pathology 
remain uncertain. The elimination of senescent cells that accumulate in other tissues 
that are not skeletal muscle would influence the SASP and inflammation. Indeed, 
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whilst the effect of removal of senescent cells on skeletal muscle mass and function 
was not investigated in the Demaria et al. (2014) P16-3MR study, decreased 
concentrations of inflammatory SASP factors were reported in the fat of GCV-treated 
p16-3MR.  
7.5 Limitations of the current studies 
One limitation of the study is the age of the mice used as part of the studies. The age 
used (24-months-old) as data from our group (Jackson, 2020, McArdle et al., 2019) 
and others (Brooks and Faulkner, 1988) show that mice begin to display 
characteristics in frailty, with a loss of muscle mass and function. 
Another limitation is the marker for senescence, p16. Senescence in skeletal muscle 
has been identified using p21, and not p16.  
Another limitation is the lack of diversity in the genders of the mice. The mice used 
in Chapters 4 and 6 were all male, however, due to the collaborative nature of this 
study, the P16-3MR mice used in Chapter 5 were of both sexes. Women and non-
human female mammals are underrepresented in studies, whereby researchers 
assume results from males apply to females (Beery and Zucker, 2011). Researchers 
avoid the inclusion of females because of concerns that hormonal cycles decrease 
the homogeneity of study populations and confound effects of experimental 
manipulations (Beery and Zucker, 2011). Many drug studies using males often 
generate different results from those for women (Soldin and Mattison, 2009). In 
future studies, mice of each gender would be investigated in sufficient numbers to 
identify any gender related differences or trends in data.  
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Another limitation to the overall study was the multiplex cytokine analysis. The 
cytokine analysis performed in Chapters 3, 5, 6 made use of a 23-plex senescence 
cytokine array, the analysis on adult and old plasma and muscle in Chapter 4 were 
performed using a 33-plex array. This has caused issues whereby some cytokines 
were present on one array and not on another, preventing full comparison of 
cytokine between the different models used in this thesis (Table 7.1).  
 




Summary of cytokine analysis between different models of senescence. Old WT 
mice (24-months-old) compared with adult (8-12 months old) WT mice. GCV 
treated old (26-months-old) P16-3MR mice treated mice, compared with PBS 
treated old (26-months-old) P16-3MR mice. Fisetin treated old (24-months-old) 
WT mice compared with vehicle treated control old WT mice. Changes represent 
significant changes within the plasma of the mice compared with their controls.  
Cytokines WT P16-3MR Fisetin
BCA-1/CXCL13 - - -
CTACK/CCL27 - - -
ENA-78/CXCL5 - - -
Eotaxin/CCL11
Eotaxin-2/CCL24 - - -
Fractalkine/CX3CL1 - - -
G-CSF - p=0.0525
GM-CSF














IL-16 - - -
IL-17 -
IP-10/CXCL10 - - -
I-TAC/CXCL11 - - -
KC/CXCL1
MCP-1/CCL2
MCP-2/CCL8 - - - -
MCP-3/CCL7 - - -
MCP-5/CCL12 - - -
MDC/CCL22 - - -
MIP-1α/CCL3
MIP-1β/CCL4
MIP-2/CXCL2 - - -
MIP-3α/CCL20 - - -
MIP-3β/CCL19 - - -
RANTES/CCL5
SCYB16/CXCL16 - - -
SDF-1α/CXCL-12 - - -
TARC/CCL17 - - -
TECK/CCL25 - - -
TNFα
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7.6 Future directions.  
7.6.1 Identification of the source of increased plasma cytokines in old mice and 
humans. 
Inflammaging describes the chronic, low-grade systemic inflammation seen in ageing 
(Franceschi et al., 2000). The source of such inflammatory cytokines is unclear, but 
this inflammation appears to occur in the absence of infection and is primarily driven 
by endogenous signals. Data suggest that besides persistent infections; cell debris, 
misplaced self-molecules, and misfolded/oxidized proteins are major contributors to 
inflammaging (Franceschi and Campisi, 2014).  
Data provided in this thesis and in other studies have supported a role for muscle, at 
least in part, in contributing to this systemic inflammation although data presented 
in this thesis do not support a role for senescence either in the systemic inflammation 
or in the muscle production of cytokines/chemokines.  
Clearly, additional analysis is required to identify the source of the systemic 
inflammation in old mice (and humans) and to identify the components of this 
inflammation that may be potentially responsible for activation of NF-kB in muscle 
and the development of sarcopenia.  
7.6.2 Examination of the local effects of muscle – derived cytokines on other cells 
and tissues. 
The modified production of cytokines by skeletal muscle during ageing may not 
contribute in a significant way to the plasma concentration of cytokines/chemokines, 
but it may be that the release of cytokines/chemokines may play a role in the 
development of dysfunction in local tissues and cells. Of note is the local effect on 
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the peripheral nerve, interaction of which is crucial to maintenance of muscle mass 
and function. Additional studies on the effect of modified release of 
cytokines/chemokines is therefore warranted.  
7.6.3 Lack of clear markers of senescence, particularly in terminally differentiated 
muscle cells. 
None of the current markers for senescence are completely specific for senescence 
and are used in combination to characterise cellular senescence. The additional 
complication of the continued action of resident mononuclear stem cells in muscle 
(satellite cells) in proliferating and then differentiating to fuse and form terminally 
differentiated multinuclear cells provides an additional level of complexity. A number 
of classical indices of senescence are also involved in this cell cycle arrest and 
differentiation and a further understanding of the overlap of these processes in 
muscle tissue is required. 
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Centre for Integrated research into Musculoskeletal Ageing (CIMA). 
Do resident senescent cells drive the ageing phenotype of skeletal muscle? 
Loss of skeletal muscle mass and function are critical factors in the development of 
frailty. The number of senescent cells increases with age in rodents (Krishnamurthy 
et al., 2004) and primates (Kreiling et al., 2011). We hypothesise that these cells 
trigger a local and/or systemic chronic inflammatory response leading to the rapid 
loss of muscle mass and function and that eliminating senescent cells will correct the 
accelerated loss of muscle mass and function in rodent models of sarcopenia. 
Initial studies have investigated whether a C2C12 mouse muscle cell line could be 
induced into senescence and if so, whether key senescence-associated molecules are 
upregulated and/or released as the senescence–associated secretory phenotype 
(SASP). 
Myoblasts were treated with Etoposide (50µM) to induce senescence and monitored 
for up to 5 days for SA-β-Gal staining and for p16 and p21 by immunocytochemistry. 
Myoblasts exhibited a significantly altered morphology, increased β-Galactosidase 
activity, and p16 and p21 levels compared with untreated healthy controls.  
These data suggest that C2C12 myoblasts can undergo senescence. Further work will 
characterise the SASP of muscle cells and parallel work will elucidate the 
accumulation of senescent cells with age in a range of tissues of mouse ageing models 
and determine the effects of this accumulation on muscle. 
Work generously funded by the BSRA.   
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Do resident senescent cells drive ageing of skeletal muscle? 
Shigdar S (shigdars@liv.ac.uk)1, Staunton C1, Richardson A2, Vasilaki A1, McArdle A1 
1Department of Musculoskeletal Biology, William Henry Duncan Building, Institute of 
Ageing and Chronic Disease, University of Liverpool, UK. MRC-Arthritis Research UK 
Centre for Integrated research into Musculoskeletal Ageing (CIMA).  
2University of Oklahoma Health Science Center and Oklahoma City VA Medical 
Center. 
Loss of muscle mass and function are critical factors in the development of frailty, 
leading to immobility, falls and need for residential care, making sarcopenia one of 
the major factors in poor quality of life in old age. Despite this, only modest progress 
has been made in determining the mechanism(s) by which age-associated muscle loss 
occurs and this represents a critical barrier to developing optimal therapies for frailty 
in older people.  
As we age, some individual cells within the body lose their ability to divide and grow 
(become senescent), these cells produce molecules, including inflammatory 
cytokines, which are known to be detrimental to tissues. We hypothesise that the 
production of these molecules by senescent cells either in close proximity to (resident 
stem cells) or distant to (fat cells) the muscle plays a major role in muscle loss with 
old age. 
Preliminary data has characterised senescence in muscle stem cells (myoblasts) in 
culture and will now examine muscles of old mice for evidence of senescent 
myoblasts. Future studies will use a transgenic mouse in which senescent cells can be 
abolished. We hypothesise that this will prevent age-related loss of muscle mass and 
strength and lead to the development of novel therapies. 
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9.1.3 Institute of Ageing and Chronic Disease Science Day - 2018 
Shigdar S.1, Staunton C.1, Vasilaki A.1, McArdle A.1  
1Department of Musculoskeletal Biology, William Henry Duncan Building, Institute of 
Ageing and Chronic Disease, University of Liverpool, UK, L7 8TX. MRC-Arthritis 
Research UK Centre for Integrated research into Musculoskeletal Ageing (CIMA). 
shigdars@liv.ac.uk 
Do Resident Senescent Cells Drive the Ageing Phenotype Of Skeletal Muscle? 
Loss of skeletal muscle mass and function are critical factors in the development of 
frailty. The number of senescent cells increases with age in rodents (Krishnamurthy 
et al., 2004) and primates (Kreiling et al., 2011). We hypothesise that these cells 
trigger a local and/or systemic chronic inflammatory response leading to the rapid 
loss of muscle mass and function and that eliminating senescent cells will correct the 
accelerated loss of muscle mass and function in rodent models of sarcopenia. 
Initial studies have investigated whether a C2C12 mouse muscle cell line could be 
induced into senescence and if so, whether key senescence-associated molecules are 
upregulated and/or released as the senescence associated secretory phenotype 
(SASP). 
Myoblasts were treated with Etoposide to induce senescence and monitored for up 
to 5 days for SA-β-Gal staining, immunocytochemistry and western blot analysis. 
Myoblasts exhibited a significantly altered morphology, increased β-Galactosidase 
activity, and cyclin-dependent kinase inhibitor levels compared with untreated 
healthy controls.  
These data suggest that C2C12 myoblasts can undergo senescence. Further work will 
characterise the SASP of muscle cells and parallel work will elucidate the 
accumulation of senescent cells with age in a range of tissues of mouse ageing models 
and determine the effects of this accumulation on muscle. 
Work generously funded by the BSRA.  
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9.1.4 Experimental Biology – 2018 
Shigdar S. 1 (shigdars@liv.ac.uk), Staunton C.1, Vasilaki A.1, McArdle A.1  
1MRC-Arthritis Research UK Centre for Integrated research into Musculoskeletal 
Ageing (CIMA), Department of Musculoskeletal Biology, Institute of Ageing and 
Chronic Disease, William Henry Duncan Building, University of Liverpool, UK. 
Do Resident Senescent Cells Drive The Ageing Phenotype Of Skeletal Muscle? 
Loss of skeletal muscle mass and function are critical factors in the development of 
frailty. The number of senescent cells increases with age in rodents (Krishnamurthy 
et al., 2004) and primates (Kreiling et al., 2011). We hypothesise that these cells 
trigger a local and/or systemic chronic inflammatory response with the production of 
Senescence Associated Secretory Phenotype molecules (SASPs), including 
inflammatory cytokines leading to muscle dysfunction and loss. We further 
hypothesise that eliminating senescent cells will correct the accelerated loss of 
muscle mass and function in mouse models of sarcopenia. 
Initial studies have investigated whether a C2C12 mouse muscle myoblast cell line 
could be induced into senescence and if so, whether key senescence associated 
molecules (such as p16, p21, and p53) are upregulated and/or released as part of the 
SASP. 
Myoblasts were treated with the topoisomerase II inhibitor, Etoposide, to cause DNA 
damage and induce senescence. Treated C2C12 myoblasts were monitored for up to 
5 days for Senescence Associated β-Galactosidase (SAβ-Gal) staining, 
immunocytochemistry for p16 and p21, and western blot analysis for p16, p21, and 
p53 on cell lysates. Treated myoblasts exhibited a significantly altered morphology, 
increased SAβ-Gal activity, and cyclin-dependent kinase inhibitor levels compared 
with untreated healthy controls.  
These data suggest that C2C12 myoblasts can be induced into a senescent 
phenotype. Further work will characterise the SASP of C2C12 cell enriched media, 
adult and old murine skeletal muscle cell lysates, as well as plasma from these mice. 
Parallel work will determine the accumulation of senescent cells with age in a range 
of mouse tissues from a range of models (CuZnSOD-/-, p16-3MR, and WT) and 
determine the effects of this accumulation on skeletal muscle function. 
References 
Kreiling, J.A., M. Tamamori-Adachi, et al. (2011). Age-associated increase in heterochromatic marks in 
murine and primate tissues. Aging Cell 10, 292-304. 
Krishnamurthy, J., C. Torrice, et al., (2004). Ink4a/Arf expression is a biomarker of aging. J Clin Invest 
114, 1299-1307. 
Work generously funded by the British Society for Research into Ageing and the 
Rosetrees Trust. 
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9.1.5 Experimental Biology – 2018 
Shigdar S. 1 (shigdars@liv.ac.uk), Staunton C.1, Vasilaki A.1, McArdle A.1  
1MRC-Arthritis Research UK Centre for Integrated research into Musculoskeletal 
Ageing (CIMA), Department of Musculoskeletal Biology, Institute of Ageing and 
Chronic Disease, William Henry Duncan Building, University of Liverpool, UK. 
Do Resident Senescent Cells Drive The Ageing Phenotype Of Skeletal Muscle? 
Loss of skeletal muscle mass and function are critical factors in the development of 
frailty. The number of senescent cells increases with age in rodents (Krishnamurthy 
et al., 2004) and primates (Kreiling et al., 2011). We hypothesise that these cells 
trigger a local and/or systemic chronic inflammatory response with the production of 
senescence associated secretory phenotype molecules (SASPs), including 
inflammatory cytokines leading to muscle dysfunction and loss. We further 
hypothesise that eliminating senescent cells will correct the accelerated loss of 
muscle mass and function in mouse models of sarcopenia. 
Initial studies have investigated whether key senescence associated molecules (such 
as p16, p21, and p53) are upregulated in aged (24 months old) compared to young (3 
months old) C57BL6 WT mice skeletal muscles, and to characterise any potential 
SASPs produced. 
Quadriceps from young and old mice were subjected to western blot analysis for 
senescence associated cyclin-dependent kinase inhibitors; p16, p21 and p53. 
Quadriceps were also snap frozen and cryosectioned transversely (12μm thickness) 
before being subjected to immunohistochemistry for p21 and p53, and a range of 
other senescent markers. Western blot analysis results outlined that muscle from 
aged mice showed a significantly increased expression of p16, p21, and p53 
compared to that of young skeletal muscles (p<0.05).  
In light of this data, we found that aged murine skeletal muscle expresses a range of 
senescence associated markers and current studies are characterising the senescent 
content (SASP) of plasma from these mice using a multiplex ELISA to try and 
determine its impact on aged skeletal muscle function.  
Future work will examine the skeletal muscle as well as other tissues as such as the 
neuronal tissue and adipose tissue from young and old mice in a range of mouse aging 
models (CuZnSOD-/-, p16-3MR, and WT) to determine the effects of this accumulation 
and its role in skeletal muscle structure and function.  
References 
Kreiling, J.A., M. Tamamori-Adachi, et al. (2011). Age-associated increase in heterochromatic marks in 
murine and primate tissues. Aging Cell 10, 292-304. 
Krishnamurthy, J., C. Torrice, et al., (2004). Ink4a/Arf expression is a biomarker of aging. J Clin Invest 
114, 1299-1307. 
Work generously funded by the British Society for Research into Ageing and the 
Rosetrees Trust.  
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Shigdar S. 1 (shigdars@liv.ac.uk), Staunton C.1, Brooks S., Vasilaki A.1, Richardson A., 
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Chronic Disease, William Henry Duncan Building, University of Liverpool, UK. 
Senescence in myoblasts; role in age-related muscle dysfunction  
Loss of muscle mass and function are critical factors in the development of frailty 
although the mechanisms involved are poorly understood. The number of senescent 
cells increases with age1-2. It is proposed that the presence of these cells plays a role 
in age-related muscle dysfunction via chronic activation of the nuclear factor k-B (NF-
κB) mediated inflammatory pathway3. We hypothesise that resident satellite, or 
potentially other cells local to muscle, become senescent and exert detrimental 
effects on mature muscle fibres; including the chronic activation of NF-κB via the 
senescence associated secretory phenotype molecules (SASP) by the bystander 
effect4. 
In vitro studies have also investigated whether C2C12 myoblasts could become 
senescent, whether senescence associated cyclin-dependent kinase inhibitors (CDKI) 
are upregulated, and to determine the nature of the SASP. Myoblasts were treated 
with Etoposide to induce senescence. Treated myoblasts exhibited significantly 
altered morphology consistent with a senescent phenotype, increased SA-β-Gal 
activity, CDKI levels, and SASP factors (IL-6, IL-12(p40), and RANTES), compared with 
untreated cells.  
Additional studies examined muscles from old (24months) and young (3months) 
C57BL6 Wild-Type (WT) mice for evidence of increased senescence markers. Muscles 
from old mice had a significantly increased (4-fold) content of senescence CDKIs 
compared with muscles of young mice (p<0.05). 
Data suggest that myoblasts can develop a senescent phenotype. Further work will 
investigate the effect on mature myotubes co-cultured with senescent myoblasts on 
NF-κB activity. Furthermore, we will determine the role of senescence in vivo on 
skeletal muscle and NF-κB activity in muscle using p16-3MR mice and senolytic 
agents.  
Work generously funded by the British Society for Research into Ageing and the 
Rosetrees Trust. 
1. Krishnamurthy, J., C. Torrice, et al., (2004). Ink4a/Arf expression is a biomarker of aging. J Clin 
Invest 114, 1299-1307. 
2. Kreiling, J.A., M. Tamamori-Adachi, et al. (2011). Age-associated increase in heterochromatic 
marks in murine and primate tissues. Aging Cell 10, 292-304. 
3. Vasilaki A, McArdle F, Iwanejko LM, McArdle A. (2006). Adaptive responses of mouse skeletal 
muscle to contractile activity: The effect of age. Mech Ageing Dev. 127(11):830-9.   
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